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Chapter 1
General introduction and outline of this thesis
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The brain and the spinal cord together fulfill the role of the central nervous system. In this 
system, incoming signals are processed and converted into concrete sensations like pain or 
touching. This system also forms and sends commands to their targets leading to desired 
actions like muscle contraction, enabling us to walk, talk or eat. The peripheral nervous system 
facilitates the transfer of the incoming and outgoing signals between the central nervous 
system and its target (organs). Accurate sensation and muscle control are therefore completely 
dependent on a fully functional peripheral nervous system. 
Due to its crucial function, peripheral nerve injuries can be life-changing events, impacting a 
patients function, autonomy and quality of life.1, 2 They occur in 3% of all extremity traumas, 
most commonly as a result of motor vehicle accidents and penetrating traumas.3 The socio-
economic impact of peripheral nerve injuries is so substantial that maximum efforts should 
be made to obtain maximal recovery rates.4 This thesis aims to fulfill a role in the efforts to 
improve outcomes of peripheral nerve injuries. 
ANATOMY
The peripheral nervous system is composed of an extensive network of peripheral nerves. 
The anatomy of a peripheral nerve is illustrated in figure 1. A peripheral nerve is a bundle 
containing a varying amount of fascicles that are held together by the epineurium, a layer 
of connective tissue. These fascicles intermingle with each other along the course of the 
nerve. Each fascicle consists of a bundle of axons, encompassed by layers of perineurial cells 
and collagen, the perineurium.5 Each individual axon is surrounded by endoneurium.6 These 
extracellular matrix components (epineurium, perineurium and endoneurium) are pivotal in 
axon guidance and triggering intracellular signals, which should be taken into account when 
restoring peripheral nerve injuries.7
Axons are long, tubular offshoots of nerve cell bodies (neurons). Most neurons have multiple 
other cytoplasm-protrusions besides the axon, which are much shorter than axons. These so 
called dendrites receive stimuli from other cells and if stimuli are strong enough, they are 
converted in the cell body to an electrical stimulus (action potential) which is transmitted by 
the axon. Most axons branch towards their ends (axon terminals), making connections with 
other neurons or target cells by synaptic junctions. Action potentials are transmitted through 
these junctions by the release of neurotransmitters. At a neuromuscular junction this release 
causes activation of muscle fibers, resulting in muscle contraction. The location of the neuron 
cell-body and the synaptic junctions of its axon determines its function.6, 8 
Oxygen and other essential nutrients for the cells and their processes in the peripheral nervous 
system are provided by diffusion from intrinsic and extrinsic vessels, the vasa nervorum. The 
extrinsic vasculature runs along the surface of the nerve, supplying the epineural and perineural 
regions. The internal vasculature is located inside the fascicles, the endoneurial compartment.9, 
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10 Considering its function, optimization of revascularization of repaired peripheral nerves 
hypothetically forms an opportunity to improve nerve regeneration outcomes. 
Figure 1. Cross sectional anatomy of a peripheral nerve. (Used with permission of the American Society of 
Regional Anesthesia and Pain Medicine. All rights reserved.)
NERVE SUBDIVISIONS
Besides sensory, motor and mixed nerves, the peripheral nervous system can be subdivided 
in multiple other ways. When studying the direction of the transmitted stimuli, one can 
distinguish either afferent (towards the central nervous system) and efferent (away from the 
central nervous system) nerve fibers. Motor fibers are classified as efferent, sensory fibers are 
mostly afferent. The somatic versus autonomic nervous system are distinguished based on 
their control mechanism. The somatic system comprises voluntary actions that we can control 
like the movement of skeletal muscles. Actions of internal organs like cardiac contraction 
and digestive movements of the colon are involuntary and belong to the autonomic nervous 
system.11 
On a axonal level, axon fibers can be subdivided into either myelinated and unmyelinated 
axons. Myelin, which consist for approximately 80% of lipids, is formed by Schwann cells in 
the peripheral nervous system. Each Schwann cell wraps around one segment of an axon 
many times to form a myelin sheet: an internode.12 The amount of myelin that is formed by the 
Schwann cells is related to the diameter and the function of the axon and neuron.13 The gaps 
between each of the internodes are called nodes of Ranvier and contain many sodium and 




potassium channels.14 As a response to an action potential that is send off from the neuron, 
these sodium channels open, causing an influx of positive sodium ions that rejuvenate the 
action potential. Through this mechanism, myelin helps to prevent action potentials from 
decaying during their travel down the entire length of the axon.15 The transmitted action 
potentials are also accelerated by the presence of myelin. Because nodes of Ranvier are 
not myelinated, the action potentials only slow down at each node, leading to saltatory 
conduction; ‘jumping’ propagation of the action potential from node to node.16 Unmyelinated 
axons lack the insulating layer of myelin, resulting in less rapid and less efficient transmission 
of action potentials.17, 18 
Based on the level of myelination and the conduction velocity, nerve fibers can be divided 
into three classes by Erlanger and Gasser19: group A) heavily myelinated fibers, group B) 
moderately myelinated fibers, group C) unmyelinated fibers. Group A fibers contain fibers 
responsible for somatic motoric control, proprioception, vibration, light touch and fast pain. 
Autonomic nerve fibers belong to group B. Pressure, slow pain, crude touch and temperature 
are transmitted by group C fibers. The thicker the axon, the thicker the myelin sheath and 
the faster the nerve conduction velocity.20 The importance of adequate levels of myelin for 
each type of nerve fiber is emphasized by diseases like multiple sclerosis, which is caused by 
demyelination of the central nervous system.21 Presence of myelinating cells (Schwann cells) 
at the site of a nerve injury is therefore hypothesized to be crucial for adequate peripheral 
nerve regeneration. 
PATHOPHYSIOLOGY OF NERVE REGENERATION
Seddon, later supplemented by Sunderland, refined a classification concerning the severity of 
peripheral nerve injury. Grade I, neuropraxia, includes the loss of the myelin sheath, without 
damage to the axon. When the myelin sheath and the axon are damaged but the nerve 
casings (endoneurium, perineurium, epineurium) are still intact, one speaks of a grade II nerve 
injury, axonotmesis. In grade III, (endoneurium) and grade IV (endoneurium and perineurium), 
the connective tissues surrounding the axons are additionally injured. Grade V is a complete 
transection of the nerve (myelin, axon, endoneurium, perineurium, epineurium), neurotmesis.22, 
23 Grade VI is a later proposed addition to the classification and describes different grades of 
injury along the course of the nerve.24 
In large axon injuries or injuries close to the neuron cell body, neuron death can occur. In 
cases with axonal injury distant from the neuron, axons are able to regenerate. Considering 
their complex composition, injured peripheral nerves require complex recovery processes 
to restore their function. This starts with Wallerian degeneration; damaged cells die by 
apoptosis and axonal and myelin debris distal to the injury is phagocytosed by activated 
macrophages.25 Part of the damaged and nearby lying Schwann Cells change their gene and 
protein expression, resulting in non-myelinating, proliferating Schwann Cells.26, 27 Wallerian 
degeneration blends into nerve regeneration when the neurons, macrophages and Schwann 
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cells start secreting trophic factors as a response to the injury.13, 28, 29 A so called growth cone 
is formed at the proximal nerve stump.30, 31 Angiogenic trophic factors (like VEGF-a) stimulate 
angiogenesis, which provides the needed oxygen and nutrients to align the proliferating 
Schwann cells in ‘Bands of Büngner’.32, 33 These bands guide regenerating axons, enhanced 
by neurotrophic factors (like NGF, BDNF, GDNF) that are produced by Schwann cells and 
neurons, in the right direction.34 Extracellular matrix components are rebuild as a result of 
the expression and secretion of extracellular matrix proteins by Schwann cells.28 Eventually, 
remyelination and reinnervation occurs and the phenotype of Schwann cells is reversed back 
to a myelinating phenotype.35 This process is illustrated in figure 2. Presence of angiogenic 
trophic factors, neurotrophic factors and extracellular matrix proteins at the regenerating 
nerve stump facilitates axon regeneration and should therefore be considered as target to 
improve outcomes of nerve injuries. 
Figure 2. The process of Wallerian degeneration and nerve regeneration. After nerve injury, activated 
macrophages phagocytose the axonal and myelin debris. Activated Schwann cells, macrophages 
and neurons secrete trophic factors that initiate the formation of Bands of Bügner, resulting in axon 
regeneration. Absence of those essential factors can lead to poor nerve regeneration, scar tissue 
formation and end organ degeneration. (Used with permission of Mayo Foundation for Medical Education and 
Research, all rights reserved.)




NERVE RECONSTRUCTION OPTIONS & SHORTCOMINGS 
The described process occurs in the first days to weeks after peripheral nerve injury. With 
a regeneration speed of 1-3mm per day, axon regeneration in proximal nerve injuries can 
take up to months before the target muscle is reached.36, 37 The critical time frame for nerve 
regeneration to occur is 12-18 months after the nerve injury.38 Delayed regeneration leads 
to worse or absent functional outcomes, which is attributed to 1) degeneration of synaptic 
acetylcholine receptors which leads to less receptiveness of muscle fibers for reinnervation, 
2) difficulty to recover from muscle denervation atrophy that increases as denervation time 
extends 39 and 3) deterioration of the endoneurial tubes in the distal nerve stumps, leading 
to less guidance and less axons that successfully reach the denervated muscle fibers.40, 
41 Maximal nerve regeneration efficiency/speed should be pursued to obtain maximal 
functional outcomes. 
Spontaneous successful reinnervation after a peripheral nerve injury depends on the 
severity of nerve injury, representing the degree of internal disorganization. Neuropraxia, 
axonotmesis and incomplete nerve lesions have good prospects for axon regeneration when 
treated conservatively.38 More extensive lesions or complete transections most often do not 
spontaneously lead to acceptable outcomes. Therefore, spontaneous nerve regeneration is 
sometimes awaited in closed, blunt trauma cases, while sharp transection nerve injuries are 
preferably surgically restored within 72 hours.38, 42 The severity of the nerve injury, the time 
elapsed since the injury and the distance between the proximal nerve stump and the target 
muscle should all be considered when deciding to operate on a peripheral nerve injury. 
Direct coaptation of both nerve ends by suturing the epineurium is the preferred surgical 
restoration technique, but only if this can be obtained in a tension-free manner. When this 
condition cannot be met, one can use nerve grafts (autologous or allogenous) or conduits 
(natural or synthetic) to bridge the nerve gap.
Autografts
Nerve autografts are currently used as the gold standard in peripheral nerve repair.43 They 
are readily available, provide Schwann Cells and other important neurotrophic factors, 
contain the desired ultrastructure to guide regenerating axons and are immunologically 
inert. Unfortunately, autografts require the sacrifice of autologous nerves which are limited 
available and can result in donor side morbidity like loss of sensation or painful neuroma 
formation.44, 45 Especially in big nerve branch injuries or multiple injured nerves, autograft 
sources fall short to restore all defects, emphasizing the need for autograft substitutes that 
result in equal functional outcomes. 
Allografts
Efforts to replace the role of autografts have led to the development of allogenous nerve 
grafts, currently the second-best option in cases with extensive peripheral nerve injuries.46, 
47 To eliminate immune rejection of the allograft, techniques to decellularize the donor 
nerves have been studied. This decellularization process leads to the loss of Schwann cells 
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and important neurotrophic factors, but retains the ultrastructure of the nerve. Since 2007, 
only one decellularized nerve allograft has been FDA approved and is currently readily 
available in daily clinical practice. Although sensory nerve gaps have been successfully 
repaired with these Avance® Nerve Grafts, reported outcomes of long segment, large 
diameter and mixed and motor nerve gaps are consistently inferior to that of autografts.43, 
46, 48 Absence of Schwann cells, intrinsic angiogenic trophic factors, neurotrophic factors 
and extracellular matrix proteins are hypothesized to cause the inferiority of allografts. 
Conduits
Natural conduits like veins have been used to bridge peripheral nerve gaps in the past, 
but synthetic conduits have gained more scientific and clinical interest over the years. The 
NeuraGen® Nerve Guide is a collagen type 1 conduit that was FDA approved in 2001.49 
Conduits lack Schwann cells, a guiding ultrastructure and angiogenic and neurotrophic 
factors. They have only led to satisfactory outcomes in small-caliber sensory nerve gaps 
up to 3cm.50, 51 
MESENCHYMAL STEM CELLS
Schwann cells, the guiding ultrastructure (particularly in conduits), angiogenic and 
neurotrophic factors are removed in nerve allografts and conduits. Replacing these 
components is logically suggested as the solution to enhance outcomes of allografts 
and conduits to a level equal to that of autografts. As described, Schwann cells fulfill 
a key role in multiple processes during Wallerian degeneration, axon regeneration and 
stimulus transmission, by producing neurotrophic, angiogenic and extracellular matrix 
factors and by forming myelin.32 Therefore Schwann cells are considered as the obvious 
required supplementation to the listed autograft substitutes. Although Schwann cells 
did demonstrate potential as nerve regeneration catalysts, they need to be derived from 
nerve tissue. Thus their use requires the sacrifice of an autologous nerve; exactly what 
is intended to be prevented when using nerve autograft substitutes.52, 53 Mesenchymal 
stem cells (MSCs) are precursor cells used in numeral medical fields due to their trophic 
characteristics and differentiation capacities. Environmental signals influence MSCs 
to produce trophic factors or to differentiate into specific cell types, tailored to the 
surrounding regenerating tissue.52, 54, 55 The use of these MSCs as a supplementation 
to the previously described nerve autograft substitutes is a hopeful research topic.56, 57 
Differentiation of MSCs into Schwann cell-like cells prior to implementation in peripheral 
nerve injuries is also a suggested strategy to replace the missing Schwann cells. Although 
this concept is supported by several in vitro studies, in vivo outcomes still need to show if 
this strategy is cost- and time-efficient.52, 58, 59 Mesenchymal stem cells can be obtained from 
mesenchymal tissues like dental pulp, bone marrow and adipose tissue. In contradiction 
to dental pulp and bone marrow, adipose tissue is easily and less invasively accessible. 
Higher MSC-yields and rapid proliferation in culture are additional benefits of adipose 
derived MSCs.60-63  





Optimization of processed nerve allografts
In studies performed prior to this thesis, the focus first was on optimization of nerve allograft 
processing/decellularization techniques. Histological analysis of Avance® nerve grafts 
revealed remaining cellular debris in the grafts, potentially leading to immunologic responses 
or blockage of ingrowing axons. In an effort to improve these aspects, elastase was added 
to the decellularization protocol. Elastase demonstrated to significantly reduce the amount 
of cellular debris and immunogenicity of nerve allografts. Subsequently, cold storage (4°C) 
of decellularized nerve allografts resulted in a less damaged ultrastructure of the grafts 
compared to frozen storage (-80°C) techniques.64 Elastase-processed, cold stored allografts 
demonstrated improved functional outcomes in a rodent model compared to frozen stored 
allografts that were decellularized without elastase. In a bigger nerve defect model (rabbit) 
however, autografts still outperformed these optimized decellularized nerve allografts.65 
Mesenchymal stem cells
To be able to test if MSCs can supplement decellularized allografts and conduits, a delivery 
technique needed to be defined that would not be traumatic to either the MSCs or the nerve 
substitute, in contradiction to previously described injection techniques.66 Even distribution 
of MSCs and an efficient method were additional requirements. Dynamic seeding, by which 
MSCs are rotated in the presence of a decellularized nerve allograft, led to a nontraumatic, 
homogenously distributed attachment of MSCs to the surface of nerve allografts.67 The 
process of decellularizing allografts and seeding them with MSCs in a rat model is illustrated 
in figure 3. The interaction between MSCs and the extracellular matrix of the nerve allografts 
led to enhanced expressions of multiple trophic genes in vitro, which was partly confirmed 
by quantification of the produced trophic factors.68 Taking this seeding strategy to an in vivo 
rodent model, it was shown that the seeded MSCs survived up to 29 days and that the MSCs 
did not migrate to surrounding tissues.69 It also led to enhanced expressions of angiogenic 
factors.70 It would therefore be interesting to not only study the long term functional outcomes 
after nerve repair with MSC-seeded allografts, but also to analyze if the MSCs improve 
vascularization of the nerve allografts.  
Figure 3. Nerve harvest, decellularization and seeding techniques. (Used with permission of Mayo Foundation 
for Medical Education and Research, all rights reserved.)




Many different evaluation techniques have been described to quantify the level of nerve 
regeneration. Histology enables us to analyze the inside of the nerve. Stained ultrathin sections 
of nerves reveal information about the number of axons, the axon area, the myelinated fiber 
area and the total nerve area. The N-ratio, which is composed of the total myelinated fiber 
area divided by the total nerve area, is an often used measure to express the amount of 
sprouting axons.71
Nerve conduction capacities can be quantified by electrophysiology, compound muscle 
action potentials (CMAP). An artificial action potential is evoked proximal to the nerve graft. 
The amplitude of that signal is measured in the muscle distal to the nerve graft. The bigger 
the amplitude of the distally measured signal, the better the nerve regeneration process 
has occurred.65, 72  
Although one could argue if histology and electrophysiology measurements are direct or 
indirect measures of nerve regeneration, muscle function represents the most relevant 
outcome factor for motion. Isometric tetanic force has been described to most reliably 
represent muscle function and has been validated in rodent models. A stimulus is introduced 
to the nerve graft, and the resulting muscle contraction force is quantified.73 
As denervation of a muscle will result in muscle atrophy and shrinking of the muscle, the 
size and mass of a muscle after nerve reconstruction also provide information on successful 
reinnervation. Although the muscle mass is easy to obtain, it does require the sacrifice of 
the animal. Ultrasound measurements of the cross-sectional area of (re)innervated muscles 
can be obtained non-invasively and can therefore be used to study nerve regeneration over 
time.74, 75  
GENERAL AIMS AND OUTLINE OF THIS THESIS
The ideal future perspective is an off-the-shelf nerve substitute that can be used in peripheral 
nerve injuries, resulting in functional outcomes equal to those of autograft nerves. The 
specific aim of this thesis was to examine whether the in vivo outcomes of nerve allografts 
and conduits can be improved by the addition of adipose derived Mesenchymal Stem Cells, 
either undifferentiated or differentiated into Schwann cell-like cells. If so, MSC seeding 
might have clinical potential in peripheral nerve injury cases with shortage or inadequate 
autologous nerve graft material. As part of this objective we aimed to get more insight 
through which mechanisms these cells potentially influence nerve regeneration.  We first 
intended to examine in vitro if and how differentiated MSCs could be dynamically seeded 
on nerve grafts and then we aimed to study the gene expression profiles of the seeded 
MSCs. Subsequently, we set the goal to analyze the in vivo effects of MSCs regarding 
vascularity and functionality. This hopefully would give us the opportunity to be able to 
explain if and how MSCs affect nerve regeneration. In order to evaluate if the described 
techniques can be applicable to a clinical setting, we eventually aimed to dynamically 




seed human MSCs on human nerve grafts or on clinically available nerve substitutes and to 
analyze their gene expression profiles after seeding; hopefully setting the stage for clinical 
application somewhere in the near future. 
As preliminary step for the other chapters, the current knowledge on differentiation of 
MSCs into Schwann cell-like cells is summarized in chapter 2. It sets the fundament of why 
differentiated MSCs deserve to be studied in the perspective of peripheral nerve repair, 
besides undifferentiated MSCs. The ability of differentiated MSCs to be dynamically seeded 
onto processed nerve allografts like undifferentiated MSCs is examined and described in 
chapter 3, enabling a fair comparison of the in vitro and in vivo potential of both cell types. 
Gene expression profile changes of differentiated and undifferentiated MSCs after seeding 
on nerve allografts, affected by the extracellular matrix of the nerve allograft, are studied at 
various time points after seeding in chapter 4. As revascularization is hypothesized to be an 
essential factor for successful nerve regeneration, we first tested and validated new evaluation 
strategies for nerve vascularization in chapter 5. In chapter 6, this is extrapolated to an in 
vivo study in which the level of vascularization in nerve allografts seeded with differentiated 
and undifferentiated MSCs is quantified and compared to the vascularization of unseeded 
allografts, autografts and normal nerves. The potential of differentiated and undifferentiated 
stem cell seeding to improve functional outcomes after peripheral nerve repair is studied 
in a rat sciatic nerve defect model in chapter 7. Functional results of MSC-seeded nerve 
allografts are compared to unseeded allografts and autografts over time and at two long 
term end points. To translate the described strategies to a more clinically applicable model, 
the study in chapter 8 focuses on the potential of human MSCs to be seeded onto clinically 
available nerve graft substitutes. The consequences of the interaction between the MSCs 
and the extracellular matrix of the nerve graft substitutes on a gene expression level are 
studied and described in chapter 9. In chapter 10, the acquired results of all chapters are 
related to each other, discussed and placed in a broader perspective. An English and a Dutch 
summary are provided in chapter 11. 
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ABSTRACT
Mesenchymal stem cells (MSCs) have considerable translational potential in a wide variety 
of clinical disciplines and are the cellular foundation of individualized treatments of auto-
immune, cardiac, neurologic and musculoskeletal diseases and disorders. While the cellular 
mechanisms by which MSCs exert their biological effects remain to be ascertained, it has 
been hypothesized that MSCs are supportive of local tissue repair through secretion of 
essential growth factors. Therapeutic applications of MSCs in peripheral nerve repair have 
recently been reported. This review focuses on how MSCs can promote nerve regeneration by 
conversion into Schwann-like cells, and discusses differentiation methods including delivery 
and dosing of naive or differentiated MSCs, as well as in vitro and in vivo outcomes. While 
MSC-based therapies for nerve repair are still in early stages of development, current progress 
in the field provides encouragement that MSCs may have utility in the treatment of patients 
with peripheral nerve injury.
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INTRODUCTION
To achieve successful repair of peripheral nerve segmental defects, nerve autografts still 
supersede the results of all commercially available nerve graft substitutes (bioabsorbable 
conduits, vessels or processed allografts).1 Nerve autografts are limited in availability and their 
harvest from patients automatically generates donor side morbidity. The application of MSCs 
has been actively considered for in vitro and in vivo studies seeking to improve outcomes of 
peripheral nerve reconstruction. MSCs potentially provide the necessary biological support 
for nerve substitutes to equate results obtained by autografts.2, 3 Prior studies have also 
evaluated the application of Schwann cells to nerve graft substitutes and have demonstrated 
active expression of neurotrophic factors with encouraging outcomes. 4 However, clinical 
application of this technology is impractical, as it would require harvest of autologous nerve 
tissue to obtain autologous Schwann cells and extensive time to culture and grow the requisite 
number of Schwann cells for adequate seeding of the nerve graft substitutes.  Alternatives to 
autologous Schwann cells would be the differentiation of autologous MSCs from the patient 
into Schwann-like cells. In vitro targeted stimulation of autologous MSCs has resulted in 
differentiation into Schwann-like cells without having to sacrifice autologous nerves.4, 5 Hence, 
autologous MSCs can be harvested from the patient, differentiated into Schwann-like cells 
and be delivered to the site of nerve repair or seeded onto nerve graft substitutes to improve 
the regenerative environment.  Important topics addressed in this review include methods for 
how to differentiate MSCs into Schwann-like cells, how to deliver naive or differentiated MSCs 
and the regenerative potential of differentiated MSCs compared to undifferentiated MSCs. 
MESENCHYMAL STEM CELLS
MSCs can be isolated from a variety of tissues from the stromal vascular fraction that are 
extrinsic to blood vessels. They are most frequently obtained from either bone marrow or 
adipose tissue. Multiple studies have compared bone marrow and adipose MSCs and  both 
sources yield viable MSCs that comply with minimal criteria for MSCs as defined in 2006 by 
the International Society for Cellular Therapy.6 Key properties of MSCs include that they 
are plastic adherent, multi-potent and express canonical mesenchymal stem cell markers 
(CD44 and CD90), while other markers are absent (CD34 and CD45).6, 7 In contrast to bone 
marrow, adipose tissue is more easily accessible and requires only minimally invasive methods 
(liposuction vs bone marrow harvest) to obtain adequate quantities of MSCs, while having a 
similar effect on nerve regeneration.8, 9 MSCs that are derived from the stromal vascular fraction 
of adipose tissue are easily expanded and differentiated.10, 11 These properties render adipose 
derived MSCs of particular interest for clinical applications compared to less accessible bone 
marrow derived MSCs.
A well-established method to derive MSCs from adipose tissue consists of mechanically 
disrupted and enzymatically digested tissues. The fat tissue obtained by liposuction is minced 
and enzymatically digested using collagenase type I. The undigested tissue is removed by 
filtration and the filtered solution is suspended in standard culture media containing a-MEM. 
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For clinical applications, this media is supplemented with platelet lysate (PL) to obtain zoonotic 
free clinical grade MSCs. We note that although Fetal Bovine Serum (FBS) suffices for research 
applications, the cell populations that emerge upon proliferative expansion in PL versus 
FBS may differ in their molecular properties and these differences may result in functional 
differences in cell therapy applications. Upon centrifugation, low density adipocytes emerge 
at the top of the tube, while stromal cells from the vasculature of fat tissue are collected as a 
pellet. The pellet can be re-suspended in MEM containing growth supplements (e.g., PL or 
FBS) and antibiotics (e.g., penicillin/streptomycin solution) for subsequent culture as adherent 
MSCs.7, 11 Overall, deriving MSCs from adipose tissue is well-described and technically simple 
to perform making it advantageous for clinical applications. 
MECHANISM OF ACTION
There are two major hypotheses on how MSCs establish tissue regeneration. The first 
proposes that the exogenously administered MSCs have a structural function in tissue 
injury and thus differentiate in vivo into tissue that requires repair. Growth factors and other 
paracrine molecules produced by the surrounding tissue stimulate the MSCs to differentiate 
into the requisite cell type. Supportive studies at best only infer this mechanism. Orbay and 
colleagues labeled undifferentiated MSCs and reported that they were still detected after 
3 months and expressed Schwann cell proteins in a rat-model.12 Tomita and colleagues 
reported in a rat-model that a small fraction of their GFP-labeled MSCs were still present 
after 8 weeks and expressed myelin protein, suggesting that some trans-differentiation into 
Schwann cells occurred.4 In this model, MSCs may be able to both repair and replace injured 
tissue. However, to date this model for MSC function remains largely untested. While there 
is no question that cellular differentiation is required for neuronal development, it is not 
clear whether therapies relying on MSCs replicate the normal differentiation of Schwann 
cells.
The second hypothesis for MSCs has more recently emerged and this concept poses that 
MSCs have trophic functions that are important for extracellular matrix remodeling and 
tissue regeneration.13 At least a subset of MSCs are derived from pericytes, which are 
released upon tissue damage or disease. The proteins and molecules produced by the 
MSCs can enhance angiogenesis, inhibit scar formation and stimulate tissue regeneration.14 
In addition to maximizing the intrinsic regenerative capacity of the tissue, MSCs have key 
immunomodulatory roles. After the initial immunologic response to injury, pro-inflammatory 
cytokines produced by NK cells and T lymphocytes ‘activate’ the MSCs. MSCs subsequently 
prevent the inappropriate and overaggressive activation of T lymphocytes and decrease the 
cytotoxic activity of NK cells through feedback loops.15, 16 This ‘trophic’ concept has been 
corroborated by findings in multiple in vitro and in vivo studies of enhanced gene expression 
and growth factor production after the introduction of MSCs to damaged tissue.17, 18 Overall, 
MSCs most likely have a trophic function and their role in enhancing nerve regeneration is 
to maximize the intrinsic regenerative capacity of the nerve and minimize the inappropriate 
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infl ammatory response after nerve-injury. A dual function, in which a small fraction of the 
MSCs has a structural function by replacing injured tissue-cells, while the remaining part of 
the MSCs maximizes the intrinsic regenerative capacity of the injured tissue by producing 
growth factors and cytokines, is not inconceivable. The described different functions of 
MSCs are shown in fi gure 1. 
In light of the hypotheses for the mechanisms of action of MSCs, several key questions need 
to be addressed prior to clinical implementation. These include the role of differentiation 
of MSCs prior to administration, the optimal dosing and time frame of application of 
differentiated versus undifferentiated MSCs and how MSCs need to be administered 
regardless of differentiation status.  
APPLICATION OF MSCS
An important aspect for the clinical application of MSCs is that outside factors like local 
anesthetics or contrast medium can infl uence the viability of MSCs and should be taken 
into account in studies on the potential of MSCs for clinical applications. 19, 20  Although the 
outcomes of preclinical and clinical research on the use of MSCs have been promising in 
a wide variety of clinical disciplines, further research to determine the optimal doses and 
time points of implantation, the long-term risks and the long-term effi cacy are needed to 
optimize outcomes of MSC-supported tissue regeneration.21, 22
Figure 1. Schematic overview of the (hypothesized) subset of functions of mesenchymal stromal cells.
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MSCS IN PERIPHERAL NERVE REPAIR
Differentiation of MSCs into Schwann-like cells
The neural induction of MSCs by chemicals combined with growth factors is the most established 
method to obtain Schwann cell-like differentiation. The induction protocol by Kingham and 
colleagues is widely used and includes two preparation steps with ß-mercaptoethanol (for 24 
hours) and all-trans-retinoic acid (for 72 hours). Subsequently the cells are placed in growth 
medium enriched with a differentiation cocktail containing Platelet-derived growth factor 
(PDGF-AA), basis fibroblast growth factor (bFGF), Forskolin and a member of the Neuregulin 
family (Neuregulin-1 ß1, Glial growth factor-2 or Heregulin- ß1). After 2 weeks in differentiation 
medium, the morphology of MSCs is altered into an elongated spindle shape, characteristic 
of Schwann cells. Immunohistochemistry and Western blot analysis after differentiation has 
revealed expression of several phenotype-specific surface markers, including GFAP, S100 and 
p75-NTR. 2, 4, 5, 11, 17, 23-25 Studies have demonstrated this protocol is also suitable for human 
MSCs and that the function of those differentiated cells is analogous to Schwann cells. 4, 26 
Regardless of the fact that the effect of differentiated MSCs needs to be further examined 
and confirmed, these findings imply that research on targeted stimulation of MSCs could be 
applied in humans in the future and therefore has a serious clinical relevancy.  The additional 
timing and cost of differentiation need to be justified prior to human trials. 
The components of Kingham’s induction protocol each have specific biological functions. 
Forskolin activates adenylyl cyclase which increases the level of intracellular cyclic adenosine 
monophosphate (cAMP). cAMP causes an increase in the mitogenic responses of Schwann 
cells27, in response to the mitogenic actions of the growth factors PDGF and bFGF/FGF2.28 
The neuregulin-1 family plays a crucial role in the actual development and evolution of 
Schwann cells. Their presence activates cascades promoting Schwann cell differentiation and 
expansion. The level of Neuregulin-1 (NRG1) determines differentiation of Schwann cells into 
myelinating or non-myelinating cells that are responsible for the development of group C 
nerve fibers. NRG1 levels determines axon size, which enables the myelinating Schwann cells 
to optimize myelin sheath thickness.29, 30 Kingham’s protocol is currently the preferred method 
to obtain Schwann-like cells from adipose derived MSCs. The effect of altering the dosages 
of the different components of the differentiation protocol on the ultimate function of the 
Schwann-like cells is an interesting prospect for future research.
As targeted neurogenic stimulation to induce differentiation of MSCs is an expensive, time-
consuming and inefficient process requiring several weeks of laboratory-based preparation 
time, efforts have been made to find alternative approaches. Safford and colleagues used 
a chemical induction medium with butylated hydroxyanisole, potassium chloride, valproic 
acid, Forskolin, hydrocortisone and insulin to differentiate murine and human MSCs. Within 
5-6 hours following neuronal induction, they observed dramatic cell morphological changes 
in cytoskeletal organization and membrane appearance in MSC cultures which persisted 
up to 5 days. Beyond 5 days however, the differentiated MSCs lost viability and perished 
within 14 days of culture.10 The induction protocol of Anghileri involves the culturing of 
MSCs for 72 hours in growth medium with exogenous bFGF (FGF2) and human epithelial 
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growth factor as mitogenic factors to facilitate formation of cellular spheres. The spheres 
were induced to differentiate in media containing BDNF and all-trans-retinoic acid. After 
four weeks of culture, only half of the MSCs demonstrated the characteristic neuronal 
morphology, which expressed nestin and neuronal markers MAP-2 and NeuN, but lacked 
the expression of glial markers S100 and GFAP.31 Ahmadi and colleagues compared the 
method of Anghileri to the chemical induction protocol of Woodburry and colleagues. 
Woodburry included an optimization step in which MSCs are initially induced by addition 
of ß-mercaptoethanol (BME) for 24 hours followed by induction of neural differentiation 
using dimethylsulfoxide (DMSO), BME and butylated hydroxyanisole for 1 to 5 days. 
Ahmadi noted the differentiation protocol of Anghileri significantly improved MSC survival 
and increased MSC viability, indicating the use of potentially toxic substances (e.g., DMSO 
and BME) may not be necessary and could be avoided for MSC differentiation.32, 33 Thaler 
and colleagues confirmed the toxic effect of DMSO by demonstrating DMSO can initiate 
epigenetic changes which increased cell apoptosis.34 Despite the attempts to equal the 
efficiency of Kingham’s differentiation protocol by alternative chemical induction methods, 
none have resulted in high percentages of viable Schwann-like cells. In an ideal scenario, 
MSCs can be differentiated by natural, non-toxic compounds that are largely available, cost-
effective and which do not influence the viability of MSCs.
In an effort to find a method meeting the requirements listed above, studies have been 
performed on the effect of nerve tissue/nerve leachate to cell cultures, co-culture of MSCs 
with Schwann cells and the electrical stimulation of MSCs. The induction culture medium of 
Liu and colleagues consisted of 1cm fragments of rat sciatic nerves soaked in normal growth 
medium (i.e., DMEM and 10% FBS). After 2 days, nerve fragments were removed and adipose 
tissue derived MSCs were further cultured in the sciatic nerve leachate for another 3 days. 
Cells adopted a spindle-shape within 48 hours and reflected by expression of S100 and 
GFAP proteins as was confirmed by immunohistochemistry and western blot analysis, but 
the nerve autografts required for this protocol would not create a clinically viable therapeutic 
solution.18 Liao compared three methods to induce adipose tissue derived MSCs, including 
(I) neural induction with chemicals only (i.e., media with 2% DMSO for 5 hours), (II) neural 
induction by chemicals combined with growth factors (i.e., NGF, bFGF/FGF2 and BDNF, as 
well as the cAMP-related drug Forskolin) for 2 weeks, and (III) neural induction by co-culture 
of MSCs with Schwann cells. Immunohistochemistry and gene expression analysis showed 
higher mRNA levels for S100, nestin and GFAP in method II and III compared to method 
I. Similar to Liu and others,  autologous Schwann cells would pose a practical problem 
for the clinical implementation of method III.35 Das and colleagues differentiated MSC 
into Schwann-like cells by electrical stimulation to alter cellular membrane potential. The 
majority of electrically induced MSCs (>80%) showed Schwann cell markers S100 and p75 
and enhanced secretion of NGF compared to chemically induced MSCs or undifferentiated 
MSCs.36 Although electrical differentiation is promising and may mimic aspects of normal 
neuronal cell differentiation, physical methods for differentiation have remained largely 
unexplored and it remains unclear whether electrical stimulation will have practical benefits 
compared to differentiation with growth factors. 
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Methods of administration and cell dosage
The desired method of cell delivery depends on the intended mechanism of action of MSCs. 
MSCs need to be delivered within the ultrastructure of nerves to fulfill a structural function or 
need to be able to migrate to the site of injury. Micro-injection of the MSCs has been described, 
but the consequences of injection to cell viability and the resulting ultrastructural trauma to 
the nerve are potential concerns. Jesuraj and colleagues reported the pressure build-up in 
the syringe and needle during injection reduces viability of cells after needle passage. (46) In 
contrast, Onishi and colleagues reported that adipose derived MSCs were fairly robust within a 
range of fluid pressures within the syringe upon expulsion. 37, 38 Studies that examined the viability 
of bone marrow derived MSCs post-injection have various conclusions ranging from no viability 
changes to a temporarily affected viability, to a reduced viability. 39-41 Increasing the needle 
gauge may intuitively reduce cell damage, but inserting a larger needle in a processed nerve 
graft is practically almost impossible and can easily cause tearing of the epineurium. In addition, 
uncontrolled micro-injection leads to a non-uniform distribution of cells and may result in local 
accumulation of clusters of MSCs that potentially block the ingrowth of the regenerating nerve 
rather than enhancing it.38 The calibers of myelinated axon fibers (2 to 22µm) in proportion to the 
average diameter of MSCs (17.9 – 30.4µm) also may be problematic when MSCs are injected in 
the nerve allograft.42-44 In case of using hollow nerve conduits, injection of MSCs will not harm 
the conduit itself, but it can still cause decreased viability of the cells and might obstruct axonal 
ingrowth. Furthermore, leakage of cells out of the nerve substitute is a recognized problem; the 
study by Jesuraj and colleagues showed only 10% of cells were successfully transferred after one 
million cells were injected.38 The injection of MSCs in nerve substitutes is not clinically applicable 
due to low and uncontrollable delivery efficiencies and the potential damage to the cells and the 
nerves. Hence, future studies may consider alternative delivery methods for both differentiated 
and undifferentiated MSCs.     
Intravenous injection of MSCs has been investigated as an alternative to MSC-injection that 
prevents nerve-damage and cell-leakage and focuses on the more likely trophic function of MSCs. 
Although the vasculature potentially delivers a subset of MSCs to the area of injury, the cells may 
not accumulate to a critical mass to enhance nerve regeneration. In addition, the relatively large 
size of MSCs causes entrapment in capillaries.45 MSCs can also be administered by intramuscular 
injection which delivers cells locally with preservation of the nerve. Intramuscular injection of 
MSCs in the gastrocnemius muscle resulted in a significantly improved functional recovery and 
neuro-conduction velocity compared to intravenous injection of MSCs or sham injection.46 It has 
been reported that intramuscular injection of MSCs leads to enhanced nerve regeneration.47 
Even though these findings are promising, the described techniques still require injection of cells 
which potentially decreases the viability of the cells. The enhanced outcomes after intravenous 
and intramuscular injection of MSCs, do confirm the previously suggested trophic function of 
MSCs.
Soaking nerve grafts in MSC-solutions is another described method of cell delivery. Thompson 
and colleagues compared the injection of cells to a soaking technique in which the nerve 
samples were pretreated with a micro-needle roller. Injection led to a higher number of cells 
in the inner and middle zones of the nerves, while soaking delivered a higher number of cells 
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in the outer zone.48 Dynamic seeding has been successful in  vascular tissue engineering and 
resulted in a more efficient and uniform distribution of cells compared to static seeding  with 
seeding efficiencies ranging from 38% to 90%.49 This strategy was applied to a nerve-model by 
Rbia and colleagues. They non-traumatically seeded MSCs on the surface of a processed nerve 
allograft with the use of a bioreactor. This resulted in a uniform distribution of MSCs that were 
adhered to the nerve graft.50 The cells did not migrate into the nerve allograft and the interaction 
between the MSCs and the nerve surface resulted in an upregulation of neurotrophic factors that 
potentially enhance nerve regeneration within the nerve graft.50 Overall, dynamic seeding results 
in a uniform distribution of MSCs on nerve allografts that enables the cells to interact with the 
nerve ultrastructure with a high efficiency without harming the cells nor the nerve ultrastructure. 
To date, this is the most promising delivery method of MSCs to allograft nerves and might form 
the bridge towards individualized peripheral nerve repair in clinical practice. 
Jesuraj and colleagues used a concentration of 1 x10^5 cells/5uL to inject and compared it to 
a concentration of 10^6 cells/5uL. Their analysis revealed an injection efficiency of 10% for the 
1x10^6 cells (100.000 cells) and 40% for the 1x10^5 cells (40.000 cells) of which only the larger 
dose was trackable by in vivo fluorescence. 38 Thompson and colleagues also soaked or injected 
their 10mm allograft segments with 1x10^6 cells/5uL, but did not report a total efficiency. 48 Rbia 
and colleagues used 1x10^6 cells to dynamically seed their nerve segments and reported a 
seeding efficiency of 89.2%, suggesting that almost 900.000 cells were attached to the surface 
of the 10mm nerve segment before in vivo implementation. 50 Wang and colleagues also used 
1x10^6 MSCs, diluted in 1mL fluid, to inject in the gastrocnemius muscle.46 Despite the wide 
variety of delivery efficiencies, there seems to be consensus that at least 1x10^6 MSCs need to 
be presented to the nerve graft to generate noticeable biological effects. However, no studies 
on the optimal dosing of MSCs have been reported. Dynamic seeding of MSCs appears to be a 
reliable, effective and well-studied delivery method (see table 1).
None of the methods of administration reported to date have been specifically tested on 
differentiated MSCs, so direct comparisons between undifferentiated and differentiated MSCs 
with respect to their delivery efficiency are lacking. This could be a potential decisive factor 
as it has been emphasized that differentiation of MSC may decrease their potential to attach 
to surfaces.51 It is essential that delivery methods are tested on differentiated MSCs as well as 
undifferentiated MSCs as the impact on clinical application is significant with respect to cost and 
time.  
Differentiated MSCs versus undifferentiated MSCs in vitro
The in vitro capabilities of differentiated MSCs in peripheral nerve repair have been extensively 
evaluated. Kingham and colleagues found that differentiated MSCs significantly extended the 
number and the length of formed neurites by motor neuron-like cells compared to undifferentiated 
MSCs.11 In another study of Kingham, enhanced expression was observed for nerve growth 
factor (NGF), brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor 
(GDNF), vascular endothelial growth factor-A (VEGF-A) and angiopoietin-1 in differentiated 
MSC compared to undifferentiated MSCs.17 ELISA analysis demonstrated enhanced secretion 
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of BDNF, GDNF, angiopoietin-1 and VEGF-A upon differentiation of MSCs. These increased 
levels of growth factors resulted in higher total neurite outgrowth, longer neurites and a better 
angiogenic potency after removal of the factors that stimulate differentiation from the growth 
medium.17 Tomita found similar results and showed differentiated human MSCs produced higher 
levels of neurotrophic factors like BDNF, NGF and GDNF compared to undifferentiated MSCs. 
The secretion of these neurotrophic factors resulted in a significantly increased percentage of 
neuron-bearing neurites, and a significant increase in both neurite length and number of neurons.4 
Ladak also demonstrated that co-culture of differentiated MSCs with dorsal root ganglion 
neurons led to longer and more arborous neurite outgrowth than undifferentiated MSCs.23 
As described previously, the same result was found with differentiated human MSCs.26 In vitro 
studies that examined the interaction between undifferentiated and differentiated MSCs with a 
processed nerve allograft showed persistent enhanced expression of neurotrophic genes that 
subsequently led to the secretion of neurotrophic growth factors.52, 53 In general, differentiated 
MSCs enhance the expression of neurotrophic genes and the secretion of neurotrophic proteins, 
resulting in increased neurite outgrowth in vitro. These in vitro results are promising and support 
the hypothesis that differentiated MSCs have a trophic function in nerve regeneration. The 
remark needs to be made that any agent or growth factor added to the growth medium may 
become embedded in the extracellular matrix (ECM) and might not be completely washed 
out after removal of the differentiation media.  Thus, the enhanced gene expressions and the 
increased neurite outgrowth could still be the effect of direct stimulation by the added growth 
factors instead of being positively influenced by the differentiated MSCs. In vivo research could 
eliminate this discrepancy. 







10-40% • Delivers a high number of 
MSCs in the inner and middle 
nerve zones
• Reduced viability of MSCs
• Damage to the ultrastructure of 
the nerve
• Leakage of cells (conduits)
• Local accumulation of MSCs
Intravenous 
injection
100% • No damage to the 
ultrastructure of the nerve
• No cell leakage
• Reduced viability of cells
• Entrapment of MSCs in capillaries




100% • Locally delivers MSCs
• No damage to the 
ultrastructure of the nerve
• No cell leakage
• Reduced viability of cells
• Low number of MSCs at 
regeneration site
Soaking Unknown • Delivers MSCs in the outer 
nerve zones
• Preserved viability of MSCs
• Damage to the nerve (micro-
needle roller)
Seeding 89.2% • Uniform distribution of MSCs
• Preserved viability of MSCs
• No damage to the 
ultrastructure of the nerve
• No cell leakage
• Interaction between MSCs and 
extracellular matrix is required
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Differentiated MSCs versus undifferentiated MSCs in vivo
When seeded on a conduit and transplanted in a rat-model, differentiated MSCs characterized 
by Kingham and colleagues increased the distance of axon regeneration and enhanced 
vascularity in nerve conduits compared to undifferentiated MSCs. These findings show 
that neurotrophic and angiogenic factors produced by differentiated MSCs interact with 
regenerative mechanisms that support repair of injured nerves by enhancing vascularization 
and improved nerve regeneration.17 Ladak and colleagues found in vivo that differentiated 
MSCs seeded in a nerve conduit resulted in an equal number of regenerating axons across 
the nerve gap compared to seeded Schwann cells. However, the improved axon regeneration 
did not translate into improved electrodiagnostic parameters or increased muscle weight.23 
Keilhoff and colleagues compared the outcomes of Schwann cells, undifferentiated MSCs 
and differentiated MSCs injected in a devitalized muscle. The authors found both Schwann 
cells and differentiated MSCs contribute to appropriate regeneration while undifferentiated 
MSCs did not exhibit the ability to improve nerve repair.47 Kappos showed in a rat sciatic 
nerve gap model that the addition of differentiated human MSCs to a nerve conduit led 
to functional outcomes (sciatic functional index and gastrocneumius muscle mass) that 
exceeded the results of undifferentiated human MSCs and Schwann cells.54 In contrast, other 
studies showed low potential of the Schwann-like cells. Fox and colleagues demonstrated in 
a rat model that primary Schwann cells did not have a beneficial effect on nerve regeneration 
after 4 weeks when injected into nerve grafts.55 Orbay and colleagues evaluated the effects of 
differentiated and undifferentiated MSCs when seeded in silicone tubes and compared the 
outcomes to empty silicone tubes and nerve grafts. Although the functional outcomes of both 
MSC-groups were significantly better than those of the other groups, there were no significant 
differences between differentiated or control MSCs.24 Watanabe compared undifferentiated 
MSCs, differentiated MSCs and Schwann cells in a rat facial nerve gap model and came to 
similar conclusions in that all groups had a comparable amount of nerve regeneration and all 
cell based strategies gave functional results close to that of autografts.56 
The advantages and disadvantages of differentiated versus undifferentiated MSCs in vitro 
and in vivo are presented in table 2. Although the majority of in vitro studies demonstrated a 
larger trophic potential of differentiated MSCs compared to undifferentiated MSCs, the in vivo 
outcomes were less unanimous. These conflicting results may be due to the embedded growth 
agents in the ECM that is generated in cell culture. Differences in differentiation methods, 
dosing and efficiency of cell delivery methods, and the composition of the nerve substitutes 
could affect the persistence of differentiation in vivo in the absence of the differentiation 
medium and could account for different outcomes. Further careful studies are required to 
confirm differentiated MSCs preserve their described enhanced trophic function in vivo.
CONCLUSION
Adipose derived MSCs are easy to access, deFfigrive, expand and can be successfully 
differentiated into Schwann-like cells. Therefore, adipose derived MSCs, and in particular 
adipose derived MSCs differentiated into Schwann-like cells have been broadly studied in 
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the effort to improve the outcomes of peripheral nerve repair/reconstruction. The neural 
induction of MSCs by chemicals combined with growth factors (PDFG-AA, bFGF/FGF2, 
Forskolin, neuregulin-1/NRG1) remains the preferred method to obtain Schwann cell-
like differentiation and has been validated for human MSCs differentiation. To obtain the 
putative trophic effect of MSCs, they should be delivered in a timely and non-traumatic 
method. Dynamic seeding of MSCs on nerve grafts meets these criteria. Despite the wide 
interest in the use of both differentiated and undifferentiated MSCs in peripheral nerve 
repair, the optimal delivery and dosing of differentiated MSCs is a rather under-explored 
research topic. The advantages of using undifferentiated versus differentiated MSCs 
remain to be further defined. In vitro studies have shown that differentiated MSCs permit 
enhanced expression of neurotrophic genes and the secretion of neurotrophic proteins, 
resulting in increased neurite outgrowth when compared to undifferentiated MSCs. The 
beneficial effect of differentiated MSCs has not yet been convincingly confirmed in in vivo 
studies. Future studies are needed to determine the ideal method of delivery and optimal 
dosages of differentiated and undifferentiated MSCs to nerve allografts to ascertain their 
regenerative potential for peripheral nerve reconstruction. These studies should consider 
the ultimate goal of clinical applications, as well as be cognizant of the time and cost issues 
of peripheral nerve reconstruction/repair.
Table 2. Overview of the pros and cons of the use of undifferentiated versus differentiated MSCs in vitro 
and in vivo for peripheral nerve repair. MSCs = mesenchymal stem cells.
Cell type
In vitro In vivo
Pros Cons Pros Cons
Undifferentiated 
MSCs
• No extended 
preparation time
• No extra 
preparation costs
• Less expression 
of neurotrophic 
genes
• Less production 
of neurotrophic 
growth factors 
• No extended 
preparation time


















• Extended number 
and length of 
neurites




• Extra preparation 
costs










• Extra preparation 
costs
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Although undifferentiated MSCs and MSCs differentiated into Schwann-like cells have been 
extensively compared in vitro and in vivo, studies on the ability and efficiency of differentiated 
MSCs for delivery to nerve allografts are lacking. As this is essential for their clinical potential, 
the purpose of this study was to determine the ability of MSCs differentiated into Schwann-
like cells to be dynamically seeded on decellularized nerve allografts and to compare their 
seeding potential to that of undifferentiated MSCs. 
 
Methods
Fifty-six sciatic nerve segments from Sprague-Dawley rats were decellularized and MSCs were 
harvested from Lewis rat adipose tissue. Control and differentiated MSCs were dynamically 
seeded on the surface of decellularized allografts. Cell viability, seeding efficiencies, cell 
adhesion, distribution and migration were evaluated.
 
Results
The viability of both cell types was not influenced by the processed nerve allograft. Both cell 
types achieved maximal seeding efficiency after 12 hours of dynamic seeding, albeit that 
differentiated MSCs had a significantly higher mean seeding efficiency than control MSCs. 
Dynamic seeding resulted in a uniform distribution of cells among the surface of the nerve 
allograft. No cells were located inside the nerve allograft after seeding.
 
Conclusion
Differentiated MSCs can be dynamically seeded on the surface of a processed nerve allograft, 
in a similar fashion as undifferentiated MSCs. Schwann-like differentiated MSCs have a 
significantly higher seeding efficiency after 12 hours of dynamic seeding. We conclude that 
differentiation of MSCs into Schwann-like cells may improve the seeding strategy and the 
ability of nerve allografts to support axon regeneration. 
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INTRODUCTION
When it is impossible to repair an injured peripheral nerve by direct coaptation of the nerve 
ends, there are several options that can be used to restore the nerve’s function. These include 
interposition nerve autografts, processed nerve allografts or bio-absorbable hollow conduits. 
While many studies have compared these options, the autologous nerve remains the gold 
standard in clinical practice, especially for restoration of major motor nerves.1, 2 The limited 
availability and length of autografts requires the development of a replacement nerve that 
results in equal functional outcomes.3 Although their regenerating potency still needs to be 
improved, processed allografts have shown to be a promising option.2, 4-6
Stem cells are believed to be an important control element in tissue regeneration by producing 
proteins and molecules that enhance angiogenesis, inhibit scar formation, stimulate tissue 
regeneration and have immunomodulatory effects.7, 8 Their use has demonstrated potential to 
provide the needed extra biological support to processed nerve allografts.9-13 Adipose tissue 
is a valuable source for mesenchymal stem cells (MSCs) from the stromal vascular fraction as 
it is easily accessible and contains relatively large amounts of rapidly proliferating MSCs.14-18
Schwann cells, the original facilitators of nerve regeneration, have been confirmed as even 
better providers of biological support to processed nerve allografts than MSCs.19 However, 
their harvest requires the sacrifice of autologous nerve tissue. Another option to obtain 
Schwann-like cells is to chemically differentiate MSCs into Schwann-like cells.20-23 Several 
in-vitro studies have demonstrated the potential of differentiated Schwann-like MSCs in 
peripheral nerve repair, resulting in increased neurite outgrowth of motor neurons compared 
to undifferentiated MSCs.19, 24, 25
The trophic function of MSCs that results in enhanced gene expression and production of 
neurotrophic growth factors24, 26, does not require delivery of MSCs inside the nerve allograft. 
Because microinjection and soaking of MSCs damage both the cells and the allograft while 
reducing the number of uniformly attached cells, dynamic seeding offers a promising cell 
delivery strategy that has not been evaluated for differentiated MSCs.27-29 
The purpose of this study was to determine the ability of MSCs differentiated into Schwann-
like cells to be dynamically seeded on decellularized nerve allografts and to compare their 
seeding potential to that of control MSCs. This was investigated by three different sub-
studies that aimed to evaluate (I) the influence of processed nerve grafts on the viability of 
differentiated MSCs, (II) the seeding potential of Schwann-like MSCs on processed nerve 
grafts and temporal optimization of seeding duration, and (III) the survivability, distribution 
and migration of differentiated MSCs after seeding. 
MATERIALS AND METHODS
This study was approved by the IACUC institutional review committee and the Institutional 
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Review Board (IACUC protocol A3053-16).
Mesenchymal stem cell collection and characterization
Rat MSCs were obtained from the inguinal fat pad from Lewis rats and derived as previously 
published.18 The obtained MSCs were previously characterized by plastic adherence and 
pluripotency toward mesodermal lineages.29 For flow cytometric assessment of stem cell 
surface markers, MSCs in passage five were used. The expression of MSC surface markers 
(CD29 and CD90) and hemapoetic cell surface markers (CD34 and CD45) were tested and 
compared with three control samples. Cell suspensions were pre-incubated with Fc block 
(Purified Mouse Anti-Rat CD32, 0.5uG per 500uL; BD PharmingenTM, CA, USA) to avoid 
unspecific binding. Thereafter, CD29 antibody (CD29 antibody | HM beta 1-10; Bio-rad-
antibodies, CA, USA), CD90 antibody (CD90 Antibody | OX-7; Bio-rad-antibodies, CA, USA), 
CD45 antibody (CD45 antibody | OX-1; Bio-rad-antibodies, CA, USA) and CD34 (Mouse/Rat 
CD34 antibody; R&D systems Inc, MN, USA) were introduced to different samples. For the 
CD34-sample, the appropriate secondary reagent was added as well (Donkey Anti-Sheep IgG 
Fluorescein-conjugated antibody; R&D systems Inc, MN, USA). Cells were washed twice in 
flow cytometry buffer and centrifuged at 300g for five minutes after each wash. Finally, 7-AAD 
staining was added to each sample to exclude dead cells. Flow cytometry was performed with 
a BD FACScan flow cytometer. 
Mesenchymal Stem Cell differentiation into Schwann-like cells
MSC differentiation into Schwann-like cells was accomplished according to the extensively 
tested protocol of Kingham and colleagues.18 Briefly, after two preparatory steps with 
ß-mercaptoethanol (Sigma-Aldrich corp., MO, USA) and all-trans-retinoic acid (Sigma-Aldrich 
Corp., MO, USA), the growth medium was replaced by differentiation medium containing 
Forskolin (Sigma-Aldrich corp., MO, USA), basic fibroblast growth factor (bFGF; PeproTech, 
NJ, USA), platelet-derived growth factor (PDGF-AA; PeproTech, NJ, USA) and Neuregulin-1 
ß1 (NRG1-b1; R&D systems Inc, MN, USA). Successful MSC differentiation was verified by 
immunocytochemistry for Schwann cell marker S100 (Rabbit anti-S100; ThermoFisher 
Scientific, MA, USA), glial cell marker GFAP (Glial fibrillary acidic protein, mouse anti-GFAP; 
ThermoFisher Scientific, MA, USA) and Neurotrophin Receptor p75 (p75 NTR, rabbit anti-p75 
NTR; ThermoFisher Scientific, MA, USA). Goat anti-rabbit FITC and goat anti-mouse Cyanine-3 
(CY3) (both ThermoFisher Scientific, MA, USA) were used as secondary antibodies. Cell nuclei 
were labeled with DAPI (4’,6-diamindino-2-phenylindole, ThermoFisher Scientific, MA, USA). 
The fluorescent expression of the differentiated MSCs was compared to the expression of 
undifferentiated MSCs and Schwann cells.
Nerve allograft processing
Fifty-six sciatic nerves were obtained from 28 Sprague-Dawley rats weighing 250-350 grams 
and were decellularized according to the protocol of Hundepool and colleagues.30 In this 
5-day protocol, the nerve allografts are exposed to elastase, resulting in less cellular debris 
with preservation of the ultrastructure of the nerve. Sprague-Dawley rats were specifically 
selected as there is a known histocompatibility mismatch to Lewis rats.31, 32 The nerves were 
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sterilized using g-irradiation and stored at 4° Celsius after processing.
 
Analysis of Cell viability
To assess the influence of chemical products used to process the allografts on the MSC-
viability and to compare the vulnerability of differentiated MSCs and control MSCs, 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) 
(MTS) assays (CellTiter 96® Aqueous One Solution Cell Proliferation Assay; Promega 
Corporation, WI, USA) were carried out according to the manufacturer’s protocol.33 This assay 
is a colorimetric method to determine the number of viable cells. Living cells in culture have 
metabolic activity and will convert the added reagent in formazan. Formazan quantity is 
directly correlated to the amount of 490nm absorbance and can therefore be measured with 
an Infinite® 200 Pro TECAN Reader (Tecan Trading AG, Switzerland). 
Undifferentiated and differentiated MSCs (5,000 in 100µL growth medium per well) were 
transferred to a p-HEMA (Poly 2-hydroxyethyl methacrylate; Sigma-Aldrich Corp., MO, USA) 
coated 96-well plate, to prevent cells from migrating to the plastic surface of the well. After 
soaking in growth medium for two hours, 48 2mm-segments of processed nerve allografts 
were divided among the wells containing the cells. The medium was changed every 72 
hours; undifferentiated MSCs were cultured in normal growth medium, differentiated 
MSCs were cultured in differentiation medium. The metabolic activity of undifferentiated 
MSCs (undifferentiated MSCs + pHEMA + allograft) was compared to differentiated MSCs 
(differentiated MSCs + pHEMA + allograft) on four estimated time points (T = 1, 2, 3 and 
7 days). The remaining groups represented normal cell viability (pHEMA + undifferentiated 
MSCs and pHEMA + differentiated MSCs) and negative controls (no cells). For each group, 
the metabolic activity of three replicates per sample was tested twice on each time point. 
Colorimetric assays were performed with the Infinite® 200 Pro TECAN Reader (Tecan 
Trading AG, Switzerland) at an absorbance wavelength of 490nm. The metabolic activity of 
undifferentiated MSCs and differentiated MSCs in the vicinity of an allograft was expressed as 
a ratio of the metabolic activity of undifferentiated MSCs and differentiated MSCs without an 
allograft. The experimental design is shown in table 1.
Table 1. Experimental design experiment 1.
MSCs: Mesenchymal Stem Cells
MTS assay: (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
assay
Group Description Time points N Outcome 
measurements
I Undifferentiated MSCs + 
allograft
T1 = 1 day
T2 = 2 days
T3 = 3 days
T4 = 7 days
3 samples per 
group for each 
time point
Metabolic activity (MTS 
assay)
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Seeding efficiency, cell adhesion, distribution and migration 
A dynamic seeding strategy that was previously described for undifferentiated MSCs was used 
in this study.29 In total, 36 processed nerve graft segments of 10mm in length were soaked 
in growth medium for two hours to remove any toxic decellularization agents and divided 
among conical tubes containing 10mL growth medium with one million undifferentiated 
MSCs or differentiated MSCs per nerve. These tubes were placed on a rotating system which 
was rotated for six, 12 or 24 hours at 37°C (n = 6 per group per seeding duration). Seeding 
efficiency on each time point was determined by cell counts in the cell supernatant of all the 
different samples; this provided the average number of free floating cells in the tubes and the 
average number of cells that were adherent to the nerve.  Two supernatant samples (10mL) were 
taken out of each of the conical tubes after the seeding duration had passed. Subsequently, 
one investigator performed three cell counts on each of the supernatant samples. So for each 
nerve sample (n=6 per group per time point), 6 cell counts were averaged for final analysis in 
order to minimize potential error. 
The viability and distribution of the cells seeded on the nerve grafts was studied by live/
dead Cell Viability Assays (Invitrogen, Life Technologies Corporation, NY, USA) and Hoechst 
stain (Hoechst stain solution; Sigma-Aldrich Corp., MO, USA) and visualized using a confocal 
microscope (Zeiss LSM 780 confocal microscope). The live/dead and Hoechst stain assays 
were prepared by one investigator. Both the Live/dead stain and the Hoechst stain were 
obtained according to standardized protocols; incubation of the samples with live/dead stain 
(Invitrogen, Life Technologies Corporation, NY, USA) or Hoechst stain mixture (Hoechst stain 
solution; Sigma-Aldrich Corp., MO, USA) for 20 minutes after which the samples were washed 
with PBS. Both stains were performed on three samples per group per seeding duration. 
Cell shape and distribution was evaluated by Scanning Electron Microscopy (SEM) of the three 
remaining seeded samples per group per time point. To obtain SEM images, the samples 
were transferred to 2% Trump’s fixative solution (37% formaldehyde and 25% glutaraldehyde) 
overnight, washed in phosphate buffer, and rinsed in water and dehydrated through a graded 
series of ethanol. Subsequently, the samples were critical point dried using carbon dioxide, 
mounted on an aluminum stub and sputter-coated for 60 seconds using gold-palladium. The 
samples were imaged in a Hitachi S-4700 cold field emission scanning electron microscope 
(Hitachi High Technologies America, Inc., IL, USA) at 5kV accelerating voltage. The preparation 
and the imaging of the SEM samples were performed by the Microscopy and Cell analysis 
core lab of the Mayo Clinic. The distribution of cells on the outer surface was only assessed 
and described subjectively and were therefore not blinded. An overview of the experimental 
design is depicted in table 2.
Two extra processed nerves per group were seeded with the previously estimated optimal 
seeding duration and transferred to 10% formalin and processed and embedded in paraffin 
to evaluate the migration of cells into the nerve grafts. Three 5µM sections of the proximal- 
and mid-nerve segment were sectioned and Hoechst stained.  The Hoechst-stained cross-
sectional segments of the nerves were blinded for the objective assessment of present cells 
on the inner surface of the samples (present versus absent). The cells were visualized with a 
confocal microscope (Zeiss LSM 780 confocal microscope; Zeiss, Germany). 
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Table 2. Experimental design experiment 2. MSCs: 
Mesenchymal Stem Cells, SEM: Scanning Electron Microscopy
 
Statistical analysis
Seeding efficiencies are displayed ± Standard Error of the Mean. Significance of the 
interaction between cell type, time and outcome were analyzed with two-way ANOVA. If 
the interaction was significant, the within and between group comparisons were analyzed 
with the Kruskal-Wallis test, followed by pairwise comparisons using Wilcoxon rank-sum 
tests with Bonferroni correction. A value of p < 0.05 was considered statistically significant. 
RESULTS
Mesenchymal stem cell collection
Flow cytometric analysis showed that the cultured rat MSCs were positive for mesenchymal 
stem cell markers CD29 (88.2%) and CD90 (88.3%) and negative for the hematopoetic cell 
markers CD34 (91.1%) and CD45 (86.0%), demonstrating that MSCs were definitively the cell 
lineage utilized in this study.
Mesenchymal stem cell differentiation into Schwann-like cells
The morphology of differentiated MSCs changed in vitro in a more spindle-like shape, typical 
for Schwann cells. In contrast to undifferentiated MSCs, Schwann cells and differentiated 
MSCs showed positive immunofluorescence for Schwann cell surface markers S100 Calcium 
Binding Protein B (S100B), Glial Fibrillary Acidic Protein (GFAP) and Nerve Growth Factor 
Receptor (NGFR/P75NTR), which verified successful differentiation into Schwann-like cells 
(figure 1).18
Cell viability
The cell viability of undifferentiated and differentiated MSCs were equal and remained 
constant during the first three time points, after which the viability of both cell types slightly 
decreased. No decrease in cell viability was observed upon co-culture of MSCs with the 
processed nerve allograft. The viability of differentiated MSCs in the vicinity of an allograft 
approaches the viability of differentiated MSCs alone over time (p=0.270), while the viability 
of undifferentiated MSCs with the allograft increased over time compared to undifferentiated 
MSCs alone; the increased viability ratio between 2 and 3 days of culture was statistically 
significant (p=0.025). 





I Undifferentiated MSCs 
+ nerve allograft T1 = 6 hours
T2 = 12 hours
T3 = 24 hours
6 samples per 
group per time 
point
• Cell counts (n=6)
• Live/dead + Hoechst 
stains (n=3)
• SEM (n=3)II Differentiated MSCs + 
nerve allograft
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The differences between both cell-group ratios after 3 and 7 days of culture were statistically 
significant as well (p=0.009 and p=0.026). These results imply that chemical processing of 
nerve allografts does not generate a surface that decreases cell-viability. Interestingly, 
the demonstrated ratios suggest that the processed allograft stimulates the viability of 
undifferentiated MSCs, while this effect is not as obvious for differentiated MSCs. The 
absorbance ratios, and thus the viability ratios of the different cell cultures over time are 
shown in figure 2.
Figure 1. Differentiation of MSCs into Schwann-like cells. Immunocytochemical comparison between 
undifferentiated MSCs (a, d, g), differentiated MSCs (b, e, h) and Schwann cells (c, f, i). Cells are tested 
for the presence of Schwann cell marker S100 (a, b, c, green), glial cell marker GFAP (d, e, f, red) and 
neurotrophin Receptor p75 (g, h, i, green). Cell nuclei are DAPI-stained (blue). 
Cell adhesion
After six hours of seeding, only 24.38% (±6.34) of undifferentiated MSCs and 43.33% (±3.02) 
of differentiated MSCs were attached to the processed nerve allografts. Subsequently, 
these percentages increased to 80.00% (±1.73) (undifferentiated MSCs) and 94.54% (±1.50) 
(differentiated MSCs) after 12 hours of dynamic seeding and changed to 82.00% (±5.92) 
(undifferentiated MSCs) and 77.50% (±6.67) (differentiated MSCs) after 24 hours. ‘Between 
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group’ analyses did not show any signifi cant differences. ‘Within group’ analyses showed a 
signifi cant interaction between seeding effi ciency and seeding duration for undifferentiated 
MSCs (p=0.021) and differentiated MSCs (p=0.007). Pairwise comparisons revealed that the 
increase between 6 and 12 hours of seeding (p=0.029) undifferentiated MSCs was statistically 
signifi cant, but not between 12 and 24 hours (p=0.486). The increased seeding effi ciency 
between 6 and 12 hours and the decrease between 12 and 24 hours of seeding of differentiated 
MSCs were statistically signifi cant (both p=0.029). Considering a shorter seeding duration is 
more cost effective and time effi cient, the optimal dynamic seeding duration was determined 
to be 12 hours for both groups. The seeding effi ciencies at different time points are shown in 
fi gure 3.
Cell distribution and migration
Dynamic seeding resulted in a layer of viable cells on the surface of the processed nerve 
allograft with no major differences in distribution between the cell-types and different 
seeding durations. Virtually no dead cells were apparent on the processed nerve allograft 
during dynamic seeding, which suggests that only viable cells are able to attach to the nerve. 
Although subjective, the differentiated MSCs seem to seed in a more clustered fashion than 
undifferentiated MSCs (fi gure 4a-b). Hoechst stain (not shown) and SEM of the surface of the 
seeded nerve grafts showed a similar distribution and illustrated that the cells retain their 
typical shapes during dynamic seeding (fi gure 4c-f). None of the cross-sectional segments of 
the proximal and mid-portion of the nerves showed migration of both undifferentiated MSCs 
and differentiated MSCs into the nerve graft (fi gure 4g-h). 
Figure 2. Metabolic activity of undifferentiated and differentiated MSCs after a processed nerve allograft 
was introduced to their well. The activity is expressed as a ratio of the metabolic activity of MSCs without 
a processed nerve allograft. Undifferentiated MSCs had a signifi cantly higher metabolic ratio after 3 
(p=0.009) and 7 (p=0.026) days of culture. Error bars = SEM. **=p<0.01, *=p<0.05
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Figure 3. Seeding effi ciency of three different seeding durations. The effi ciency is expressed as a 
percentage of the cells provided per nerve (1 million cells). The increase between 6 and 12 hours of 
seeding (p=0.029) undifferentiated MSCs was statistically signifi cant. The increased seeding effi ciency 
of differentiated MSCs between 6 and 12 hours and the decrease between 12 and 24 hours were also 
statistically signifi cant (both p=0.029). Error bars = SEM. *=statistical signifi cance, p<0.05
DISCUSSION
The overall purpose of this study was to determine (I) the infl uence of processed nerve grafts 
on the viability of differentiated MSCs, (II) the seeding potential and optimal seeding duration 
of differentiated MSCs on processed nerve grafts, and (III) the survivability, distribution and 
migration of differentiated MSCs after seeding. The reagents used to process the nerve 
allografts in this study30 did not infl uence the metabolic activity of either differentiated MSCs 
or undifferentiated MSCs. Similar to undifferentiated MSCs, the  differentiated MSCs were 
successfully seeded on a processed nerve allograft using a previously reported dynamic 
seeding strategy29, without compromising the quality of the inner nerve ultrastructure. The 
optimal dynamic seeding time for both groups was 12 hours, which led to the attachment of 
viable undifferentiated MSCs and differentiated MSCs to the surface of the processed nerve 
allograft. Both types of MSCs distributed among the nerve allograft in a uniform manner and 
did not migrate into the ultrastructure of the nerve allograft. 
In vitro, Schwann-like MSCs support superior neurite outgrowth when co-cultured with motor-
neurons and express higher levels of neurotrophic and angiogenic genes compared to 
undifferentiated MSCs.18, 19, 24, 25 The potential for uncontrolled proliferation or differentiation 
of MSCs into non-neural lineages is another argument to differentiate MSCs before 
implementation. The pluripotency of undifferentiated MSCs makes them diffi cult to control in 
vivo. The concern that their potential to promote neoangiogenesis and to regulate the immune 
response may lead to tumor growth or metastasis has been described, but has not been 
confi rmed yet.34, 35 The disadvantages of differentiating MSCs into Schwann-like cells include 
the additional effort and extended preparation time which may delay the period between 
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nerve-injury and surgery. In vivo studies demonstrating no differences in functional outcomes 
compared to undifferentiated MSCs also favor the use of undifferentiated MSCs in the clinical 
setting.36, 37 The absence of in vivo differences is potentially caused by the hypothesized 
limited survivability of differentiated cells10 or an inefficient delivery of differentiated MSCs. 
Published delivery methods vary widely, while none of the delivery methods has specifically 
been tested on differentiated MSCs. Thus, to date there is no compelling evidence for the use 
of either undifferentiated MSCs or differentiated MSCs for seeded nerve allografts used for 
segmental motor nerve reconstruction.
Figure 4. 
Undifferentiated MSCs (left) 
and differentiated MSCs (right) 
seeded on a nerve allograft. 
4a-b. Viable cells are visualized 
in green, dead cells in red 
(not present). 4c-f. Scanning 
Electron Microscopy images of 
undifferentiated MSCs seeded 
onto a nerve allograft (left) and 
differentiated MSCs seeded 
on a nerve allograft (right) in 
multiple magnifications (500X, 
2000X and 3000X), showing the 
different morphology of the 
cells when seeded on the nerve 
allograft. 4g-h. Cross-sectional 
images of the mid-portions 
of processed nerve allografts 
seeded with undifferentiated 
(left) and differentiated (right) 
MSCs. Cell nuclei are Hoechst-
stained (bright blue). The inner 
ultrastructure of the nerve does 
not contain any cells.
Cell-injection and nerve-
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soaking in cell-solutions are used as delivery methods of MSCs with the rationale that they 
have a structural function as Schwann cells that need to be delivered within the nerve allograft 
itself. Injection may be traumatic to both MSCs and the ultrastructure of the nerve allograft and 
results in an unequal distribution of the delivered cells.27, 38-40 The average diameter of MSCs 
exceeds the calibers of myelinated axon fibers, suggesting that MSCs can block axon ingrowth 
when delivered inside the nerve graft.41-43 Soaking techniques deliver lower number of cells in a 
nonuniform distribution.28 
It has been recently reported that growth factors and cytokines produced by MSCs may 
enhance nerve regeneration, while not necessitating intraneural placement of the MSCs.7, 44 The 
straightforward dynamic seeding strategy of Rbia and colleagues successfully attaches large 
numbers of undifferentiated MSCs to the surface of a processed nerve allograft without harming 
the inner ultra-structure of the allograft.29 The same technique resulted in the same optimal 
seeding duration for undifferentiated MSCs in this study, indicating a high reproducibility of the 
Rbia method. The seeding of differentiated MSCs is less well established and differentiation of 
cells may decrease their potential to attach to processed nerve allografts, possibly due to their 
changes in cellular morphology (e.g., spindle-like shape).10 This study demonstrated there was 
no decrease in attachment efficiency when MSCs are differentiated. Based on our experience, 
dynamic seeding of differentiated MSCs onto a processed nerve allograft is possible and results 
in a uniform distribution of large amounts of differentiated MSCs (and undifferentiated MSCs) 
on the surface of the nerve allograft which has not been accomplished by other previously 
described methods. 
Both cell types have previously shown to produce neurotrophic and angiogenic factors and 
have been allocated an immunomodulatory role. 7, 18, 19, 24, 25, 44 The porous epineurium of the 
processed nerve allografts (demonstrated in figure 3) allows for these factors to both regulate 
the immune response and angiogenesis in the surroundings of the regenerating nerve, and 
stimulate nerve regeneration inside the nerve allograft, while the cells remain on the outer 
surface of the graft. The seeded MSCs form an addition to the circulating stem cells normally 
attracted to the regenerating nerve, also functioning from outside the epineurium. 
A limitation of this study is the in vitro setting, which may not translate into results expected for an 
in vivo setting. In vitro studies permit testing of the seeding potential of undifferentiated MSCs 
and differentiated MSCs without having to sacrifice extra animals. With the described strategy, it 
would approximately take up two to five weeks after nerve injury to obtain a processed allograft 
seeded with patient’s own (undifferentiated or differentiated) MSCs. Although peripheral 
nerve injuries are ideally repaired as soon as possible after injury, a two- or five-week delay that 
eventually leads to the desirable improved nerve regeneration would be clinically applicable. 
Furthermore, the utility of methods to deliver undifferentiated MSCs and differentiated MSCs 
to the surface of a nerve graft relies on the idea that MSCs at least have a partly trophic function 
and that growth factors and cytokines produced by them will migrate through the epineurium 
and enhance nerve regeneration. This hypothesis needs to be confirmed both in vitro and in 
vivo. The current study is the essential first step in testing this hypothesis. 
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We successfully differentiated MSCs into Schwann-like cells and dynamically seeded them 
onto a processed nerve allograft. The viability of undifferentiated MSCs and differentiated 
MSCs was not influenced by the processed nerve allograft. Both cell types distributed equally 
among the nerve allograft, remained on the surface of the allograft and did not migrate into 
the graft. Thus, seeding of nerve allografts with Schwann-like MSCs can be further considered 
for in vivo studies for nerve repair. 
Conflict of interest statement
None of the authors has a conflict of interest. This study was funded by the NIH R01, ‘Bridging the gap: 
angiogenesis and stem cell seeding of processed nerve allograft’. 1 RO1 NS102360-01A1
Acknowledgements
We thank Patricia F. Friedrich for assistance with the preparations of the experiments. 




1.  Rbia N, Shin AY. The Role of Nerve Graft Substitutes in Motor and Mixed Motor/Sensory Peripheral 
Nerve Injuries. J Hand Surg Am 2017: 42: 367-77.
2.  Giusti G, Willems WF, Kremer T, et al. Return of motor function after segmental nerve loss in a rat 
model: comparison of autogenous nerve graft, collagen conduit, and processed allograft (AxoGen). 
J Bone Joint Surg Am 2012: 94: 410-7.
3. FF IJ, Nicolai JP, Meek MF. Sural nerve donor-site morbidity: thirty-four years of follow-up. Ann Plast 
Surg 2006: 57: 391-5.
4.  Cho MS, Rinker BD, Weber RV, et al. Functional outcome following nerve repair in the upper 
extremity using processed nerve allograft. J Hand Surg Am 2012: 37: 2340-9.
5.  Moore AM, MacEwan M, Santosa KB, et al. Acellular nerve allografts in peripheral nerve regeneration: 
A comparative study. MUSCLE NERVE 2011: 44: 221-34.
6.  Whitlock EL, Tuffaha SH, Luciano JP, et al. Processed allografts and type I collagen conduits for 
repair of peripheral nerve gaps. MUSCLE NERVE 2009: 39: 787-99.
7.  Caplan AI. Adult Mesenchymal Stem Cells: When, Where, and How. Stem Cells Int 2015: 2015: 
628767.
8.  Cao F, Liu T, Xu Y, Xu D, Feng S. Culture and properties of adipose-derived mesenchymal stem cells: 
characteristics in vitro and immunosuppression in vivo. Int J Clin Exp Pathol 2015: 8: 7694-709.
9.  Moattari M, Kouchesfehani HM, Kaka G, et al. Chitosan-film associated with mesenchymal stem 
cells enhanced regeneration of peripheral nerves: A rat sciatic nerve model. J Chem Neuroanat 
2017: 88: 46-54.
10.  Fairbairn NG, Meppelink AM, Ng-Glazier J, Randolph MA, Winograd JM. Augmenting peripheral 
nerve regeneration using stem cells: A review of current opinion. World J Stem Cells 2015: 7: 11-26.
11.  Zhao Z, Wang Y, Peng J, et al. Repair of nerve defect with acellular nerve graft supplemented by 
bone marrow stromal cells in mice. Microsurgery 2011: 31: 388-94.
12.  Wang Y, Zhao Z, Ren Z, et al. Recellularized nerve allografts with differentiated mesenchymal stem 
cells promote peripheral nerve regeneration. Neurosci Lett 2012: 514: 96-101.
13.  Hundepool CA, Nijhuis TH, Mohseny B, Selles RW, Hovius SE. The effect of stem cells in bridging 
peripheral nerve defects: a meta-analysis. J Neurosurg 2014: 121: 195-209.
14.  Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J. Same or not the same? Comparison 
of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem 
Cells Dev 2012: 21: 2724-52.
15.  Mahmoudifar N, Doran PM. Mesenchymal Stem Cells Derived from Human Adipose Tissue. 
Methods Mol Biol 2015: 1340: 53-64.
16.  Yoshimura H, Muneta T, Nimura A, et al. Comparison of rat mesenchymal stem cells derived from 
bone marrow, synovium, periosteum, adipose tissue, and muscle. Cell Tissue Res 2007: 327: 449-62.
17.  Safford KM, Hicok KC, Safford SD, et al. Neurogenic differentiation of murine and human adipose-
derived stromal cells. Biochem Biophys Res Commun 2002: 294: 371-9.
18.  Kingham PJ, Kalbermatten DF, Mahay D, et al. Adipose-derived stem cells differentiate into a 
Schwann cell phenotype and promote neurite outgrowth in vitro. Exp Neurol 2007: 207: 267-74.
19.  Ladak A, Olson J, Tredget EE, Gordon T. Differentiation of mesenchymal stem cells to support 
peripheral nerve regeneration in a rat model. Exp Neurol 2011: 228: 242-52.
20.  di Summa PG, Kingham PJ, Raffoul W, et al. Adipose-derived stem cells enhance peripheral nerve 
regeneration. J Plast Reconstr Aesthet Surg 2010: 63: 1544-52.
21.  Ao Q, Fung CK, Tsui AY, et al. The regeneration of transected sciatic nerves of adult rats using 
chitosan nerve conduits seeded with bone marrow stromal cell-derived Schwann cells. Biomaterials 
2011: 32: 787-96.
22.  Chen X, Wang XD, Chen G, et al. Study of in vivo differentiation of rat bone marrow stromal cells into 
schwann cell-like cells. Microsurgery 2006: 26: 111-15.
23.  Tomita K, Madura T, Mantovani C, Terenghi G. Differentiated adipose-derived stem cells promote 
Proefschrift.indd   56 19-07-21   22:26
3
MSC-seeding on processed nerve allografts
57
myelination and enhance functional recovery in a rat model of chronic denervation. J Neurosci Res 
2012: 90: 1392-402.
24.  Kingham PJ, Kolar MK, Novikova LN, Novikov LN, Wiberg M. Stimulating the neurotrophic and 
angiogenic properties of human adipose-derived stem cells enhances nerve repair. Stem Cells Dev 
2014: 23: 741-54.
25.  Tomita K, Madura T, Sakai Y, et al. Glial differentiation of human adipose-derived stem cells: 
implications for cell-based transplantation therapy. Neuroscience 2013: 236: 55-65.
26.  Liu Y, Zhang Z, Qin Y, et al. A new method for Schwann-like cell differentiation of adipose derived 
stem cells. Neurosci Lett 2013: 551: 79-83.
27.  Jesuraj NJ, Santosa KB, Newton P, et al. A systematic evaluation of Schwann cell injection into 
acellular cold-preserved nerve grafts. J Neurosci Methods 2011: 197: 209-15.
28.  Thompson MJ, Patel G, Isaacs J, et al. Introduction of neurosupportive cells into processed acellular 
nerve allografts results in greater number and more even distribution when injected compared to 
soaking techniques. Neurol Res 2017: 39: 189-97.
29.  Rbia N, Bulstra LF, Bishop AT, van Wijnen AJ, Shin AY. A simple dynamic strategy to deliver stem 
cells to decellularized nerve allografts. Plast Reconstr Surg 2018.
30.  Hundepool CA, Nijhuis TH, Kotsougiani D, et al. Optimizing decellularization techniques to create 
a new nerve allograft: an in vitro study using rodent nerve segments. Neurosurg Focus 2017: 42.
31.  Hudson TW, Zawko S, Deister C, et al. Optimized acellular nerve graft is immunologically tolerated 
and supports regeneration. Tissue Eng 2004: 10: 1641-51.
32.  Kumta S, Yip K, Roy N, Lee SK, Leung PC. Revascularisation of bone allografts following vascular 
bundle implantation: an experimental study in rats. Arch Orthop Trauma Surg 1996: 115: 206-10.
33.  Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for 
cell growth assays in culture. Cancer Commun 1991: 3: 207-12.
34.  Volarevic V, Markovic BS, Gazdic M, et al. Ethical and Safety Issues of Stem Cell-Based Therapy. Int 
J Med Sci 2018: 15: 36-45.
35.  Lazennec G, Jorgensen C. Concise review: adult multipotent stromal cells and cancer: risk or 
benefit? Stem Cells 2008: 26: 1387-94.
36.  Orbay H, Uysal AC, Hyakusoku H, Mizuno H. Differentiated and undifferentiated adipose-derived 
stem cells improve function in rats with peripheral nerve gaps. J Plast Reconstr Aesthet Surg 2012: 
65: 657-64.
37.  Watanabe Y, Sasaki R, Matsumine H, Yamato M, Okano T. Undifferentiated and differentiated 
adipose-derived stem cells improve nerve regeneration in a rat model of facial nerve defect. J 
Tissue Eng Regen Med 2017: 11: 362-74.
38.  Garvican ER, Cree S, Bull L, Smith RK, Dudhia J. Viability of equine mesenchymal stem cells during 
transport and implantation. Stem Cell Res Ther 2014: 5: 94.
39.  Agashi K, Chau DY, Shakesheff KM. The effect of delivery via narrow-bore needles on mesenchymal 
cells. Regen Med 2009: 4: 49-64.
40.  Mamidi MK, Singh G, Husin JM, et al. Impact of passing mesenchymal stem cells through smaller 
bore size needles for subsequent use in patients for clinical or cosmetic indications. J Transl Med 
2012: 10: 229.
41.  Sunderland S, Lavarack JO, Ray LJ. The caliber of nerve fibers in human cutaneous nerves. J COMP 
NEUROL 1949: 91: 87-101.
42.  Ryu YJ, Cho TJ, Lee DS, Choi JY, Cho J. Phenotypic characterization and in vivo localization of 
human adipose-derived mesenchymal stem cells. Mol Cells 2013: 35: 557-64.
43.  Ge J, Guo L, Wang S, et al. The size of mesenchymal stem cells is a significant cause of vascular 
obstructions and stroke. Stem Cell Rev 2014: 10: 295-303.
44.  Caplan AI, Hariri R. Body Management: Mesenchymal Stem Cells Control the Internal Regenerator. 
Stem Cells Transl Med 2015: 4: 695-701.
Proefschrift.indd   57 19-07-21   22:26
Proefschrift.indd   58 19-07-21   22:26
Chapter 4
Gene expression profi les of diff erentiated and 
undiff erentiated adipose derived mesenchymal 
stem cells dynamically seeded onto a 
processed nerve allograft
Femke Mathot, Nadia Rbia, Roman Thaler, Allen T. Bishop, 
Andre J. van Wijnen, Alexander Y. Shin
Gene. 2020 January;724:144151





Differentiation of mesenchymal stem cells (MSCs) into Schwann-like cells onto processed 
nerve allografts may support peripheral nerve repair. The purpose of this study was to 
understand the biological characteristics of undifferentiated and differentiated MSCs before 
and after seeding onto a processed nerve allograft by comparing gene expression profiles.
Methods
MSCs from Lewis rats were cultured in maintenance media or differentiated into Schwann-like 
cells. Both treatment groups were dynamically seeded onto decellularized nerve allografts 
derived from Sprague-Dawley rats. Gene expression was quantified by quantitative polymerase 
chain reaction (qPCR) analysis of representative biomarkers, including neurotrophic (GDNF, 
PTN, GAP43, PMP22), angiogenic (CD31, VEGF1), extracellular matrix (ECM) (COL1A1, 
COL3A1, FBLN1, LAMB2) or cell cycle (CAPS3, CCBN2) genes. Gene expression values were 
statistically evaluated using a 2-factor ANOVA with repeated measures. 
Results
Baseline gene expression of undifferentiated and differentiated MSCs was significantly altered 
upon interaction with processed nerve allografts. Interaction between processed allografts 
and undifferentiated MSCs enhanced expression of neurotrophic (NGF, GDNF, PMP22), 
ECM (FBLN1, LAMB2) and regulatory cell cycle genes (CCNB2) during a 7-day time course. 
Interactions of differentiated MSCs with nerve allografts enhanced expression of neurotrophic 
(NGF, GDNF, GAP43), angiogenic (VEGF1), ECM (FBLN1) and regulatory cell cycle genes 
(CASP3, CCNB2) within one week.
Conclusions
Dynamic seeding onto processed nerve allografts modulates temporal gene expression 
profiles of differentiated and undifferentiated MSCs. These changes in gene expressions may 
support the reparative functions of MSCs in supporting nerve regeneration in different stages 
of axonal growth.
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INTRODUCTION 
Although many efforts have been made to find a neural tissue substitute equivalent to nerve 
autografts, autografts currently remain the gold standard in the reconstruction of critical 
nerve defects. 1-5 Nerve allografts are a promising option, but decellularization is required to 
prevent an immune response in the recipient. While necessary for successful transplantation, 
decellularization removes all cellular components including Schwann cells from allograft nerve 
tissues.6, 7 Schwann cells are fundamental for peripheral nerve formation and play a critical role in 
peripheral nerve regeneration by producing axonotrophic factors and providing remyelination.8, 
9 It has been postulated that direct or indirect addition of growth factors may enhance nerve 
regeneration in processed nerve allografts, replacing or mimicking the function of the absent 
Schwann cells. Yet, direct delivery of growth factors has not resulted in improved outcomes 10-12, 
suggesting that cellular mechanisms are necessary for the growth factors to be functional.
Indirect delivery of growth factors could be provided by mesenchymal stromal cells (MSCs). 
MSCs are biologically important for tissue repair and regeneration by influencing the immune 
system, enhancing angiogenesis and inhibiting scar formation.13, 14 MSCs are mostly obtained 
from either bone marrow or adipose tissue. Adipose tissue can be easily harvested and contains 
large amounts of MSCs that proliferate rapidly in optimized cell culture medium.15-18 When 
added to decellularized nerve allografts, adipose-derived MSCs produce growth factors that 
support tissue repair in response to interactions with the extracellular matrix (ECM)  of the 
allograft nerve.19-24 
The interaction between the ECM of the decellularized nerve allograft and the MSCs influences 
the differentiation state of MSCs and their growth factor production.25, 26 It has been proposed 
that inducing neural differentiation of MSCs prior to the addition to a decellularized allograft, 
may enhance nerve regeneration when compared to undifferentiated MSCs. Multiple studies 
have shown that it is possible to differentiate adipose derived MSCs into Schwann-like cells 
18, 27-29 and in vitro studies demonstrated increased neurite outgrowth of motor neurons when 
exposed to differentiated MSCs compared to  undifferentiated MSCs.22, 30-36 While it is plausible 
that the biological properties of differentiated MSCs may be altered upon interaction with the 
ECM of nerve allografts, there is a paucity of molecular data that characterizes these putative 
differences. The purpose of this study was to evaluate temporal profiles of gene expression 
in undifferentiated and differentiated MSCs at multiple time points after dynamic seeding 37, 
38 onto a decellularized nerve allograft. Determination of differences in gene expression may 




This study was approved by the IACUC institutional review committee and the Institutional 
Review Board (IACUC protocol A3053-16). The experimental design is shown in table 1.
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Table 1. Experimental design.
MSCs = mesenchymal stromal cells
qPCR analysis = quantitative polymerase chain reaction analysis
Mesenchymal stromal cell collection and characterization
Rat mesenchymal stromal cells were obtained from the inguinal fat pad of isogenic Lewis 
rats and derived as previously described.16 Lewis rat MSCs were previously characterized by 
adherence to plastic, pluripotency towards mesodermal lineages, the presence of stem cell 
surface markers CD29 and CD90 and the absence of hemapoetic cell surface markers CD34 
and CD45.37, 38 MSCs were cultured in normal growth medium consisting of a-MEM (Advanced 
MEM (1x); Life Technologies Corporation, NY, USA), 5% platelet lysate (PLTMax®; Mill Creek 
Life Sciences, MN, USA), 1% Penicillin/Streptomycin (Penicillin-Streptomycin (10.000 U/mL; 
Life Technologies Corporation, NY, USA), 1% GlutaMAX (GlutaMAX Supplement 100X; Life 
Technologies Corporation, NY, USA) and 0.2% Heparin (Heparin Sodium Injection, USP, 1.000 
USP units per mL; Fresenius Kabi, IL, USA).
Mesenchymal Stem Cell differentiation into Schwann-like cells
The differentiation protocol of Kingham and colleagues was used to differentiate MSCs into 
Schwann-like cells.16 This protocol describes MSC-culture in differentiation medium that 
consists of 70 mL forskolin (Sigma-Aldrich corp., MO, USA), 5 mL of basis Fibroblastic Growth 
Factor (bFGF; PeproTech, NJ, USA), 2.5mL of Platelet Derived Growth Factor (PDGF-AA; 
PeproTech, NJ, USA), and 10 mLof Neuregulin 1-b1 (NRG1-b1; R&D systems Inc, MN, USA) 
per 50mL normal growth medium. In accordance with the protocol, differentiation of MSCs 
was confirmed by immunocytochemistry for Schwann cell markers S100 (Rabbit anti-S100; 
ThermoFisher Scientific, MA, USA), GFAP (Glial fibrillary acidic protein, mouse anti-GFAP; 
ThermoFisher Scientific, Waltham, MA, USA) and neurotrophin Receptor p75 (p75 NTR, rabbit 
anti-p75 NTR; ThermoFisher Scientific, Waltham, MA, USA). Differentiation markers were 
visualized with two different secondary antibodies (goat anti-mouse Cyanine-3 and goat anti-
rabbit FITC; ThermoFisher Scientific, Waltham, MA, USA) and cell nuclei were labeled with 
DAPI (4’,6-diamindino-2-phenylindole, ThermoFisher Scientific, Waltham, MA, USA). Immuno-
Group Description Time points N Outcome measurements
I Undifferentiated 
MSCs + nerve 
allograft
T- = processed nerve 
allografts only
Tc = cells only
T0 = directly after seeding
T1 = 1 day after seeding
T2 = 3 days after seeding
T3 = 7 days after seeding
T4 = 14 days after seeding






• Neurotrophic genes 
• NGF, GDNF, PTN, 
GAP43, PMP22
• Angiogenic genes 
• CD31, VEGF1
• ECM genes 
• COL1A1, COL3A1, 
FBLN1, LAMB2
• Regulatory cell cycle genes
• CASP3, CCBN2
• Reference gene 
• GAPDH
II Differentiated 
MSCs + nerve 
allograft
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signals reflection protein expression in differentiated MSCs was compared to expression in 
Schwann cells and undifferentiated MSCs. 
Nerve allograft decellularization
65 sciatic nerves were obtained from 33 Sprague-Dawley rats (Envigo, Madison, WI, USA) 
weighing 250-350 grams and were processed according to the protocol of Hundepool 
and colleagues.7 Sprague-Dawley rats were specifically selected, because there is a known 
histocompatibility mismatch with Lewis rats.39, 40 The nerves were sterilized using g-irradiation 
and stored at 4°C for a maximum of 24 hours. 
Dynamic MSC seeding 
The 65 processed nerve allografts of 10mm in length were dynamically seeded for 12 hours 
with either 1x106 undifferentiated or differentiated MSCs from Lewis rats. This method has 
been previously demonstrated to be successful for both cell types.37, 38 Once the seeding 
was completed, the seeded nerve allografts were placed in normal growth medium in 6-well 
plates. The growth medium was changed every 72 hours.
Real Time Reverse Transcriptase Quantitative Polymerase Chain Reaction (qPCR) 
analysis
Gene expression of decelllularized allografts dynamically seeded with undifferentiated and 
differentiated MSCs was measured for 5 duplicates per group at 6 different time points. Cells 
were harvested directly after seeding (T0) and 1 (T1), 3 (T2), 7 (T3), 14 (T4) and 21 (T5) days after 
seeding. Baseline gene expression (Tc) of both cell groups was obtained from 5 samples of 
undifferentiated and differentiated MSCs, while 5 unseeded decellularized allograft samples 
served as negative controls (T-).
At each time point, nerve tissues where frozen at -80°C in Qiazol. Each sample was minced with 
a sterile needle to enable ribonucleic acid (RNA) extraction according to the manufacturer’s 
protocol (Direct-zolTM RNA MiniPrep Kit; Zymo Research, Irvine, CA, USA). After measuring 
RNA concentration with the NanoDropTM 2000/2000c Spectrophotometer (ThermoFisher 
Scientific, Waltham, MA, USA), complementary deoxyribonucleic acid (cDNA) was obtained 
in a concentration of 10ng/µL. Expression of mRNAs was determined by qPCR analysis for the 
neurotrophic markers nerve growth factor (NGF), glial cell line-derived neurotrophic factor 
(GDNF), pleiotrophin (PTN), growth associated protein 43 (GAP43) and peripheral protein 22 
(PMP22); for the angiogenic markers platelet endothelial cell adhesion molecule 1 (PECAM1/
CD31) and vascular endothelial cell growth factor alpha (VEGF1); for extracellular matrix (ECM) 
markers collagen type I (COL1A1), collagen type III (COL3A1), Fibulin 1 (FBLN1) and laminin 
subunit beta 2 (LAMB2); and for regulatory cell cycle markers caspase 3 (CASP3) and Cyclin B2 
(CCBN2). Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) served as reference gene. 
Primers were manufactured by Sigma and are listed in table 2. Function descriptions for the 
evaluated genes are provided in table 3. After preparing the reactions containing primers, 
real time-qPCR master mix (Qiagen, MD, USA) and cDNA, the reactions were amplified by 
real time-qPCR using a thermocycler (Bio-rad Laboratories, Inc., CA, USA) with the following 
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parameters: an initial step at 95oC for 15 min followed by 50 cycles of 95oC for 20s, 60oC 
for 35s and 72Co for 35s. All mRNA levels were calculated using the 2-ΔΔCT method and 
expressed relative to GAPDH as housekeeping gene.  
Statistical analysis
The results of qPCR measurements of both undifferentiated and differentiated MSCs over 
time were analyzed per gene using a 2-factor Analysis Of Variance (ANOVA) with repeated 
measures on one factor. Post-hoc multiple comparisons were evaluated by the Mann Whitney-U 
test with Bonferroni correction. Data are expressed as the mean difference plus or minus the 
standard error of the mean (SEM). Significance was set at a=0.05. The interaction between the 
cell-types and the ECM was estimated by comparing the baseline gene-expression of both 
cell types (Tc) to the gene-expression of both groups immediately after seeding onto the 
processed nerve graft (T0). Relative differences in gene expression between undifferentiated 
and differentiated MSCs were also calculated. 
Table 2. mRNA primer sequences.
Gene ID Biology Forward primer Reverse primer
GAPDH Household gene TACCAGGGCTGCCTTCTCTTG GGATCTCGCTCCTGGAAGATG
CYCA Household gene AGGATTCATGTGCCAGGGTG CTCAGTCTTGGCAGTGCAGA
PGK1 Household gene CGTGATGAGGGTGGACTTCA GCAGCAACTGGCTCTAAGGA
NGF Neurotropic marker CACTCTGAGGTGCATAGCGT CTATTGGTTCAGCAGGGGCA
GDNF Neurotropic marker CTGACCAGTGACTCCAATATGC TTAAGACGCACCCCCGATTT
PTN Neurotropic marker GCCGAGTGCAAACAAACCAT TGATTCCGCTTGAGGCTTGG
GAP43 Neurotropic marker GATAACTCGCCGTCCTCCAA CTACAGCTTCTTTCTCCTCCTCA
PMP22 Neurotropic marker GTCTGGTCTGCTGTGAGCAT GCCATTGGCTGACGATGGTG
VEGF Angiogenic marker AGAAAGCCCATGAAGTGGTGA GCTGGCTTTGGTGAGGTTTG
CD31 Angiogenic marker TTGTGACCAGTCTCCGAAGC TGGCTGTTGGTTTCCACACT
COL1A1 ECM protein AAGTCTCAAGATGGTGGCCG TCGATCCAGTACTCTCCGCT
COL3A1 ECM protein CCCGGCAACAATGGTAATCC GACCTCGTGCTCCAGTTAGC
FBLN1 ECM protein GCAGACACCTTTCGCCAAGA CGTGACAGCCCTCAGAAAGA
LAMB2 ECM protein AGTACCCACACGGATGGAGTG CTCGAGAACAGCCAGGTACA
CASP3 Cell apoptosis protein GGAGCTTGGAACGCGAAGAA ACACAAGCCCATTTCAGGGT
CCNB2 Cell cycle component ACCAGTGCAGATGGAGACAC GACTGCAAAGCCTCAAGCTG
Proefschrift.indd   64 19-07-21   22:26
4
Interaction between MSCs and a nerve allograft
65
Table 3. Function descriptions of the evaluated genes.
RESULTS
Adipose Derived Mesenchymal stem cell differentiation into Schwann-like cells
Similar to Schwann cells, the differentiated MSCs showed positive immunofluorescence for 
Schwann cell surface markers S100, GFAP and NTR p75 and morphologically changed to 
a spindle-like shape. Undifferentiated MSCs showed no expression of the tested markers 
(figure 1). Thus, the Schwann cell differentiation protocol we used induces the expected 
phenotypic changes under our experimental conditions.  
Quantitative PCR analysis 
QPCR analysis of unseeded decellularized nerve allografts did not result in detectable 
levels of mRNA. Hence, decellularization effectively prevented detection of RNA as 
expected, and indicates that any expression values obtained with nerve allografts are 
directly derived from the MSCs that were seeded. 
Genes Functional description
NGF Guides axonal growth and promotes Schwann cell activity.41, 42
GDNF Promotes survival of neurons and axonal sprouting. 41, 43
PTN Neuronal protection and axon regeneration.44
GAP43
Prominent component in axonal growth cones.45-47
Plays a key role in the formation of new connections at the neuromuscular junction.48, 
49
PMP22 Important component of myelin and promotes Schwann cell growth and differentiation.40, 51
VEGF Induces proliferation and migration of vascular endothelial cells, plays a key role in angiogenesis.52, 53 Neuronal growth stimulator and neuroprotector.52, 54-56
CD31 Involved in the formation and stabilization of the lateral junctions between adjacent endothelial cells, maintaining the vascular permeability barrier and angiogenesis. 57-59
COL1A1
Encodes for a major component of type I collagen, which influences axonal growth.
Component of the ECM of nerves that enables Schwann cell adhesion, growth and 
differentiation.9, 60, 61
COL3A1
Encodes for a major component of type III collagen, which influences axonal growth.
Component of the ECM of nerves that enables Schwann cell adhesion, growth and 
differentiation.9, 60, 61
FBLN1 Prominent in the matrix of the perineurium of peripheral nerves.62
LAMB2 Component of the basement membrane of muscles at the neuromuscular junctions.
63, 
64
CASP3 Crucial mediator in cell apoptosis of Schwann cells.65, 66
CCNB2 Forms mitosis promotic factor complexes with Cyclin-dependent kinase (Cdk).67, 68
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Figure 1. Differentiation of MSCs into Schwann-like cells. Immunocytochemical comparison between 
undifferentiated MSCs (A-D-G), differentiated MSCs (B-E-H) and Schwann cells (C-F-I). Cells are tested 
for the presence of Schwann cell marker S100 (A-B-C, green), glial cell marker GFAP (D-E-F, red) and 
neurotrophin Receptor p75 (G-H-I, green). Cell nuclei are DAPI-stained (blue). Magnification: 40X.
Neurotrophic gene expression
Baseline gene expression 
Expression of NGF (0.987 ±0.071, p<0.001) and GDNF (0.312 ±0.031, p<0.001) was significantly 
higher in undifferentiated MSCs than in differentiated MSCs. The GAP43 expression did not 
significantly differ between the cell types (p=0.127). Expression of PMP22 (0.009 ±0.004, 
p=0.049) and PTN (2.044 ±0.278, p=0.002) was significantly elevated in differentiated MSCs. 
Interaction
Compared to gene-expression before seeding, seeding of undifferentiated MSCs led to a 
significant decrease in NGF (-0.62 ±0.151; p=0.002) and GDNF expression (-0.403 ±0.034; 
p<0.001), but no significant changes in the expression of GAP43, PTN and PMP22. Seeding 
of differentiated MSCs caused a significant upregulation of NGF (+1.154 ±0.151; p<0.001) 
and GDNF expression (+0.159 ±0.034; p<0.001), a significant decrease in GAP43 expression 
Proefschrift.indd   66 19-07-21   22:26
4
Interaction between MSCs and a nerve allograft
67
(-0.111 ±0.019; p<0.001) and no significant changes in the expression of PMP22 and PTN.
Gene expression over time
In general, expression of NGF, GDNF and PMP22 in undifferentiated MSCs appeared to 
increase after 3 days of culture and remained elevated over the subsequent days until day 
7, while expression of GAP43 and PTN remained low. In differentiated MSCs, expression 
of NGF, GDNF and GAP43 was especially high during the first 3 days after seeding, while 
the PTN and PMP22 expression in differentiated MSCs increased after 7 days of culture. 
All neurotrophic expression curves are displayed in figure 2 with asterisks demonstrating 
significant differences between groups.
Angiogenic gene expression
Baseline gene expression
Baseline CD31 expression did not significantly differ between undifferentiated and 
differentiated MSCs (p=0.414). VEGF1 expression was significantly higher in differentiated 
MSCs than in undifferentiated MSCs before seeding (19.351 ±3.138, p=0.003).
Interaction
Seeding the different cell-groups on a decellularized nerve allograft led to enhanced 
expression of CD31 but this trend in mRNA levels was not statistically significant. Enhanced 
VEGF1 expression for both undifferentiated MSCs (+67.121 ±9.064; p<0.001) and 
differentiated MSCs (+36.522 ±9.064; p=0.004) after seeding was statistically significant.
Gene expression over time 
Generally, CD31 expression in undifferentiated and differentiated MSCs peaked 24 hours 
after seeding and declined to minimal expression at 7 days after which the expression 
remained low. ANOVA analysis did not demonstrate a significant interaction between 
culture duration, cell type and CD31 expression (p=0.094). ANOVA analysis showed a 
significant interaction between cell-type, time and VEGF1 expression (p=0.001). The VEGF1 
expression curve followed the same pattern in both groups: it peaked directly after seeding 
and reached a plateau phase from 7 days onwards. All angiogenic expression curves are 
depicted in figure 3. 
Extracellular matrix gene expression
Baseline gene expression
The baseline expression of COL1A1 (p=0.134) and LAMB2 (p=0.232) did not significantly 
differ between undifferentiated and differentiated MSCs. Differentiated MSCs had a 
significantly higher expression of COL3A1 (13.119 ±5.492, p=0.049), while undifferentiated 
MSCs showed significantly higher FBLN1 expression (1.767 ±0.446, p=0.013). 
Interaction 
The interaction with the ECM of decellularized nerve allografts led to significantly enhanced 
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expression of COL3A1 in undifferentiated MSCs (+186.328 ±50.264; p=0.011), but did not 
appreciably alter expression of COL1A1, FBLN1 and LAMB2. For differentiated MSCs, the 
interaction resulted in a significant enhanced expression of FBLN1 (1.918 ±0.386; <0.001) 
but no changes in the COL1A1, COL3A1 and LAMB2 gene expression. 
Gene expression over time
The temporal expression of extracellular matrix genes exhibited significant differences 
between cell type (figure 4). In general, the temporal expression profiles of COL1A1 and 
COL3A1 in undifferentiated and differentiated MSCs did not differ substantially from each 
other. ANOVA analysis only demonstrated a significant interaction between and within 
groups for COL3A1 expression over time (p=0.027). For undifferentiated MSCs, a significant 
decrease in COL3A1 between 3 days and 7 days after seeding (p=0.050) was observed, 
while for differentiated MSCs a significant increase between 14 and 21 days after seeding 
(p=0.007) was measured. There was a significant interaction between and within groups 
for FBLN1 expression (p<0.001). The FBLN1 expression in both groups started high, slowly 
decreased in the first week and increased from 7 days onwards. A significant interaction 
between cell-types (p=0.001) was found for the LAMB2 expression, while no within-group 
differences were found over time. Overall, the LAMB2 expression in undifferentiated 
MSCs slowly seemed to climb, reaching maximal levels at 21 days after seeding, while the 
expression of LAMB2 in differentiated MSCs appeared to decline slowly. 
Cell regulatory gene expression
Baseline gene expression
The baseline expression of CCBN2 (1.613 ±0.580, p=0.049) and CASP3 (0.867 ±0.081, 
p<0.001) in undifferentiated MSCs was significantly higher than in differentiated MSCs. 
After seeding
After seeding, the gene expression in undifferentiated MSCs of CASP3 was significantly 
enhanced (0.983 ±0.279; p=0.018), while CCBN2-expression significantly decreased (-1.638 
±0.501; p=0.040). Seeding of differentiated MSCs resulted in a significant enhanced 
expression of CASP3 (2.501 ±0.279; p<0.001) and CCBN2 (1.796 ±0.501; p<0.001). 
Gene expression over time
Overall, CASP3 expression of both cell-groups was high directly after seeding, but 
decreased afterwards and mRNA levels remained steady from 7 days onwards. ANOVA 
analysis showed a significant interaction between culture duration and the mean CASP3 
expression (p<0.001), but no significant differences between groups (p=0.404). CCNB2 
expression had a significant interaction with the cell-type and culture duration (p<0.001). 
In general, CCBN2 expression of undifferentiated MSCs was low during the first 3 days 
after seeding and then slowly increased, reaching a peak after 21 days. In differentiated 
MSCs there was a peak measured after 1 day and then the expression slowly decreased. All 
expression values for cell cycle regulatory genes are presented in figure 5 with significant 
differences between groups as indicated.
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Figure 2. Graphs of mean measured gene expressions of neurotrophic markers GAP43, GDNF, NGF, 
PMP22 and PTN in undifferentiated and differentiated MSCs over a time period of 21 days after 
dynamically seeding both cell-types on a processed nerve allograft. Error bars = Standard Error of the 
Mean. * = significant difference between groups (p<0.05).
Figure 3. Graphs of mean measured gene expressions of angiogenic markers platelet endothelial 
cell adhesion molecule 1 (PECAM1/CD31) and vascular endothelial cell growth factor alpha (VEGF1) in 
undifferentiated and differentiated MSCs over a time period of 21 days after dynamically seeding both 
cell-types on a processed nerve allograft. Error bars = Standard Error of the Mean. * = significant difference 
between groups (p<0.05).
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Figure 4. Graphs of mean measured gene expressions of extracellular matrix markers collagen 
type I (COL1A1), collagen type III (COL3A1), Fibulin 1 (FBLN1) and laminin subunit beta 2 (LAMB2) 
in undifferentiated and differentiated MSCs over a time period of 21 days after dynamically seeding 
both cell-types on a processed nerve allograft. Error bars = Standard Error of the Mean. * = significant 
difference between groups (p<0.05).
Figure 5. Graphs of mean measured gene expressions of regulatory cell cycle markers caspase 3 (CASP3) 
and Cyclin B2 (CCBN2) in undifferentiated and differentiated MSCs over a time period of 21 days after 
dynamically seeding both cell-types on a processed nerve allograft. Error bars = Standard Error of the 
Mean. * = significant difference between groups (p<0.05).
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DISCUSSION 
In this study, the gene expression profiles of undifferentiated and differentiated MSCs 
before and after seeding on a decellularized nerve allograft were analyzed. There is 
little consensus about which stem cell types are most optimal for use in clinical human 
peripheral nerve regeneration studies due to the ambiguity in their mechanism of action. 
We examined the expression of a large panel of genes that have a known role in nerve 
regeneration and compared their expression in undifferentiated MSCs to differentiated 
MSCs, before and after they interacted with the ECM of decellularized nerve allografts. 
Interaction between MSCs and the nerve allograft
Compared to undifferentiated MSCs, the differentiation of MSCs into Schwann-like cells 
led to significantly enhanced mean expressions of the neurotrophic genes PMP22 and 
PTN, the angiogenic gene VEGF1 and extracellular matrix gene COL3A1. Expression of 
other neurotrophic genes (i.e., NGF and GDNF), the extracellular matrix gene FBLN1, and 
cell growth and survival related genes CCBN2 and CASP3 was significantly decreased 
after differentiation. When comparing the gene expression of both undifferentiated and 
differentiated cell states before and after the introduction to the ECM of decellularized 
nerve allografts, it was demonstrated that the interaction initially led to enhanced 
expression of VEGF1, COL3A1 and CASP3 in undifferentiated MSCs and increased mRNA 
levels of NGF, GDNF, VEGF1, FBLN1, CASP3 and CCBN2 in differentiated MSCs. 
Our results corroborate studies that describe interactions between the ECM and MSCs 
which led to significant changes in their gene expression profiled and the observation that 
differentiation of MSCs leads to enhanced expression of VEGF1.26, 69 Possible explanations 
for the reduced expression of NGF and GDNF in undifferentiated MSCs directly after 
seeding may include the lack of surgical host factors and the original (motor) function of 
the nerves used.70, 71
Gene expression over time
The short-term measurements (immediate post seeding, 1 day and 3 days after seeding) 
indicate differentiated MSCs express high levels of neurotrophic (NGF, GDNF, GAP43), 
angiogenic (VEGF1), tissue supportive (FBLN1) and cell regulatory genes (CASP3, 
CCNB2) which decrease over time. Undifferentiated MSCs appear to have a smaller 
role in the short term and only express high levels of VEGF1 and CASP3. The effect of 
undifferentiated MSCs are seen in the long term (7, 14 and 21 days after seeding) by 
expressing enhanced levels of neurotrophic (NGF, GDNF, PMP22), extracellular matrix 
(FBLN1, LAMB2) and cell regulatory genes (CCNB2). In this later phase, the expression 
of factors from differentiated MSCs is less than undifferentiated MSCs. The expression 
of tissue supportive genes COL1A1 and COL3A1 remained stable over time in both cell 
types. The gene expression cascades presented here suggest that a combination of both 
differentiated and undifferentiated cells would lead to an optimal regenerative micro-
environment for decellularized nerve allografts, by providing growth factors that stimulate 
axon ingrowth after implementation. 
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When considering whether differentiated or undifferentiated cells should be used upon 
translation into future human clinical studies, the extra costs and preparation time required for 
the differentiation of MSCs should be taken into account. Clinically, differentiation would lead 
to an extended period of 3 weeks between injury and repair. This must also be balanced with 
the hypothetical malignant potential of differentiated MSCs compared to undifferentiated 
MSCs.72, 73
Limitations
A limitation of the current in vitro setting is the lack of an effective tissue repair environment 
which is present in an in vivo setting.70 However, an in vitro setting lends itself perfectly to 
evaluate the mechanisms in a thorough manner while limiting the number of animals used. 
Future in vivo animal studies are needed to corroborate these in vitro findings. Rat tissues 
were exclusively used in order to easily correlate the results to functional outcomes of nerve 
allografts seeded with undifferentiated and differentiated MSCs in an in vivo rat-model, which 
is the logical next step prior to the translation to human tissue. The current rat-model enables 
us to explore the underlying mechanism of action of differentiated versus undifferentiated 
MSCs in peripheral nerve repair, before these studies are translated to a more clinically 
applicable model. 
We did not examine the effect of changed gene expression profiles on secreted growth 
factors.  Although ELISA analysis could have contributed to our findings, it is a costly technique 
and attempts to correlate mRNA expression to protein secretion have had variable success.74 
The gene expression levels of many different genes that are relevant for nerve regeneration 
have been examined and compared. The disadvantage of testing many genes at many 
different time points is that a statistical type I error is more likely to occur. Corrections were 
used to adjust for multiple comparisons, limiting the power of our findings. This numerical 
consideration emphasizes the significance of the findings that were statistically significant.  
We found several significant differences within and between groups over time. As expected, 
extracellular matrix genes like COL1A1 and COL3A1 were highly expressed, while the 
expression of most other genes was a hundredfold less. However, due to the different cellular 
function of the genes we examined, these differences do not define the relevance of the 
findings. All genes have their basic level of expression that was (significantly) influenced by the 
ECM of the decellularized nerve allograft. To make a valid expression comparison between 
differentiated versus undifferentiated cells, we deliberately displayed expression levels only 
as a ratio of our housekeeping gene (GAPDH), instead of calculating a ratio of their baseline 
gene expression (cells only).
These limitations notwithstanding, gene expression profiles of cell types before and after 
interacting with the ECM of decellularized nerve allografts have not been described and 
compared to this extent before. The evaluation to three weeks after seeding enabled us to 
describe a potential expression cascade of both cell-types when used in combination with 
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an decellularized nerve allograft.7 The validated dynamic seeding strategy that ensures the 
atraumatic delivery of viable MSCs on the surface of processed allografts is an additional 
strength of this study.37, 38
As indicated above, the in-vitro set up should first be translated to an in-vivo model to confirm 
the stimulatory effects of different MSC states on peripheral nerve regeneration. A repetition 
of the current study with human undifferentiated and differentiated MSCs with clinically 
available nerve graft substitutes (collagen conduits or decellularized allograft nerve) would be 
a logical next step for clinical translation. 
CONCLUSION
Differentiation of MSCs in Schwann cell-like cells changes their baseline gene expression 
profile. The gene expression profile of both differentiated MSCs and undifferentiated MSCs 
changes when the MSCs interact with the ECM of a decellularized nerve allograft after being 
dynamically seeded on their surface. Differentiated MSCs are likely to play a major role 
on the short-term nerve regeneration by expressing high gene-levels in the first 72 hours 
after seeding, while the effect of undifferentiated MSCs appears a week after seeding. The 
differences in gene-profile and effective phases suggests that both cell-types can affect nerve 
regeneration in different ways and at different time points.
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Nerve regeneration involves multiple processes which enhance blood supply that can be 
promoted by growth factors. Currently, tools are lacking to visualize the vascularization patterns 
in transplanted nerves in vivo. The purpose of this study was to describe three-dimensional 
visualization of the vascular system in the rat sciatic nerve and to quantify angiogenesis of 
nerve reconstruction.
Materials and Methods
In 12 Lewis rats (weighing 250 – 300 grams), 10 mm sciatic nerve gaps were repaired with 
ipsilateral reversed autologous nerve grafts. At 12 and 16 weeks of sacrifice, Microfil® contrast 
compound was injected in the aorta. Nerve autografts (N=12) and contralateral untreated 
nerves (N=12) were harvested and cleared while preserving the vasculature. The amount of 
vascularization was measured by quantifying the vascular surface area using conventional 
photography (two dimensional) and the vascular volume was calculated with micro-computed 
tomography (three dimensional). For each measurement, a vessel/nerve area ratio was 
calculated and expressed in percentages (vessel%). 
Results
The vascular volume measured 3.53 ± 0.43% in autografts and 4.83 ± 0.45% vessels in controls 
at 12 weeks and 4.95 ± 0.44% and 6.19 ± 0.29% vessels at 16 weeks, respectively. The vascular 
surface area measured 25.04 ± 2.77 % in autografts and 26.87 ± 2.13% vessels in controls at 12 
weeks, and 28.11 ± 3.47% and 33.71 ± 2.60% vessels at 16 weeks respectively. The correlation 
between both methods was statistically significant (P=0.049).
Conclusions
Both methods are considered to successfully reflect the degree of vascularization. Application 
of this technique could be used to visualize and objectively quantify angiogenesis of the 
transplanted nerve graft. Moreover, this simple method is easily reproducible and could be 
extrapolated to any other desired target organ ex vivo in small animals to investigate the 
vascular network. 
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INTRODUCTION
It has been postulated that blood supply affects nerve regeneration1-7, as it is reported 
that vascular endothelial cells directly guide the regeneration of peripheral nerve axons.7 
Angiogenesis can be enhanced through growth factors8, in particular angiopoietin-1 (Ang-1); 
an important angiogenic factor that promotes vascular stabilization9 and vascular endothelial 
growth factor (VEGF) which enhances intraneural angiogenesis.2 To quantify blood vessels in 
nerve grafts or conduits, previous studies have focused on immunohistochemical staining.10-12 
Unfortunately, the amount of (neo)angiogenesis was not evaluated in these studies.  
Histomorphometric analyses are used to describe angiogenesis, but are limited in the ability 
to identify the three-dimensional interconnectivity of the vasculature in serial histological 
sections 13, 14 and focuses on representing superficial blood flow.15. Connectivity defines the 
maximal number of branches that may be cut without separating the structure.15 Insight in the 
connectivity of the vascular tree may contribute to crucial description of neovascularization 
patterns. Therefore, two-dimensional measures of vasculature deliver incomplete 
information.13 Three-dimensional reconstruction of blood vessels in sciatic nerves of the rat 
has been technically difficult because the average diameter of the small endoneural vessels 
in the rat is 8.8 mm.16 
Micro-computed tomography (micro CT) facilitates the visualization of contrast enhanced 
microvessels and could separate vessels from surrounding tissues, such as bone, fat tissue or 
nerve.17 It provides three-dimensional volume imaging with spatial resolution at the micrometer 
scale and is applied in many fields, for instance in tumor visualization, cardiovascular plaque 
imaging15, 17 and evaluation of surgical angiogenesis in bone allotransplantation models.18-20
As technology continues to evolve, modern micro CT systems are more commonly available 
and are capable of generating very small voxels with short scan acquisition times allowing 
both ex vivo and in vivo scanning.15 Moreover, due to voxels as small as 1 μm, the vascular 
system in rat and even mice could now be visualized.13, 14, 21, 22 As perfusion with a radiopaque 
contrast agent is the only requirement to delineate the vascular tree, a closer-meshed network 
of smaller vessels, contrast enhanced micro CT can become a powerful tool in quantifying 
angiogenesis.13 
Information collected from conventional photography may complement the micro CT. 
Photographs could be analyzed by measuring the ratio of vessel area and total nerve area 
digitally.23 More conventional methods such as manual vessel counts per sub-segment of the 
nerve, providing a vessel density per mm2, have also been described.24 These techniques 
have never been verified and are questionably representative for the entire quantification 
of the nerve vasculature when used solely. However, with evolving technology, the quality 
of conventional photography has improved and there are numerous photo editing software 
programs available providing a cost-effective way to measure vessel and nerve surface areas. 
The purpose of this study was to describe three-dimensional visualization of the vascular 
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system in the rat sciatic nerve and to quantify angiogenesis of nerve reconstruction. The micro 
CT and conventional photography were used to objectively quantify vascular volume and 
vascular surface area, respectively, as measurements of angiogenesis in rat nerve. 
MATERIALS AND METHODS
Animal experiments were approved by our Institutional Animal Care and Use Committee 
(IACUC A3348-18). For this study, male Lewis rats (Envigo, USA) were used, weighing between 
250 – 300 grams. All animals were housed with ad libitum access to food and water, with a 12-
hour light-dark cycle after surgery. 
Experimental design
In 12 Lewis rats, unilateral 10 mm sciatic nerve gaps were repaired with ipsilateral reversed 
autologous nerve grafts to create a mismatch in the alignment of the nerve fibers.25, 26 This group 
was considered the gold standard for nerve repair. Rats survived for either 12- or 16 weeks. At the 
time of the sacrifice, autograft nerves (N=6 per time point) and the contralateral nerve samples 
as untreated, control samples (N=6 per time point) were harvested. The nerve vasculature was 
preserved to obtain the vascular volume and vascular surface area measurements.
Surgical procedure
After anesthesia in an isoflurane chamber, rats were shaved, prepped and positioned in the 
nosecone to maintain anesthesia throughout the procedure. Preoperatively the following were 
administrated subcutaneously; infection prophylaxis provided by Enrofloxacin (Baytril, Bayer, 
Germany, 10mg/kg), 5 ml of NaCl 0.9% solution to prevent dehydration and Buprenorphine SR 
(Buprenorphine SR-LAB, ZooPharm pharmacy, 0.6mg/kg) for pain control. During surgery, body 
temperature was maintained at 37°C with a heating pad.  
The sciatic nerve was fully exposed proximally from the inferior margin of the piriformis muscle 
to approximately 5 mm distal to the bifurcation, under an operating microscope (Zeiss OpMi 6, 
Carl Zeiss Surgica, Oberkochen, Germany). A 10 mm segment of the sciatic nerve was excised 
by sharp transection with microsurgical scissors. The nerve graft was reversed and reconstructed 
with six 10-0 nylon (Ethilon, Ethicon Inc., Sommerville, NJ, USA), epineural interrupted sutures 
on either side of the anastomosis. Wounds were closed in layers, approximating muscle with 
two 5-0 absorbable interrupted sutures (5-0 Vicryl Rapide, Ethicon Inc., Sommerville, NJ, USA). 
The skin was closed subcutaneously, using the same suture. Postoperatively, the rats were kept 
warm with towels. The rats were observed weekly until completion of the experiment. 
Perfusion of contrast
Twelve and 16 weeks postoperatively, rats were sacrificed. Access for aortic infusion catheter 
placement was achieved via the abdomen. A large midline incision was made in the abdomen 
to expose the aorta and vena cava. A small retractor was used to retract the digestive organs 
providing stable exposure of the aorta and vena cava throughout the experiment. The fat 
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surrounding the thoracic aorta and vena cava was cleaned using cotton tip applicators taking 
care not to harm the vascular structures. The thoracic aorta and vena cava were ligated 
proximally with a 5-0 Vicryl suture (5-0 Vicryl Rapide, Ethicon Inc., Sommerville, NJ, USA) which 
was kept long to act as grip sutures. The ligation was placed as proximal as possible and distal 
to any large hepatic bifurcations, depending on the anatomic variation. The aorta was dissected 
from the vena cava distally using cotton tip applicators. This was performed approximately 1 
cm proximal to the iliac bifurcation. A loose 5-0 Vicryl suture was placed under the aorta. To 
facilitate the passage of contrast, a 24 Gauge catheter (Jelco IV Catheter Radiopaque, Smiths 
Medical International, UK) connected to an IV tubing system, was introduced in the aorta just 
distally to the proximally placed grip sutures, while keeping the aorta on tension by slightly 
pulling the grip sutures (figure 1). After the catheter was fixated with the previously placed 
suture around the aorta distally, 2-3 ml of saline (NaCl 0.9%) was infused through the tubing 
system to evaluate the patency of the aorta. The needle was removed off the cannula, while 
maintaining the cannula in the artery. Care was taken that the tip of the cannula would still be 
proximal to the iliac bifurcation, so that the contrast would reach both limbs. A yellow-colored 
(MV-122) Microfil® compound (MV 8ml, diluent 15 ml, and curing agent 1.2 ml, Flow Tech, Inc., 
Carver, MA, USA) in a 50 cc syringe was connected to the tubing system to be infused in the 
aorta. While putting pressure on the insertion site using gauze, the perfusion was performed 
with constant perfusion of approximately 100 mmHg. The perfusion was continued until the 
syringe was empty and yellow nailbeds on either paw were observed. After the perfusion was 
completed, a clamp was placed on the cannula to prevent leakage of the infused contrast. The 
rat was kept at room temperature while the agents cured for at least 90 minutes. 
 
Figure 1. Schematic drawing of the insertion 
of the catheter into the rat aorta. Long sutures 
indicate the grip sutures that have ligated 
the aorta and vena cava proximally. Short cut 
suture serves to hold catheter in place while 
injecting the Microfil® contrast compound 
into both common iliac arteries of the rat. (with 
permission of the Mayo Foundation, Copyright 
Mayo Foundation 2019)




After the vascular bed was perfused successfully and the contrast had cured, the sciatic nerve was 
exposed and harvested extending to approximately 3 mm on either side of the anastomoses. 
Nerve samples were collected in phosphate buffered saline (PBS) and cleared for five days by 
immersion in graded series of ethyl alcohol as follows: the samples were first placed in 25% 
ethyl alcohol and at successive 24-48 hour intervals the concentration was raised to 50%, 75%, 
95% and 100%. As the final step, the samples were immersed in methyl salicylate. If tissue had 
not cleared, a second clearing starting from 95% ethyl alcohol stage was performed to repeat 
the final steps of the clearing procedure. This procedure allowed clearing of all structures, with 
exception of the opacified microvascular structures that were filled with contrast. 
Micro CT for calculating the vascular volume
After clearing had taken place, the samples were scanned in a SkyScan 1276 micro CT (Bruker 
Corporation, Billerica, MA, USA) at 40 kV voltage, 200 µA current and 10 µm resolution to 
calculate vascular volume. Three samples were scanned at a time, taking approximately 26 
minutes per scan with frame averaging set at three in order to reduce noise. Three-dimensional 
images of the samples were reconstructed using Hierarchical InstaRecon software (NRecon, 
1.7.4.2., InstaRecon, 2.0.4.0. InstaRecon). This software was used to adjust the following 
parameters while reconstructing the images; Beam Hardening Correction (%) was set at 51, Ring 
Artifact Correction at 9, Smoothing at 1, Post alignment compensation and Histogram windows 
were manually adjusted for each scan. After obtaining reconstruction of the images, AnalyzePro 
software (AnalyzeDirect, Inc., Overland Park, KS, USA) was used to measure the volume of the 
vasculature and the volume of the total nerve. A vessel/nerve area ratio was calculated and 
expressed in percentages (vessel%).  
Photography for calculating the vascular surface area
After micro CT scanning was completed, the nerve samples were stretched by suturing both 
nerve ends onto a solid holder. Detailed pictures of the samples were obtained using a Canon 
5D Mark IV camera, (Manual Mode, ISO 200, 1/200th of a sec, f/16), a Canon MP-E 65mm Macro 
lens and a Canon MT-26-RT Twin Lite Macro strobe light source. During photography, samples 
were placed in a petri dish with methyl salicylate in order to obtain clean photographs allowing 
for the specimen to be separated from the background for better measurement. The petri dish 
was placed on a black background to achieve maximum contrast with the yellow vessels in the 
nerve samples. Polarized light was used to reduce reflections and a 1:1 magnification was used 
to ensure consistency of the pictures. To correct for the surface area that altered depending 
on the angle of the image, two pictures of each nerve sample were obtained; one of the front 
whereafter the holder was flipped and the picture of the other side was obtained. With NIS-
Elements software (NIS-Elements BR 4.51.01), the total vessel area and the total nerve area in 
the graft were measured in a blinded fashion. For each image, a vessel/nerve area ratio was 
calculated and expressed in percentages. The ratios of the two images (front and back) were 
averaged per sample. 
Statistical analysis
The vascular volume and the vascular surface area were analyzed and compared to the 
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untreated side (control). A nonpaired student t-test for comparisons between groups was used 
for statistical investigation. Correlations were analyzed using Pearson’s correlation test. Results 
were reported as the mean and standard error or the mean (SEM), and the level of significance 
was set at α ≤ 0.05. 
RESULTS
Macroscopic appearance of the vessels in nerve samples
After the clearing process, the nerve samples were transparent and vessels were filled with 
Microfil®. For 3D imaging, the micro CT was used and allowed visualization of the vessels 
in space (figure 2). The size and position of the vessels were visualized. Figure 3 shows the 
macroscopic images of the nerve autografts at 12- and 16 weeks and a control sample at 12 
weeks obtained with a conventional digital camera. Sutures are clearly visible and were used 
to set the borders of the analysis frame. As demonstrated, the microvasculature was clearly 
visualized. The smallest diameter of blood vessels detected was 9.3 µm using micro CT and 
7.4 µm using conventional photography. 
Figure 2. Micro computed tomography (micro CT) images of nerve samples. Micro CT images of the same 
samples visualized in Figure 2. Control nerve at 12 weeks (A), nerve autograft at 12 weeks (B) and nerve 
autograft at 16 weeks (C). Nerve samples are positioned from proximal to distal (left to right respectively). 
Scale bar is set a 1 millimeters (mm). 
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Figure 3. Macroscopic images of nerve samples obtained with conventional digital photography. 
Microvessels could be clearly seen in the control nerve at 12 weeks (A), nerve autograft at 12 weeks (B) 
and nerve autograft at 16 weeks (C). Sutures that are used to repair the graft are visible in nerve autograft 
groups (B+C) and depict the border of the analyzed frame. Nerve samples are positioned from proximal 
to distal (left to right respectively). Scale bar is set at 1 millimeters (mm). 
Figure 4. Vascular volume of 
control and nerve autograft 
samples at 12 and 16 weeks using 
micro CT.  Results are expressed 
as a percentage (vessel %) of the 
total nerve area and are given 
as the mean ±SEM. *Indicates 
significance at p<0.05. 
Figure 5. Vascular surface area 
of control and nerve autograft 
samples at 12 and 16 weeks using 
digital photography. Results 
are expressed as a percentage 
(vessel %) of the total nerve area 
and are given as the mean ±SEM. 
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Vascular volume measured with micro CT
The vascular volume was successfully measured using the micro CT. At 12 weeks, autograft 
nerves measured 3.53 ± 0.43% and control nerve samples measured 4.83 ± 0.45% vessels. 
At 16 weeks, this was 4.95 ± 0.44% and 6.19 ± 0.29% vessels for autografts and controls, 
respectively. These outcomes are depicted in figure 4. 
Vascular surface area measured with conventional photography
After 12 weeks, the vascular surface area was 25.04 ± 2.77% and 26.87 ± 2.13% vessels for 
autografts and control nerves, respectively. At 16 weeks, photography measured 28.11 ± 
3.47% vessels for autografts and 33.71 ± 2.60% vessels for controls (figure 5). 
Correlations
The vascular volume and vascular surface area were significantly correlated with both time 
points and groups (r=0.951, p=0.049). 
DISCUSSION
In this study, the authors successfully measured the vasculature of the sciatic nerve in rats to 
provide more insight in the amount of angiogenesis and the patterns of neoangiogenesis 
occurring in nerve regeneration. The limited options available to visualize the small vessels 
of the rat had previously impeded the understanding of the underlying neoangiogenesis 
patterns after nerve graft reconstruction. 
The utility of the methods described in the current study is two-fold. First, it provides an 
objective quantification of the amount of angiogenesis, independently from the size of the 
vessels, in relation to the size of the nerve. Second, it eminently demonstrates the patterns of 
angiogenesis in (transplanted) nerves. Nerve revascularization is postulated to be composed 
of angiogenesis and neoangiogenesis; vessels that sprout into the existing vascular tree and 
vessels that create new pathways.27 However, this theory has yet to be objectively described. 
Angiogenesis is the growth of blood vessels from existing vasculature. Angiogenesis occurs 
throughout development and forms transvascular tissue pillars that expand with overall 
growth resulting in the increase in vascularity over time.28 This process could also be seen in 
our study, when comparing time points. The vascularization of nerves and in particular, the 
alignment of vessels in nerves is attributed to a directional role for regenerating axons.29, 30 
Applying the described techniques at several time points after nerve graft implementation 
may provide insight to the ratio between revascularization components. These techniques may 
demonstrate the relationship between vessel alignment and the level of nerve regeneration. 
Thus, allowing us to improve our understanding of the process and the importance of vascular 
development in nerve grafts. 
As blood vessels provide little inherent contrast, viscosity is one of the most important 
properties of the implemented vehicle.15 With viscosity levels around 20-30,  Microfil® is the 
best available compound that injects both the arterial and venous system and reaches even 
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the smallest angiogenic vessels to allow complete study of the vascular network.15 The injected 
Microfil® does not directly interact with the histology but could influence the proportion of 
axon and nerve areas during the analysis. Therefore, we would suggest harvesting other tissue 
prior to Microfil® injection to secure reliable histologic analysis.
There are a few considerations associated with these techniques. Although micro CT systems 
become more commonly available with improving quality15, costs could add up and it is still 
conceivable that micro CT devices with small effective voxel size are not available for all 
researchers. In this case, solely the described conventional photography strategy could be 
used, as it is cost-effective, simple to perform and correlates with micro volume measurements. 
However, the limitation of conventional photography is that it does not describe vascularization 
in space and lacks detailed information. As only two sides of the nerve sample are measured 
and the surface area could not be corrected for the thickness of the nerve (i.e. depth of the 
obtained photo), representation of the amount of angiogenesis using vascular surface area 
may be questionable. The difference between various groups of nerve samples, however, 
could be described with conventional photography. The use of Microfil® to fill the complete 
vascular bed including the smallest arterial and venous branches allows visualization of the 
desired vascular system but limits any other histological examination in the same samples, as 
processing is different. The micro CT has the advantage of precisely measuring vessel volume 
in relation to total measured nerve volume. Also, clearing of samples is not necessary as the 
lead pigments in Microfil® provide high contrast compared to background tissue to acquire 
complete high resolution 3D images of the vessels.17  
Our results indicate the significant correlation between the vascular volume and the 
vascular surface area measurements demonstrating that the methods could be used either 
complementary or separately, depending on the goals of the study. These methods will 
allow us to advance angiogenesis related research by improving the tools for studying and 
understanding vascular development and the mechanisms of neoangiogenesis.
CONCLUSION
This study provides accurate objective analysis of the newly formed vascular network of 
the sciatic nerve. The use of the micro CT and conventional photography provides many 
modalities for vascular exploration, allowing the exploration of the structure and organization 
of blood vessels. These imaging methods are easily reproducible and could be extrapolated 
to any other desired target organ ex vivo in small animals to investigate the vascular network. 
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Adipose derived mesenchymal stem cells (MSCs) are hypothesized to supplement tissues 
with growth factors essential for regeneration and neovascularization. The purpose of this 
study was to determine the effect of MSCs with respect to neoangiogenesis when seeded 
onto a decellularized nerve allograft in a rat sciatic defect model.  
Methods
Allograft nerves were harvested from Sprague-Dawley rats and decellularized. MSCs were 
obtained from Lewis rats. 10mm sciatic nerve defects in Lewis rats were reconstructed with 
reversed autograft nerves, decellularized allografts, decellularized allografts seeded with 
undifferentiated MSC or decellularized allografts seeded with differentiated MSCs. At 16 
weeks, the vascular surface area and volume were evaluated.  
Results
The vascular surface area in normal nerves (34.9±5.7%.), autografts (29.5±8.7%), allografts 
seeded with differentiated (38.9±7.0%) and undifferentiated MSCs (29.2±3.4%) did not 
significantly differ from each other. Unseeded allografts (21.2±6.2%) had a significantly lower 
vascular surface area percentage than normal non-operated nerves (13.7%, p=0.001) and 
allografts seeded with differentiated MSCs (17.8%, p=0.001). Although the vascular surface 
area was significantly correlated to the vascular volume (r=0.416; p=0.008), no significant 
differences were found between groups concerning vascular volumes. The vascularization 
pattern in allografts seeded with MSCs consisted of an extensive non-aligned network of 
micro-vessels with a centripetal pattern, while the vessels in autografts and normal nerves 
were more longitudinally aligned with longitudinal inosculation patterns. 
Conclusions
Neoangiogenesis of decellularized allograft nerve was enhanced by stem cell seeding, 
in particular by differentiated MSCs. The pattern of vascularization was different between 
processed allograft nerves seeded with MSCs compared to autograft nerves.  
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INTRODUCTION
Compared to decellularized allografts or bioabsorbable synthetic conduits, autograft nerves 
continue to result in superior functional outcomes after peripheral nerve repair.  One hypothesis 
for autografts superiority is the ability of autografts to revascularize.1-3 Revascularization 
of injured tissue is an essential process in tissue regeneration as it relieves injury-induced 
hypoxia at the regeneration site while facilitating the delivery of nutrients and cells essential 
for the regeneration process.4  Revascularization occurs as early as 2 days after nerve injury 
and precedes the axonal regeneration.5, 6 Hypoxia in peripheral nerves causes macrophages 
to secrete vascular endothelial growth factor (VEGF), which induces (neo)angiogenesis and 
facilitates trophic factors to arrive at the regeneration site.7 The endothelial cells of newly 
formed blood vessels have a directional function by guiding Schwann cells across the nerve-
gap, which direct the regenerating axons in the correct direction.6, 8 A sufficient volume 
of well-organized newly formed vessels in both nerve stumps is requisite for a functional 
outcome after peripheral nerve repair and has been confirmed in several animal-models.3, 
9, 10 Improved revascularization and diminished duration of avascularity has been suggested 
to prevent central fibrosis or necrosis in autografts compared to decellularized allografts, 
especially in large nerve gaps.11-14 Improved vascularization could therefore lead to improved 
nerve regeneration in decellularized allografts.  
In order to improve vascularization, numerous studies have evaluated the addition of VEGF to 
nerve reconstructions. Although some studies demonstrated improved vascularization by the 
addition of VEGF, they failed to prove any benefit of VEGF with respect to functional outcomes 
demonstrating that the addition of a single growth factor was insufficient to replicate the 
complex angiogenesis cascade.15-19
Adipose derived Mesenchymal Stem Cells (MSCs), when seeded onto decellularized 
allograft nerves, result in the production of neurotrophic and angiogenic factors, one of 
which is VEGF.20 While the exact role of MSCs (structural vs immunomodulatory) continues 
to be defined, it has been demonstrated that MSCs have a finite lifespan, stimulate tissue 
repair via release of trophic factors and produce proteins and cytokines that stimulate tissue 
regeneration with immunomodulatory effects.20-25 MSCs differentiated into Schwann-like cells 
(differentiated MSCs) in vitro lead to increased gene expressions of angiogenic (VEGF) and 
neurotrophic genes when compared to undifferentiated MSCs20, 22, 26, 27 and are considered 
nerve regeneration catalysts.19 The disadvantages of differentiating MSC include the extra 
preparation time, expense and extra handling of the cells.  The effect of differentiation thus 
needs to be carefully investigated.  
In order to equal the results of nerve autografts, efforts have been recently made to optimize 
the quality of decellularized allografts.28 To improve their outcomes a non-traumatic dynamic 
seeding strategy has been developed to seed undifferentiated and differentiated MSCs to 
the allograft surfaces, which survive up to a month in vivo.29-31 Furthermore, differences in 
gene expression levels (and thus growth factors produced) have been elucidated between 
differentiate and undifferentiated MSCs, and demonstrated that differentiated MSCs in 
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particular showed enhanced expressions of VEGF after interacting with the outer surface of 
the decellularized allografts.25, 32 
The purpose of this study was to either substantiate or invalidate the hypothesis whether 
the previously demonstrated different gene expression profiles of differentiated and 
undifferentiated MSCs would lead to different levels and patterns of vascularization when 
dynamically seeded onto processed/decellularized nerve allografts, in comparison to 
unseeded allografts and autografts. 
METHODS
This study was approved by the IACUC institutional review committee and our Institutional 
Review Board (IACUC protocol A2464-00).  A 10 mm segment of the right sciatic nerve of 20 
Lewis rats (Envigo, USA) was excised and was replaced with either (i) a reversed autograft, 
(ii) a processed/decellularized nerve allograft, (iii) a processed/decellularized nerve allograft 
seeded with undifferentiated MSCs or (iv) a processed/decellularized nerve allograft seeded 
with differentiated MSCs.  All four groups were sacrificed after 16 weeks to determine and 
compare degree and patterns of revascularization of the nerves.  The 16 week survival period 
was chosen based on previous research indicating 16 weeks is the time period in which nerve 
regeneration matures.33
Nerve allograft harvest and processing
Ten Sprague-Dawley rats (Envigo, Madison, WI, USA) weighing 250-350 grams served as 
donors of 20 sciatic nerve segments of approximately 15 mm each. Sprague-Dawley rats were 
used to obtain a major histocompatibility complex mismatch with the recipient Lewis rats, in 
order to mimic a clinical setting in which allogenous donor nerves will be used.34, 35 The rats 
were anesthetized in an isoflurane induction chamber and euthanized with an overdose of 
pentobarbital once asleep. Both sciatic nerves were carefully dissected with sharp dissecting 
scissors under an operating microscope (Zeiss OpMi6, Carl Zeiss Surgical GmbH, Oberkochen, 
Germany). Directly after their harvest, the obtained sciatic nerve segments were processed/
decellularized according to a previously published five-day protocol that includes multiple 
washing steps and emerging in elastase.28 Sterilization of the nerve segments was obtained 
with g-irradiation.
Stem cell preparation and differentiation
In accordance with a future clinical trial in which the MSCs will be harvested from a patient, 
MSCs were harvested from the inguinal fat pad of an inbred Lewis rat and processed per 
Kingham and colleagues protocol.36 The obtained MSCs were cultured in previously described 
cell culture conditions.37-39 The MSCs complied with the criteria for MSCs, defined by the 
International Society for Cellular Therapy previously: they were plastic adherent and multi-
potent and expressed canonical MSC-markers like CD44 (88.2%) and CD90 (88.3%) while 
markers such as CD34 and CD45 were absent.30, 40   
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Cell culture
The obtained MSCs were cultured in growth medium that contained a-MEM (Advanced 
MEM (1x); Life Technologies Corporation, NY, USA), 5% platelet lysate (PLTMax®; Mill Creek 
Life Sciences, MN, USA), 1% Penicillin/Streptomycin (Penicillin-Streptomycin (10.000 U/mL; 
Life Technologies Corporation, NY, USA), 1% GlutaMAX (GlutaMAX Supplement 100X; Life 
Technologies Corporation, NY, USA) and 0.2% Heparin (Heparin Sodium Injection, USP, 1.000 
USP units per mL; Fresenius Kabi, IL, USA).
Differentiation of MSCs
The differentiation of MSCs into Schwann cell-like cells was performed and verified 
according to a previously described protocol. This protocol has shown to morphologically 
change 81.5% of the MSCs exposed to the differentiation medium into a typical spindle-like 
shape and lets approximately 40-45% of the exposed MSCs express glial cell marker GFAP, 
Schwann cell marker S100 and neurotrophin receptor p75.36  After two preparatory steps 
with ß-mercaptoethanol (Sigma-Aldrich corp., MO, USA) and all-trans-retinoic acid (1:1000, 
dilution of stock; Sigma-Aldrich Corp., MO, USA), a differentiation cocktail was introduced 
to their growth medium. This differentiation cocktail consisted of Forskolin (Sigma-Aldrich 
corp., MO, USA), basic fibroblast growth factor (bFGF; PeproTech, NJ, USA), platelet derived 
growth factor (PDGF-AA; PeproTech, NJ, USA), and neuregulin-1 ß1 (NRG1-b1; R&D systems 
Inc, MN, USA).
According to the protocol, MSCs differentiation was verified by immunocytochemistry for S100, 
GFAP and neurotrophin receptor p75 (Rabbit anti-S100, mouse anti-GFAP and rabbit anti-p75 
NTR; all ThermoFisher Scientific, MA, USA). Secondary antibodies goat-anti rabbit FITC and 
goat anti-mouse Cyanine-3 (both ThermoFisher Scientific, MA, USA) were used to visualize 
the expression of the before-mentioned markers in differentiated MSCs. Undifferentiated 
MSC and Schwann cells were used as respectively negative and positive control. 
Stem cell seeding
The decellularized allografts were dynamically seeded with 1x10^6 undifferentiated or 
differentiated MSCs for 12 hours at 37°C.  Previous testing has shown that this is the most 
efficient seeding duration, leading to a seeding efficiency of 80% to 95% respectively.30, 31
Surgical procedure
Twenty male inbred Lewis rats (Envigo, Madison, WI, USA) weighing 250-300 gram, served as 
recipient rats. The surgical procedure was performed as previously described.41  The 10 mm 
section of the sciatic nerve was reversed in the autograft group. The processed allografts, either 
unseeded, seeded with undifferentiated MSC or seeded with differentiated MSCs, were used 
to reconstruct a 10 mm sciatic nerve gap in the other three groups. No immunosuppression 
was administered postoperatively. 
Non-survival procedure – measurements
During the non-survival procedures after 16 weeks, all rats (n=5) of each group were 
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anesthetized in an isoflurane induction chamber. Once asleep, the rats were euthanized with 
an overdose of pentobarbital. 
Vascular preservation
A longitudinal incision over the abdomen exposed the abdominal organs. The aorta and 
inferior vena cava were dissected carefully. A catheter was placed and fixed inside the aorta 
over which 10 cc of saline was administered to flush the vasculature. Yellow Microfil® (Flow 
Tech inc., Carver, Massachusetts, USA) was administered by aortic infusion until both toenail 
matrixes were colored, which required at least 19 mL of Microfil®.15 After 90 minutes of curing, 
the sciatic nerves were dissected and cleared in 5 days by immersing them in graded series of 
ethyl alcohol (25% - 50% - 75% - 95%) and a final day in methyl salicylate. 
Vascular surface area
To optimize the accuracy of the measured level of revascularization, the vascular surface area 
and the vascular volume were obtained. The nerve samples were stretched by suturing both 
ends onto a solid holder. While in a petri dish with methyl salicylate, detailed pictures of 
the nerve were obtained with a Canon 5D Mark III camera, a Canon 65 mm Macro lens and 
a Canon Twin Lite Macro strobe light source. Polarized light was used to reduce reflections 
and a 1:1 magnification was used to ensure consistency of the pictures. To correct for the 
3D structure of the nerve sample and the surface area that alters depending on the angle of 
observation, two pictures of each nerve sample were obtained 180 degrees rotated (i.e. front 
and back of nerve).  The solid holder provided a clear distinction between the front and the 
back of the nerve sample. The pictures were blinded before analysis. Using Image Pro Plus 
Software, the total nerve area and the total vessel area were marked and measured and a 
vessel/nerve area ratio was calculated of each picture taken. The ratios of the two pictures 
(i.e. front and back of the nerve) were averaged. The obtained photographs also enabled the 
subjective assessment of the alignment of the preserved vasculature.42
Vascular volume
With a micro-CT (Inveon Multiple Modality PET/CT scanner, Siemens Medical Solutions USA, 
Inc., Knoxville, TN), a CT scan was obtained from the nerve samples with an effective pixel 
size of 9.91mm. As the microfil was more radiopaque than the rest of the nerve, the volume 
of the total nerve and the volume of the vasculature could be measured with Analyze 12.0 
software (AnalyzeDirect, Inc., Overland Park, KS, USA). Eventually, vessel/nerve volume ratios 
were calculated for each scan.42
Correlations
The correlation between the vascular surface area and volume measurements was obtained 
to determine whether the methods are complementary to each other.
Statistical analysis
The outcome measures were analyzed with one-way ANOVA, with Bonferroni correction for 
post-hoc multiple comparisons. Correlations were analyzed with the Pearson’s correlation test. 
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Data are expressed as the mean ±SD. The level of statistical significance was set at a=0.05.
RESULTS
Differentiation of MSCs into Schwann-like cells
Differentiated MSCs all adjusted morphologically to a spindle-like shape and demonstrated 
expression of Schwann cell markers S100, GFAP and NTR p75, which is in accordance with 
Schwann cells (figure 1) and previous studies.  
Figure 1. Differentiation of MSCs into Schwann-like cells was confirmed by comparing the expression 
of Schwann cell markers S100 (A-B-C), GFAP (D-E-F) and NTR p75 (G-H-I) in the differentiated MSCs 
(B-E-H) to the expression in Schwann cells (C-F-I) and undifferentiated MSCs (A-D-G). 
Vascular surface area
Non-operated nerves had a vascular surface area percentage of 34.9±5.7%. Of the four studied 
groups, the vascular surface area was highest in the group that received allografts seeded 
with differentiated MSCs (38.9±7.0%), followed by the group with autografts (29.5±8.7%) and 
the group with allografts seeded with undifferentiated MSC (29.2±3.4%). Unseeded allografts 
(21.2±6.2%) had a significantly lower mean vascular surface area percentage than normal non-
operated nerves (13.7%, p=0.001) and allografts seeded with differentiated MSCs (17.8%, 
p=0.001) (figure 2 and 3). 
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Figure 2. The vascular surface area outcomes of autografts, allografts, allografts seeded with 
undifferentiated MSC and allografts seeded with differentiated MSCs. The unseeded allografts showed 
a significantly lower mean vascular surface percentage than allografts seeded with differentiated MSCs 
and normal nerves (both p<0.001). 
*** = p<0.001, Error bars = standard deviation of the mean.
uMSC = undifferentiated Mesenchymal Stem Cells, dMSCs = differentiated Mesenchymal Stem Cells 
Figure 3. Conventional images of the vasculature of a normal nerve (A) autografts (B), allografts (C), 
allografts seeded with undifferentiated MSC (D) and allografts seeded with differentiated MSCs (E). The 
nerves were positioned from proximal (left) to distal (right). The ingrowth of vessels seem to occured from 
both nerve ends, but from proximal in particular. The structuring of the vessels was clearly less organized 
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Revascularization pattern
The vessels of normal, non-operated nerves aligned in the same longitudinal direction as the 
axons and the vasculature is equally distributed among the entire length of the nerve. The 
preserved vessels in autograft nerves seemed to be largely longitudinally aligned consistent 
with inosculation pattern of revascularization, but were less extensively present than in normal 
nerves.  Unseeded allografts had less vascularization in general and demonstrated minimal if 
any vascularization in their mid-segment.  In both MSC-seeded allograft groups, an extensive, 
non-aligned network of micro-vessels extended from the very proximal to the very distal 
graft end with a centripetal pattern of revascularization.  In all groups, the ingrowth of vessels 
occurs from both nerve ends, but particularly from the proximal stump.  
Vascular volume
The vascular volume measurements showed the same trend as the vascular surface area 
measurements; the allografts seeded with differentiated MSCs contained the highest vascular 
volume (4.6±3.6%), the outcomes of the autografts (3.78±0.7%) and the allografts seeded with 
undifferentiated MSC (3.4±0.2%) did not differ and the unseeded allografts scored the least 
(2.7±1.0%). ANOVA analysis between groups showed no statistically significant differences 
between the groups (F=0.916; p=0.455) (figure 4 and 5).
The vascular surface area and the vascular volume measurements were significantly correlated 
(r=0.416; p=0.008). 
Figure 4. The vascular volume outcomes of autografts, allografts, allografts seeded with undifferentiated 
MSC and allografts seeded with differentiated MSCs. None of the differences between the groups was 
statistically significant.
Error bars = standard deviation of the mean 
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Figure 5. Snapshots of the obtained micro-CT scans that served for the volume measurements of normal 
nerves (A) autografts (B), allografts (C), allografts seeded with undifferentiated MSCs (D) and allografts 
seeded with differentiated MSCs (E). The nerves are positioned from proximal (left) to distal (right). The 
smallest vessels are not detected by the micro-CT due to its effective pixel size.
DISCUSSION
The purpose of this study was to determine whether the previously demonstrated different 
gene expression profiles of differentiated and undifferentiated MSCs would lead to 
different levels and patterns of vascularization when dynamically seeded onto processed/
decellularized nerve allografts. Digital photography and micro-CT imaging allowed for the 
quantification and comparison of vascularity.  
Neoangiogenesis has been previously quantified by counting of RECA-1 positive structures 
(immunohistochemical staining) and histomorphometric evaluation or the measurement 
of capillary density.20, 43-45 These methods unfortunately fall short when aiming to precisely 
quantify and describe vascularity volumes and vascularization patterns. An evaluation 
strategy in which both 2D and 3D measures can be reliably obtained was used in the current 
study in order to compare the effect of undifferentiated versus differentiated MSCs.42  
With respect to vascularization, there was an increase in the vascular surface area of 
processed allografts when seeded with undifferentiated and differentiated MSCs. 
However, only the effect of differentiated MSCs was statistically significant, suggesting that 
differentiated MSCs enhance (neo)angiogenesis to a greater extent than undifferentiated 
MSC. The enhanced expression of neurotrophic and angiogenic genes of MSCs when 
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differentiated into Schwann-like cells is the most likely mechanism of the superior degree 
of (neo)angiogenesis in processed nerve allografts seeded with differentiated MSCs.19, 20, 22, 
25-27, 32, 36, 46 The role of the growth factors in the differentiation medium that might become 
embedded in the extracellular matrix of the cells cannot be ruled out, but they are not 
specifically known to stimulate neoangiogenesis.25 The vascularization in autograft nerves 
and normal non-operated nerves did not significantly differ from both stem-cell groups. 
Revascularization in nerves is hypothesized to occur via two mechanisms: centripetal 
neovascularization (vessels sprouting into the graft from the surrounding tissues) and 
inosculation (vessels sprouting into the graft from both stump ends into the existing vascular 
tree).47 In autografts, there is still an existing vascular tree surrounded by endothelial cells 
which is likely to increase the vascularization speed and improve the alignment of vessels 
which was demonstrated in this study.1 In processed allografts, all cellular debris has been 
removed, leaving no directions for ingrowing vessels.28 In contrast to the longitudinal 
alignment of vessels in normal non-operated and autograft nerves, the vascularization of 
the stem cell-seeded nerve allografts consisted of an extensive network of micro-vessels 
distributed among the entire nerve that were not in line with the expected direction of 
axon regeneration (figure 3). Combining the described differences in revascularization 
pattern, we hypothesize the predominant mechanism of revascularization in autografts 
is inosculation, leading to well-aligned and accelerated revascularization. Centripetal 
neovascularization was hypothetically the predominant mechanism of vascularization or at 
least had a greater share in the revascularization of allografts seeded with MSCs. Based on 
the timeline of angiogenic gene expression profiles in previous research32 and the known 
limited survivability of MSCs in vivo, 29 both type of MSCs are expected to accelerated 
revascularization mainly in the first few days after seeding with a slowly diminishing effect 
up to 29 days.  
The purpose of this study was to determine the effect of type of MSCs on enhancing 
vascularization of processed nerve allografts and to compare degree and pattern of 
vascularization to autograft and allograft nerves. It is thus underpowered to perform 
functional or histological analysis. Despite the small group size however, we were able 
to clearly demonstrate the effect of MSCs on vascularity. We successfully evaluated the 
vasculature of nerves in an accurate manner and were able to objectively quantify the 
amount of (neo)angiogenesis. A future study should focus on functional outcomes.  
The effective pixel size of the used micro-CT may have caused a loss in the detection of 
the smallest vessels, particularly present in both stem cell groups. The CT-scans enabled 
us to fairly compare the volume of the bigger vessels in the operated nerve to that of the 
bigger vessels in the non-operated side, but it sub-optimally displayed the smaller vessels. 
This could partially mask the effect of stem cell seeding, as the MSCs seem to lead to the 
formation of small vessels in particular. For future research, it is advised to use a micro-CT 
scanner with a smaller effective pixel size. This is likely to increase the correlation between 
the vascular volume and the vascular surface area. 
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Although not part of the current study, the presented concept of seeding either differentiated 
or undifferentiated MSCs on the surface of decellularized nerve allografts is hypothesized 
to be clinically applicable. Off the shelve nerve allografts are already clinically available and 
potentially can be seeded with autologous MSCs, which are easily obtainable from the patient 
with peripheral nerve injury. If the hypothesized improved vascularity and functional outcome 
outweigh the extra delay in nerve repair that is necessary for cell-culture (1.5 week) has yet to 
be determined. 
This study demonstrated that the vascularization of nerve grafts can be quantified and that 
both undifferentiated and differentiated MSCs enhance revascularization of processed nerve 
allografts.  
CONCLUSION
The degree of vascularization of the processed/decellularized allograft nerves were improved 
by the addition of undifferentiated and differentiated MSCs, of which only the effect of 
differentiated MSCs was statistically significant.  Revascularization of processed/decellularized 
allograft nerves with or without MSC was mainly via centripetal revascularization compared to 
revascularization in autograft nerves, which occurred via inosculation. 
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Mesenchymal stem cells (MSCs) have the potential to produce neurotrophic growth factors 
and establish a supportive micro-environment for neural regeneration. The purpose of this 
study was to determine the effect of undifferentiated and differentiated MSCs dynamically 
seeded onto decellularized nerve allografts on functional outcomes when used in peripheral 
nerve repair. 
Methods
In 80 Lewis rats a ten millimeter sciatic nerve defect was reconstructed with (i) autograft, (ii) 
decellularized allograft (iii) decellularized allograft seeded with undifferentiated MSCs, or (iv) 
decellularized allograft seeded with MSCs differentiated into Schwann cell-like cells. Nerve 
regeneration was evaluated over time by cross sectional tibial muscle ultrasound measurements, 
and at 12 and 16 weeks by isometric tetanic force measurements (ITF), compound muscle 
action potentials (CMAP), muscle mass, histology and immunofluorescence analyses. 
Results
At 12 weeks, undifferentiated MSCs significantly improved ITF and CMAP outcomes compared 
to decellularized allograft alone, while differentiated MSCs significantly improved CMAP 
outcomes. The autografts outperformed both stem-cell groups histologically at 12 weeks. At 
16 weeks, functional outcomes normalized between groups. At both time points, the effect of 
undifferentiated versus differentiated MSCs was not significantly different. 
Conclusions
Undifferentiated and differentiated MSCs significantly improved functional outcomes of 
decellularized allografts at 12 weeks and were similar to autograft results in the majority 
of measurements. At 16 weeks, outcomes normalized as expected. Although differences 
between both cell-types were not statistically significant, undifferentiated MSCs improved 
functional outcomes of decellularized nerve allografts to a greater extent and have practical 
benefits for clinical translation by limiting preparation time and costs.
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INTRODUCTION
Peripheral nerve defects not amendable to direct end-to-end neurorrhaphy require 
reconstruction with interposition nerve graft which could be accomplished with autograft, 
allograft or synthetic bioabsorbable conduits, each with their benefits and controversies.1-3 
Decellularized nerve allografts have been proposed as an ideal alternative to overcome donor 
site morbidity and limited supply of autografts.1, 4-7 Improvement of outcomes of decellularized 
allografts by addition of host derived mesenchymal stem cells (MSCs) has been proposed to 
overcome the limitations of decellularized allograft nerves by producing trophic factors resulting 
in a favorable micro-environment for tissue regeneration.8-14 MSCs are hypothesized to not only 
stimulate tissue regeneration, but potentially form extracellular matrix components, enhance 
angiogenesis, inhibit scar formation and control immune responses.15 Adipose derived MSCs 
are easily accessible and proliferate faster than bone marrow derived MSCs, while having a 
similar effect on nerve regeneration and are thus ideal for translation to clinical use.16-18 
In comparison to undifferentiated MSCs, MSCs differentiated into Schwann cell-like cells 
express neurotrophic and angiogenic genes to a greater extent than undifferentiated MSCs in 
vitro.16, 19-21 Several in vivo studies using different MSC-delivery strategies did not demonstrate 
clear differences between the outcomes of undifferentiated and differentiated MSCs.22, 23 
Others reported that differentiated MSCs led to longer regenerating axon distance in vivo 19, 21, 
24, 25, without resulting in improved functional outcomes.21 The differentiation process of MSCs 
requires additional preparation time and expensive differentiation factors, which should be 
considered in translating bench work to clinical application.16
Recent studies have reported a non-traumatic strategy to adhere undifferentiated and 
differentiated MSCs to the surface of decellularized allografts, leading to a 29-day in vivo survival 
of seeded MSCs.26-28 The adherence of MSCs to the decellularized allograft has demonstrated 
an interaction between MSCs and the extracellularly matrix leading to enhanced expression of 
neurotrophic, angiogenic, extracellular matrix and regulatory cell cycle genes in the first three 
(differentiated MSCs) to seven (undifferentiated MSCs) days after seeding in vitro, implying a 
direct effect of differentiated MSCs after implementation while undifferentiated MSCs require 
time to interact with the environment.14 
A comparative study focusing on functional outcomes can elucidate the effect of different cells 
and their different effective phases on motor nerve regeneration. The purpose of this study was 
to determine the effect of dynamically seeding undifferentiated and differentiated MSCs onto 
decellularized nerve allografts7 with respect to functional and histologic outcomes in a rat sciatic 
nerve defect model.   
METHODS
Experimental design
After IACUC institutional review committee and our Institutional Review Board approval 
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(IACUC protocol A2464-00),  a 10 mm segmental defect of the sciatic nerve of 80 male 
Lewis rats weighing 250-300 grams (Envigo, Madison, WI, USA) was repaired with a 10 mm 
(i) reversed autograft, (ii) decellularized allograft (iii) decellularized allograft seeded with 
undifferentiated MSCs, or (iv) decellularized allograft seeded with differentiated MSCs. The 
decellularized allografts originated from Sprague-Dawley rats and were specifically chosen 
for their histocompatibility mismatch to Lewis rats.29, 30 This simulates the clinical setting where 
an allogenic processed nerve graft is seeded with autologous MSCs. After 12 and 16 weeks, 
functional, histological and immunofluorescence outcomes were evaluated. 
Nerve allograft collection, processing and seeding
Sixty sciatic nerve segments from 30 Sprague-Dawley rats (Envigo, Madison, WI, USA) 
weighing 250-350 grams served as nerve allografts. After anesthesia with isoflurane, rats were 
euthanized, shaved and sterilely prepped. The sciatic nerve was exposed, removed under an 
operating microscope (Zeiss OpMi6, Carl Zeiss Surgical GmbH, Oberkochen, Germany) and 
processed according to a previously published protocol.7 After sterilization with g-irradiation, 
nerves were stored at 4°C in Phosphate Buffered Saline (PBS) until surgery. 
Stem cell preparation and differentiation
MSCs were derived from the inguinal fat pad of inbred Lewis rats according to protocol.16 
Cells were previously characterized by plastic adherence, pluripotency towards mesodermal 
lineages, the expression of mesenchymal stem cell markers CD29 (88.2%) and CD90 (88.3%) 
and the absence of hematopoetic cell markers CD34 (91.1% absent) and CD45 (86.0% 
absent).26-28 Both cell-types were cultured in an incubator at 37°C (5% CO2) and the growth 
medium was changed every 72 hours. Passage six MSCs were used in this experiment for both 
differentiated and undifferentiated MSCs. 
MSCs-culture
The stromal cell pellet was re-suspended in normal growth medium consisting of  a-MEM 
(Advanced MEM (1x); Life Technologies Corporation, NY, USA), 5% platelet lysate (PLTMax®; 
Mill Creek Life Sciences, MN, USA), 1% Penicillin/Streptomycin (Penicillin-Streptomycin 
(10.000 U/mL; Life Technologies Corporation), 1% GlutaMAX (GlutaMAX Supplement 100X; 
Life Technologies Corporation) and 0.2% Heparin (Heparin Sodium Injection, USP, 1.000 USP 
units per mL; Fresenius Kabi, IL, USA). 
MSC differentiation
MSCs were differentiated into Schwann cell-like cells using a differentiation cocktail containing 
0.14% Forskolin (Sigma-Aldrich corp., MO, USA), 0.01% basis fibroblast growth factor (bFGF; 
PeproTech, NJ, USA), 0.005% platelet-derived growth factor (PDGF-AA; PeproTech) and 
0.02% Neuregulin-1 ß1 (NRG1-b1; R&D systems Inc, MN, USA).16 Differentiation was assessed 
by immunocytochemistry for the expression of S100 (S100; ThermoFisher Scientific, MA, 
USA), Glial fibrillary acidic protein (GFAP, mouse anti-GFAP; ThermoFisher Scientific) and 
neurotrophin receptor p75 (p75 NTR, rabbit anti-p75 NTR; ThermoFisher Scientific). Goat 
anti-rabbit fluorescein isothiocyanate (FITC) and goat anti-mouse cyanine 3 (CY3, both 
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ThermoFisher Scientific) were used as secondary antibodies. Cell nuclei were labeled with 
4’,6-diamidino-2-phenylindole (DAPI). 
Seeding Protocol for Allograft Nerves
To attach the undifferentiated and differentiated MSCs to the decellularized nerve allografts 
they were dynamically seeded according to a previously described protocol.28 Either 1x10^6 
undifferentiated MSCs or 1x10^6 differentiated MSCs in 10mL growth medium were placed 
in a conical tube containing a decellularized nerve allograft. The conical tube was then placed 
on a bioreactor that was positioned in an incubator at 37°C (5% CO2). After the bioreactor had 
rotated for 12 consecutive hour, the nerve grafts with the attached MSCs were taken out of the 
tubes and directly implemented in the Lewis rats. The dynamic seeding strategy previously 
resulted in  80% and 95% adherence of cells on the surface of the processed allografts for 
undifferentiated and differentiated MSCs respectively.27, 28 
Surgical procedure of the recipient animals
Under isoflurane anesthesia the right sciatic nerve of the Lewis rat was exposed. A 10 mm 
segment of the sciatic nerve was excised and reconstructed with a 10 mm graft under an 
operating microscope (Zeiss OpMi6, Carl Zeiss Surgical GmbH, Oberkochen, Germany). The 
epineurium was sutured with six 10-0 sutures (10-0 Ethilon, Ethicon Inc., USA), the muscle 
was approximated (6-0 Vicryl Rapide, Ethicon Inc.) and the skin was closed with a continuous 
subcutaneous suture (5-0 Vicryl Rapide, Ethicon Inc.). All rats received 5mL of 0.9% saline 
solution, 0.6mg/kg Buprenorphine and one dose of 30mg/kg diluted trimethoprim/sulfadiazine 
subcutaneously (Tribissen, Five Star Compounding Pharmacy, Clive, IA). Postoperatively, the 
rats were individually housed and provided with food and water ad libitum with a 12-hour 
light-dark cycle. 
Ultrasound measurements
The cross-sectional tibial muscle area of six randomly selected rats per group was evaluated 
with ultrasound measurements of both sides at baseline and at two, four, eight, twelve and 
sixteen weeks after surgery as previously described using a GE Vivid 7 Ultrasound system 
(General Electric, Fairfield, CT, USA).31, 32 Cross-sectional area was calculated with Adobe 
Photoshop CC 2018 (Adobe Systems Incorporated, San Jose, CA, USA). 
Nonsurvival procedure
At 12 and 16 weeks, ten rats of each group underwent a non-survival procedure. Anesthesia 
was induced by isoflurane, followed by intraperitoneal injection of Ketamine (80mg/kg) and 
Xylazine (10mg/kg) and maintained by additional doses of Ketamine (40mg/kg). 
Compound Muscle Action Potentials (CMAP) - A miniature bipolar electrode was clamped 
around the sciatic nerve proximal to the nerve graft. One ground electrode was placed in 
surrounding musculature and two recording electrodes were superficially placed in the anterior 
tibial muscle. The CMAP was measured using a VikingQuest portable electromyelogram 
(Nicolet Biomedical, Madison, WI). A non-recurrent single stimulation with a duration of 
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0.02ms at an intensity level of 2.7mA was applied. Maximal amplitude measurements were 
obtained bilaterally.33, 34
Isometric Tetanic Force (ITF) - The ITF was measured bilaterally per the protocol of Shin and 
colleagues.35 The peroneal nerve and tibial muscle were exposed and the hind limb was 
secured to a testing platform with K-wires through the femur and ankle. The tibial tendon 
was secured to a clamp in anatomical position and attached to a force transducer (MDB-50; 
Transducer Techniques, Temecula, CA, USA) whose signals were processed using LabView 
(National instruments, Austin, Texas). A miniature electrode (Harvard Apparatus, Holliston, 
MA, USA), stimulated by a bipolar stimulator (Medtronic, Minneapolis, MN, USA) was clamped 
around the peroneal nerve branch of the sciatic nerve. The muscle tension and the stimulator 
frequency were optimized after which the maximal ITF was obtained. The tibial muscle was 
kept moist with warm saline.
Wet tibial muscle mass - Rats were euthanized with an overdose of pentobarbital (Fatal Plus, 
390 mg/mL, Vortech, Dearborn, MI, USA) intraperitoneally. Tibial muscles were harvested 
bilaterally and wet muscle mass was determined after removing the tendon. 
Histology - A three millimeter segment of both peroneal nerves of all rats were collected 
and placed  into Trumps solution. Specimens were processed with 0.1M Phosphate Buffer, 
1% Osmium tetroxide in buffer, graded series of alcohol and acetone. The samples were 
infiltrated in a 50%, 75% and finally 100% epoxy resin and polymerized at 65°C for 12-18 hours. 
Samples were cut in sections at 0.6 microns, placed on slides and stained on a warming plate 
with Toluidine blue for 2-2.5 minutes. The total tissue cable area (nerve area), axon area, axon 
count and myelin area were obtained using a Nikon Eclipse 50i microscope and Image Pro 
Plus Software. The N-ratio was calculated by dividing the myelinated fiber area (axon area and 
myelin area) by the tissue cable area.36
Immunofluorescence - Both sciatic nerves of five randomly selected rats per group were 
dissected and fixed in 10% formalin for 48 hours. Nerves samples were vertically embedded 
in paraffin and sections from the exact middle were stained for Schwann cell marker S100 and 
protein gene product 9.5 (PGP9.5), a pan neuronal marker. Immunohistochemical staining was 
performed at the Pathology Research Core (Mayo Clinic, Rochester, MN, USA) using the Leica 
Bond RX stainer (Leica, Buffalo Grove, IL, USA). The S100 (rabbit polyclonal; Dako, Agilent 
Technologies Inc., Carpinteria, CA, USA) and PGP9.5 primary antibody (rabbit polyclonal; 
Dako, Agilent Technologies Inc.) were diluted to 1:5000 in Background Reducing Diluent 
(Dako, Agilent Technologies Inc.) and incubated for 60 minutes with the samples, prior to 
staining with the appropriate secondary antibody (Alexa Goat-Anti-Rabbit 488, 1:300, for 
S100 and Alexa Goat-Anti-Rabbit 568, 1:200 for PGP9.5) and counterstained with Hoechst 
33342 (all ThermoFisher Scientific, MA, USA). Images of the stained slides were obtained 
with a fluorescence laser confocal microscope (Zeiss LSM 780, Carl Zeiss Surgical GmbH, 
Oberkochen, Germany). The mean fluorescent density of both stains was measured using 
ImageJ software.  
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Statistical analysis 
All obtained images were blinded and all outcomes were expressed as a percentage of the 
contralateral side to correct for biological variability between rats. Non-physiologic outcomes 
were excluded from analysis after review by a statistician and an independent researcher. Two-
way analysis of variance (ANOVA) was used for the cross-sectional tibial area measurements. 
One-way ANOVA was used to compare all other outcome measures between groups. Post-
hoc Bonferroni was used to correct for multiple comparisons. Outcomes were expressed as 
the mean and the standard error of the mean (SEM). Outcomes of cross-sectional tibial muscle 
area were expressed as mean difference and the standard error of the mean difference. The 
level of significance was set at a>0.05.
RESULTS
MSC differentiation
Differentiated MSCs showed immunofluorescence for the markers S100, GFAP and p75 NTR, 
corresponding to Schwann cells that served as positive controls. Undifferentiated MSCs did 
not show expression of these markers (figure 1).
Figure 1. Differentiation of MSCs into Schwann-like cells. Comparison of immunocytochemistry between 
undifferentiated MSCs (A-D-G), differentiated MSCs (B-E-H) and Schwann cells (C-F-I). Cells are tested 
for the presence of Schwann cell marker S100 (green, A-B-C), glial cell marker GFAP (red, D-E-F) and 
neurotrophin Receptor p75 (green, G-H-I). Cell nuclei are DAPI-stained (blue). 40X magnificantion, white 
scale bar = 40μm.




Cross-sectional tibial muscle area (fi gure 2)
No signifi cant differences between the groups were found. Within group comparisons only 
showed signifi cant differences between the consecutive time points zero and two weeks 
after surgery for autografts, allografts and allografts seeded with differentiated MSCs. The 
lowest tibial muscle area in all groups was reached at two weeks (40-60% of the unoperated 
side) and improved up to 16 weeks, with a cross-sectional tibial muscle area ratio of 
approximately 75%. 
Figure 2. Cross-sectional tibial muscle area ratios (R/L) over time. No signifi cant differences were found 
between groups. Autografts (+15.77 ±6.56%) and unseeded allografts (+11.33 ±9.22%) had the strongest 
increase in muscle area between 8 and 12 weeks, while allografts seeded with undifferentiated MSCs 
(+16.13 ±3.83%) and differentiated MSCs (+10.87 ±9.29%) experienced their strongest increase between 
4 and 8 weeks after surgery. uMSCs = undifferentiated Mesenchymal Stem Cells;  dMSCs = differentiated 
Mesenchymal Stem Cells. Error bars = Standard error of the mean
Compound Muscle Action Potential (CMAP) (fi gure 3)
At 12 weeks, CMAP ratio of unseeded allografts (13.48 ±5.00%) was signifi cantly inferior to 
autografts (53.78 ±5.82%) (p<0.001), allografts seeded with undifferentiated MSCs (44.32 
±7.20%) (p=0.004) and differentiated MSCs (48.89 ±5.37%) (p<0.001). At 16 weeks, CMAP 
ratio was normalized between all groups, with 57.51 ±7.54% for autografts, 52.26 ±5.80% 
for allografts, 66.04 ±7.28% for allografts with undifferentiated MSCs and 61.49±8.16% for 
allografts with differentiated MSCs. 
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Isometric Tetanic Force (ITF) (fi gure 4)
The ITF ratio of allografts seeded with undifferentiated MSCs (49.74 ±6.80%) was signifi cantly 
higher compared to unseeded allografts (26.32 ±4.36%) (p=0.017) at 12 weeks. The ratio in 
autografts (44.16 ±3.32%) and allografts seeded with differentiated MSCs (43.10 ±4.59%) did 
not demonstrate signifi cant differences with any of the other groups. At 16 weeks, the ITF ratio 
of autografts (51.11 ±4.98%), allografts (56.22 ±4.44%), allografts with undifferentiated MSCs 
(56.12 ±6.51%) and allografts with differentiated MSCs (53.86 ±4.47%) did not signifi cantly 
differ. 
Figure 3. Compound muscle action potential ratios (CMAP, R/L) at 12 and 16 weeks. CMAP recovery of 
unseeded allografts was signifi cantly inferior compared to all other groups at 12 weeks 
uMSCs = undifferentiated Mesenchymal Stem Cells; dMSCs = differentiated Mesenchymal Stem Cells
* = p<0.05, ** = p<0.01, *** = p<0.001. Error bars = Standard error of the mean
Figure 4. Isometric Tetanic Force ratios (R/L) at 12 and 16 weeks. ITF recovery of unseeded allografts were 
signifi cantly inferior compared to allografts seeded with undifferentiated MSCs at 12 weeks 
uMSCs = undifferentiated Mesenchymal Stem Cells; dMSCs = differentiated Mesenchymal Stem Cells
* = p<0.05, ** = p<0.01, *** = p<0.001. Error bars = Standard error of the mean
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Muscle mass (fi gure 5)
At 12 weeks, unseeded allografts measured a signifi cantly lower tibial muscle mass 
ratio (49.54 ±2.30%) compared to autografts (59.84 ±1.64%) (p=0.021). Allografts with 
undifferentiated and differentiated MSCs measured a muscle mass ratio of 57.68 ±2.87% 
and 55.21 ±2.36% respectively. At 16 weeks, the muscle mass ratio of allografts seeded with 
undifferentiated MSCs was 59.96 ±3.79%, which signifi cantly differed from autografts (74.13 
±1.90%) (p=0.002). Unseeded allografts and allografts seeded with differentiated MSCs had 
a muscle mass ratio of 69.09 ±1.54% and 70.09 ±2.60% respectively. 
Histology 
All obtained histology and immunofl uorescence values are displayed in table 1. Figure 6 
provides representative nerve sections of the different groups. At 12 weeks, autografts had 
a signifi cant larger axon area ratio compared to unseeded allografts (p<0.001), allografts 
seeded with undifferentiated MSCs (p<0.001) and allografts seeded with differentiated 
MSCs (p=0.004). At 16 weeks, no signifi cant differences in axon area ratio between groups 
were found. The axon count, myelin area  and nerve area measures did not demonstrate 
any signifi cant differences between groups at any of the time points. Autografts had a 
signifi cant higher N-ratio compared to unseeded allografts (p=0.023) and allografts seeded 
with undifferentiated MSCs (p=0.040) at 12 weeks. At 16 weeks, autografts had a signifi cantly 
better N-ratio compared to unseeded allografts (p=0.003), allografts with undifferentiated 
MSCs (p=0.025) and allografts with differentiated MSCs (p=0.002) (fi gure 7). 
Figure 5. Wet tibial muscle mass ratios (R/L) at 12 and 16 weeks. Autografts showed a signifi cantly 
higher muscle mass recovery compared to unseeded allografts at 12 weeks, and allografts seeded 
with undifferentiated MSCs at 16 weeks. uMSCs = undifferentiated Mesenchymal Stem Cells; dMSCs = 
differentiated Mesenchymal Stem Cells. * = p<0.05, ** = p<0.01, *** = p<0.001. Error bars = Standard 
error of the mean
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Table 1. Histology and immunofluorescence outcomes obtained at 12 and 16 weeks for all groups. 
Outcomes are displayed as the mean and the standard error of the mean (SEM).
uMSCs = undifferentiated Mesenchymal Stem Cells; dMSCs = differentiated Mesenchymal Stem Cells
* = p<0.05, ** = p<0.01, *** = p<0.001. Error bars = Standard error of the mean
Figure 6. Examples of obtained images of peroneal nerve sections stained with toluidine blue at 12 weeks 
of follow-up. Scale bar upper images = 1mm, lower images = 0.5mm. 




S100 and PGP9.5 density outcomes are displayed in table 1. Examples of obtained 
immunofl uorescence images are displayed in fi gure 8. Between group comparisons showed 
no signifi cant differences in S100 and PGP9.5 density ratio at both time points. 
Figure 7. N- ratios (R/L) at 12 and 16 weeks. Autografts had a signifi cant higher N-ratio than unseeded 
allografts and allografts seeded with undifferentiated MSCs at 12 weeks and compared to other groups 
at 16 weeks. uMSCs = undifferentiated Mesenchymal Stem Cells; dMSCs = differentiated Mesenchymal 
Stem Cells. * = p<0.05, ** = p<0.01, *** = p<0.001. Error bars = Standard error of the mean
Figure 8. An overview of examples of the obtained images of nerve sections stained with S100 (Schwann 
cells, green) or PGP9.5 (axons, red) (both immunohystochemistry) at 12 weeks. Cell nuclei are DAPI 
stained and displayed in blue. The displayed images are obtained with 20X magnifi cation, white error 
bar = 0.2mm.
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DISCUSSION
Despite advances in decellularization techniques for allograft nerves, nerve autograft remain 
the gold standard for segmental defect reconstruction of critical motor or sensory nerves.1, 6 To 
overcome the limitations of decellularized allograft nerves, MSCs have been hypothesized to 
improve outcomes of decellularized allograft nerves7 by producing proteins and cytokines that 
establish a micro-environment favorable for neural regeneration.8, 12-14, 37 Differentiated MSCs 
have been demonstrated to exert their neurotrophic effect immediately after implementation 
by expressing increased levels of neurotrophic genes, while undifferentiated MSCs require 
additional time to interact with the surrounding tissue prior to expressing neurotrophic 
genes.14 The purpose of this study was to determine the effect of dynamically seeding 
undifferentiated and differentiated MSCs onto decellularized nerve allografts7 with respect to 
functional and histologic outcomes in a rat sciatic defect model, in order to determine which 
cell-type has greatest clinical potential. 
In this study, MSCs were successfully differentiated into Schwann cell-like cells16 and 
dynamically seeded onto decellularized nerve allografts.27 Compared to unseeded allografts, 
undifferentiated MSCs led to significant improvement of both ITF and CMAP (p=0.017 and 
p=0.004) outcomes at 12 weeks, while differentiated MSCs only led to significant improved 
CMAP outcomes (p<0.001). These findings correspond to the study of Hou and colleagues 
whom observed that (differentiated) MSC-seeded grafts recovered earlier than acellular 
grafts when measuring electrophysiology, with significant results at 12 weeks.38 Differences 
between groups normalized at 16 weeks which is consistent with the study of Tang and 
colleagues, that demonstrated normalizing ITF measurements at 16 weeks of follow-up.39 
Functional assessment did not result in any significant differences between both cell-types for 
all functional outcome measures at 12 and 16 weeks, which is in line with  published studies 
of Orbay and Watanabe.22, 23 The hypothesized consequences of different effective phases of 
both cell-types could not be confirmed in this study. 
At 16 weeks, no significant differences in functional outcomes between groups were found, 
except for muscle mass recovery that was significantly better in autografts than in allografts 
seeded with differentiated MSCs (p=0.002). Although muscle mass is easily obtainable, it is 
an indirect measurement of motor outcome as enlarged muscle fibers do not neccesarily 
feature improved contractility.36 ITF has been described to objectively quantify contractility of 
muscle fibers and is easily reproducible.36 The vulnerability of CMAP measurements, which is 
affected by the placement of all individual electrodes, may explain why the CMAP outcomes 
are greater than the ITF measures.40
Histologically, the autografts had significantly better N-ratios in the peroneal nerves at both 
time points compared to all other groups. Although not examined, this could be explained 
by less formation of fibrosis in autografts.41 Due to small groups and insufficient sensitivity 
of density measures, the histology outcomes could not be significantly confirmed by 
immunofluorescence outcomes, but unseeded nerve allografts subjectively seem to contain 
less Schwann cells and axons compared to all other groups. 
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Autografts were used as control group to test whether MSCs could improve outcomes of 
decellularized allografts up to a level equal to that of autografts. While an additional control 
group in which sham surgery is performed would also be interesting to have, it would require 
the undesirable and precious use of additional animals. Alternatively, outcomes of the 
operated side were normalized to the unoperated control side in order to relate the test-
outcomes to normal nerve and muscle function. 
The significant differences between groups presented at 12 weeks and normalized after 
16 weeks, insinuates that nerve regeneration in motor nerves in rats will occur after 12 
weeks independently from the type of nerve repair. This finding might be correlated to 
the demonstrated finite survival of MSCs up to 29 days in vivo; it is suggested that MSCs 
significantly enhance nerve regeneration up to 12 weeks after which the superlative 
neuroregenerative capacity of rats takes over, due to the apoptosis of the MSCs.42 The 
superlative neuroregenerative capacity of rats is a commonly described explanation and can 
be mitigated in a larger animal model.26, 39 Absent significant differences when comparing 
cross-sectional tibial muscle areas is also a likely consequence of using a small animal model 
with small cross-sectional nerve areas, relatively leading to larger standard errors and less 
significant differences between groups.31, 32 Future research should be performed on multiple 
time points in larger animal models with larger nerve gaps to potentially translate outcomes 
to humans. 
Considering the overall goal to improve outcomes of decellularized nerve allografts in clinical 
practice, clinical applicability should be considered when interpretating results. The use 
of autologous differentiated MSCs requires approximately 4-5 weeks of preparation time, 
against 2-3 weeks for undifferentiated MSCs.16 Moreover, the costs of the differentiation 
cocktail required to differentiate MSCs into Schwann Cell-like cells are high and add to the 
costs of extended cell culture. Differences between undifferentiated an differentiated MSCs 
were not statistically significant in light of the analyzed factors, but undifferentiated MSCs 
improved functional outcomes of decellularized nerve allografts to a greater extent than 
differentiated MSCs. Taking all this in consideration, undifferentiated MSCs have the greatest 
potential for bench-to-bedside application. Hypothetically, at the day of presentation in a 
clinical setting, adipose tissue can be obtained using minimally invasive techniques from 
the patient with nerve injury, MSCs can then be derived from this tissue and cultured for 
approximately 2 weeks after which the MSCs can be dynamically seeded onto an off-the-shelf 
commercially available nerve allografts, 12 hours in advance of the nerve repair. Translation 
to a larger animal model to ensure the enhanced functional outcomes, study of the capacity 
of human MSCs to be seeded on clinically available nerve allografts and FDA approval are 
potential hurdles that need to be addressed prior to application of the presented strategy in 
clinical practice. 
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CONCLUSION
Undifferentiated and differentiated MSCs significantly improved functional outcomes of 
decellularized allografts at 12 weeks in motor nerves and equaled the autograft results in the 
majority of outcome measurements. At 16 weeks, outcome measures normalized as expected. 
Considering clinical applicability, undifferentiated MSCs are more attractive as outcomes did 
not significantly differ between both cell-types, and differentiation requires increased time 
and cost.
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When direct nerve coaptation is impossible after peripheral nerve injury, autografts, 
processed allografts or conduits are used to bridge the nerve gap. The purpose of this study 
was to examine if human adipose derived Mesenchymal Stromal/Stem Cells (MSCs) could be 
introduced to commercially available nerve graft substitutes and to determine cell distribution 
and seeding efficiency of a dynamic seeding strategy. 
Methods
MTS assays examined the viability of human MSCs after introduction to the Avance® Nerve 
Graft and the NeuraGen® Nerve Guide. MSCs were dynamically seeded on nerve substitutes 
for either 6, 12 and 24 hours. Cell counts, live/dead stains, Hoechst stains and Scanning 
Electron Microscopy (SEM) revealed the seeding efficiency and the distribution of MSCs after 
seeding. 
Results
The viability of MSCs was not affected by the nerve substitutes. Dynamic seeding led to 
uniformly distributed MSCs over the surface of both nerve substitutes and revealed MSCs 
on the inner surface of the NeuraGen® Nerve Guides. The maximal seeding efficiency of 
NeuraGen® Nerve Guides (94%), obtained after 12 hours was significantly higher than that of 
Avance® Nerve Grafts (66%) (p=0.010). 
Conclusion
Human MSCs can be dynamically seeded on Avance® Nerve Grafts and NeuraGen® Nerve 
Guides. The optimal seeding duration was 12 hours. MSCs were distributed in a uniform 
fashion on the exposed surfaces. This study demonstrates that human MSCs can be effectively 
and efficiently seeded onto commercially available nerve autograft substitutes in a timely 
fashion and sets the stage for clinical application of MSC seeded nerve graft substitutes.
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INTRODUCTION
Peripheral nerve discontinuities that cannot be restored by direct end-to-end coaptation of 
nerve ends remain a clinical challenge. Despite many efforts to find an equivalent replacement, 
autologous nerve graft, which results in donor site morbidity, remains the gold standard 
in peripheral nerve reconstruction. To minimize donor site morbidity, increase the number 
of reconstructive options and improve the outcomes of peripheral nerve repair, further 
improvement of the commercially available ‘off-the-shelf’ nerve graft substitutes is essential. 
Two commercially available nerve autograft substitutes are the NeuraGen® Nerve Guide 
(approved by the Food and Drug Administration in 2001) and the Avance® Nerve Graft 
(approved by the FDA in 2007). The NeuraGen® Nerve Guide is an artificial bioabsorbable 
hollow conduit made of purified bovine type I collagen. It has demonstrated effective nerve 
regeneration in small diameter, short (<3cm) sensory nerves defects, but evidence for its 
effective use in sensory nerve defects of longer size and/or larger diameter, or in motor nerve 
defects, remains scarce and inconsistent.1-3
The Avance® Nerve Graft is a decellularized human nerve allograft that has been processed 
to remove cellular debris. This process includes decellularization with chondroitinase and 
gamma-irradiation, leading to a natural human product with a remaining ultrastructure that 
does not necessitate the use of immunosuppression. While clinical outcomes have been 
mostly with case reports and series 1, 4-6, there has been a lack of prospective clinical trials 
and valid comparisons to autografts. Their application in large motor-nerve defects remains 
controversial.1, 4, 7, 8
The hypothesis that the addition of a cells that deliver growth factors at the nerve regeneration 
site could result in enhanced nerve regeneration has been confirmed by studies reporting 
a synergistic effect of mesenchymal stromal/stem cells (MSCs) added to a nerve conduit, 
leading to improved functional outcomes in various types of nerve gaps.9-14 Similarly,  the 
enhancing effect of added MSCs or Schwann cells to processed nerve allografts has also been 
demonstrated on a gene expression and functional outcome level.15-20
A variety of non-validated delivery methods have been reported. Micro-injection has been 
extensively described to deliver the MSCs.  Acute micro-injection is known to be traumatic 
to MSCs even though cells remain metabolically active.21 Micro-injection also damages the 
ultrastructure of the allograft and when placed in the center of a hollow conduit, leakage 
occurs which may alter the effective dose of MSCs in an unpredictable manner.22-27 Dynamic 
seeding is a novel, recently described delivery method that successfully adheres MSCs in a 
uniform matter on the surface of processed nerve grafts.27, 28
Application and validation of this dynamic seeding strategy when applied to commercially 
available products like the Avance® Nerve Graft and the NeuraGen® Nerve Guide could 
enhance the clinical applicability of the described method and would enable a valid 
comparison of the two products and their capability to enhance nerve regeneration when 




In order to determine the clinical potential of dynamic seeding of MSCs, this study was 
designed to examine the interaction between MSCs and two commercially available nerve 
graft substitutes; the Avance® Nerve Graft and the NeuraGen® Nerve Guide. The purpose 
of this study was to determine (I) if the interaction of human adipose derived MSCs with the 
NeuraGen® Nerve Guide and the Avance® Nerve Graft influences cell viability, (II) if human 
adipose derived MSCs can be dynamically seeded and distribute uniformly onto these nerve 




Two experiments were designed to ascertain the interaction of the nerve graft substitutes 
with human adipose derived MSCs and to determine the optimal seeding times, survivability 
and distribution of MSCs.
Adipose Derived Mesenchymal Stem Cell Collection and Preparation
Passage five human MSCs, isolated from abdominal lipo-aspirates of a male donor were 
used in this experiment. Cells were provided by the Mayo Clinical Human Cellular Therapy 
Laboratory (Rochester, Minnesota, USA). These MSCs have been tested extensively for 
multi-lineage potential, cell surface markers (CD73, CD90, CD105, CD44, CD14, CD45) and 
RNA-sequence transcriptome profiles previously.(23-25) For MSC culture, growth media 
consisting of a-MEM (Advanced MEM (1x); Gibco by Life TechnologiesTM, Cat #12492013), 
5% platelet lysate (PLTMax®; Mill Creek Life Sciences), 1% penicillin/streptomycin (Penicillin-
Streptomycin (10.000 U/mL); Gibco by Life TechnologiesTM Cat #15140148), 1% GlutaMAX 
(GlutaMAXTM Supplement 100X; Gibco by Life Technologies, Cat #35050061) and 0.2% 
heparin (Heparin Sodium Injection, USP, 1.000 USP units per mL; NOVAPLUS®) was used 
and media was changed every 72 hours. 29-31  
Experimental Design and Measurement of Mesenchymal Stem Cell Viability
To test whether the chemical products used during processing of the Avance® Nerve 
Graft and the NeuraGen® Nerve Guide are harmful to MSCs, cell metabolic activity was 
measured using (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) (MTS) assays that were performed according to the manufacturer’s protocol 
(CellTiter 96® AQueous One Solution Cell Proliferation Assay, Promega®). Twenty-four 
2mm-segments of the Avance® Nerve Graft and the NeuraGen® Nerve Guide were soaked 
in a-MEM for two hours prior to the MTS assay. The soaked nerve substitute segments and 
5,000 MSCs dissolved in 100μL growth medium were placed into wells which were coated 
with pHEMA (Poly 2-hydroxyethyl methacrylate; Sigma Cat # P3932) to prevent migration 
of the MSCs to the plastic well. Any influence of the pHEMA coating on cell viability, was 
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eliminated by measuring the viability of two extra groups (MSCs + Avance® Nerve Graft 
and MSCs + NeuraGen® Nerve Guide) at each time point. After 1, 2, 3 and 7 days of 
incubation at 37°C the metabolic activity of three samples of each group were measured 
with the Infinite® 200 Pro TECAN Reader (Tecan Trading AG, Switzerland) at an absorbance 
wavelength of 490nm. The metabolic activity of group I (pHEMA + MSCs + Avance® Nerve 
Graft) and group II (pHEMA + MSCs + NeuraGen® Nerve Guide) were expressed as a ratio 
of the metabolic activity of the control group (pHEMA + MSCs) and compared to each other.
Experimental Design and Measurement of Cell distribution, Migration and Seeding 
Efficiency
In total, 20 Avance® Nerve Grafts and 20 NeuraGen® Nerve Guides of 10mm in length were 
used in this experiment. 18 samples per group were dynamically seeded according to the 
dynamic seeding strategy described by Rbia and colleagues.27 Prior to seeding, all nerve 
substitute segments were soaked in a-MEM for two hours as an equilibration step to restore 
the salt balance. Conical tubes containing the nerve samples and one million MSCs per 
nerve sample in growth medium were rotated in a bioreactor placed in an incubator (37°C) 
for 6, 12 and 24 hours (n=6 per group per seeding duration).
The viability of adherent MSCs was evaluated by live/dead Cell Viability Assays (Invitrogen, 
Life Technologies Corporation, NY, USA) after each of the different seeding durations. 
Hoechst staining was performed according to standard protocols (Hoechst stain solution; 
Sigma-Aldrich Corp., MO, USA) on the surface of the nerve substitutes to show the 
distribution and migration of cells after dynamic seeding. Both Live/Dead and Hoechst 
stains were performed on three samples per group per seeding duration and were visualized 
directly after seeding with a confocal microscope (Zeiss LSM 780 confocal microscope).
To study cell distribution, Scanning Electron Microscopy (SEM) (n=3 per group per 
seeding duration) was performed. Samples were fixed in 2% Trump’s fixative solution (37% 
formaldehyde and 25% glutaraldehyde) directly after seeding. After 24 hours, samples were 
washed with phosphate buffer, rinsed in water, processed through graded series of ethanol 
(final 100% ethanol), critical point dried with carbon and mounted on an aluminum stub. 
After sputter-coating for 60 seconds using gold-palladium, sample-images were taken with 
a Hitachi S-4700 cold field emission SEM (Hitachi High Technologies America, Inc., IL, USA) 
at 5kV accelerating voltage. After obtaining images of the graft surface, samples were cut 
longitudinally and imaged to reveal cell distribution on the inside of the nerve substitutes.
To reinforce the SEM-findings, two extra 10mm samples per group were seeded with 1 
million MSCs according to the estimated optimal seeding duration, fixed in 10% formalin 
and processed and embedded in paraffin. Three sections of 5µM of the proximal- and mid-
nerve substitutes were taken and Hoechst stained to evaluate for cells that migrated inside 
the nerve substitute (i.e. within the nerve allograft or nerve conduit material itself). The 
cells were visualized with a confocal microscope (Zeiss LSM 780 confocal microscope; Zeiss, 
Germany).
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To quantify seeding efficiency, cell counts of the cell supernatant after the rotation duration 
was completed, provided the number of MSCs that remained free floating in the media. 
This indirectly led to the number and percentages of MSCs that were attached to the nerve 
sample, in this manuscript expressed as seeding efficiency.32
In addition to cell counts in the supernatant, seeding efficiency of MSCs after the various 
seeding durations was further evaluated by Hoechst fluorescence staining of the seeded 
nerve substitutes using the Infinite® 200 Pro TECAN Reader (Tecan Trading AG, Switzerland) 
at an absorbance wavelength of 340/458nm. 
Statistical analysis
Cell counts were performed in triplicate per sample and are expressed as the mean percentage 
± standard deviation (SD). The different measurements were analyzed using a two-way 
ANOVA. When ANOVA indicated a significant interaction, both within and between group 
comparisons were analyzed with the Kruskal-Wallis test, followed by pairwise comparisons 
using Wilcoxon rank-sum tests with Bonferroni correction. Significance was set at a>0.05. 
RESULTS
Cell Viability upon interaction of MSCs with Nerve Graft Substitute: 
Analysis revealed no significant effect on cell viability of the pHEMA coating that was used 
in this experiment. The viability of MSCs when in presence with the Avance® Nerve Graft or 
the NeuraGen® Nerve Guide, expressed as a ratio of the viability of MSCs without either of 
the nerve substitutes in figure 1, was not affected by the presence of both nerve substitutes 
indicating that there was no detrimental interaction of the manufacturing process to MSCs. 
There were no significant differences in cell-viability between and within the two groups over 
time as well (p=0.450). 
Cell distribution, migration and seeding efficiency of MSCs on Nerve Graft Substitute 
Live/dead staining and nuclear staining using Hoechst dye revealed a uniform distribution 
of viable MSCs over the entire surface of both nerve substitutes after all seeding durations. 
Figure 2 and 3 demonstrate example images after 12 hours of seeding of live/dead staining 
and Hoechst staining respectively. Hoechst fluorescent measurements demonstrated 
increased fluorescence as seeding duration time increases (figure 4) (p=0.001), but there were 
no significant differences in Hoechst fluorescence between groups.  
Despite the different composition of the surfaces of the Avance® Nerve Graft and the 
NeuraGen® Nerve Guide, SEM images revealed a similar distribution of cells among 
their surface (figure 5). Manual quantification could not be carried out reliably due to cell 
aggregation, but assessment of the samples showed a marked increase in cell coverage 
of both nerve substitutes between 6 and 12 hours of seeding. Between 12 and 24 hours of 
dynamic seeding, there were no appreciable differences in cell coverage. The morphology of
Proefschrift.indd   132 19-07-21   22:26
8
Stem cells on nerve graft substitutes
133
Figure 1. Cell-viability over time of MSCs when combined with the Avance® Nerve Graft and the 
NeuraGen® Nerve Guide (n=3 per group per time point). Viability of MSCs in presence of the Avance® 
Nerve Graft  and the NeuraGen® Nerve Guide is expressed as a ratio of the viability of MSCs without any 
of the nerve substitutes. pHEMA coating was used in all groups presented in this figure. There were no 
significant differences between and within groups in 7 days of follow-up. Error bars: SEM. SEM = standard 
error of the mean
Figure 2. Live/Dead stains of a seeded Avance® Nerve Graft (A) and a seeded NeuraGen® Nerve 
Guide (B) after 12 hours of seeding with MSCs, show mainly living cells (green) mixed with only a few 
dead cells (red) on the surface of both nerve substitutes. 
Figure 3. Hoechst stained Avance® Nerve Graft (A) and NeuraGen® Nerve Guide (B) after 12 hours of 
dynamic seeding with MSCs show a uniform distribution of cell nuclei among both nerve substitutes 
(10X). Cell nuclei are displayed in bright blue.
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cells did not change over time. SEM images of longitudinally cut segments of the Avance® 
Nerve Graft did not show any MSCs in the inner ultrastructure of the graft after 6, 12 and 
24 hours of seeding (figure 6, left side). MSCs were present throughout the inner surface of 
the NeuraGen® Nerve Guides after 6, 12 and 24 hours, although the coverage of MSCs was 
clearly less than on the outside of the Nerve Guide (Figure 6, right side). Additionally, the 
MSC did not migrate into the substrate of the NeuraGen® Nerve Guides. These findings were 
confirmed by Hoechst staining of cross-sectional images of both groups, that revealed no 
staining of nuclei in cells inside of the Avance® Nerve Grafts but detectable nuclear staining 
of cells within the NeuraGen® Nerve Guides (figure 7). 
Figure 4. Hoechst fluorescence intensity 
of the Avance® Nerve Graft and the 
NeuraGen® Nerve Guide when seeding 
with MSCs according to increasing 
seeding durations (n=3 per group per 
time point). ANOVA analysis did not 
demonstrate a significant interaction 
between seeding duration and Hoechst 
fluorescence (p=0.001) when merging the 
groups, but within groups analysis did 
not demonstrate any significant increases 
between time points (p>0.221 for the 
Avance® Nerve Grafts and p>0.083 for 
the NeuraGen® Nerve Guides).
Figure 5. Scanning electron microscopy images showing the cell-coverage of the Avance® Nerve Graft 
(A and C) and the NeuraGen® Nerve Guide (B and D) after being dynamically seeded with human MSCs 
for 12 hours. Images A and B display overview images with 150X magnification. Images C and D display 
the areas that are encircled in red in images A and B, 500X magnification. Shown is a uniform distribution 
of partly aggregating MSCs on the porous surface of both nerve substitutes. Examples of cell contours 
are displayed in red in C and D.
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Figure 6. Cross-sectional scanning electron microscopy images of the Avance® Nerve Graft (A and C) and 
the NeuraGen® Nerve Guide (B and D) after 12 hours of dynamic seeding with human MSCs. Both nerve 
substitutes were cut longitudinally. The cross-section of the Avance® Nerve Graft shows aligned fascicles 
without the presence of any cells. The cross-section of the NeuraGen® Nerve Guide demonstrates the 
smooth inner surface of the hollow conduit, with MSCs spread out among the entire length of the nerve 
guide.
Figure 7. Hoechst-stained cross-sectional segments of the Avance® Nerve Graft (A) and the NeuraGen® 
Nerve Guide (B) after 12 hours of dynamic seeding with human MSCs. Cell nuclei, labeled in bright blue, 
are displayed among the outer surface of the Avance® Nerve Graft (left) and on both the inner and outer 
surface of the NeuraGen® Nerve Guide (right).




With the Avance® Nerve Graft, a seeding efficiency of 18.23% (± 28.12) was obtained after 6 
hours, reaching a maximum of 66.46% (± 16.01) after 12 hours that was sustained at 59.90% 
(± 28.81) after 24 hours of dynamic seeding. With the NeuraGen® Nerve Guide, the seeding 
efficiency increased from 52.08% (± 14.81) after 6 hours to 94.17% (±  4.03) after 12 hours but 
decreased to 52.50% (± 19.27) after 24 hours. 
Two-way ANOVA showed a significant interaction between seeding duration, the different 
groups and the seeding efficiency (p=0.004). Kruskal-Wallis analysis of within-group differences 
for the Avance® Nerve Grafts was significant (p=0.007). Pairwise comparisons showed that 
the increase in seeding efficiency between the first (6hr) and second (12hr) time points was 
statistically significant (p=0.006), but that the decrease between the second (12hr) and third 
(24 hr) time points was not (p=0.589). The Kruskal-Wallis analysis of within-group differences of 
the NeuraGen® Nerve Guide showed a significant interaction (p=0.024). Pairwise comparisons 
revealed a significant increase in seeding efficiency between time point 1 and 2 (p=0.029) and 
a significant decrease between time point 2 and 3 (P=0.029).
Seeding efficiencies obtained with the NeuraGen® Nerve Guide were significantly higher 
than the seeding efficiencies obtained with the Avance® Nerve Graft after 12 hours of seeding 
(p=0.010). No significant differences were found at time point 1 (p=0.055) and time point 3 
(p=0.522). The seeding efficiency over time for both groups is depicted in figure 8. 
Figure 8. Seeding efficiencies of the Avance® Nerve Graft and the NeuraGen® Nerve Guide after 
completion of 6, 12 and 24 hours of dynamic seeding with human MSCs (n=6 per group per time point). 
Both groups obtained an optimal seeding efficiency after 12 hours of dynamic seeding; the Avance® 
Nerve Graft reached a seeding efficiency of 66.46% (± 16.01), the NeuraGen® Nerve Guide reached a 
seeding efficiency of 94.17% (±  4.03). Error bars: SEM. * = significant difference, with a >0.05. SEM = 
standard error of the mean 
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DISCUSSION
We examined the clinical potential of dynamic seeding of MSCs onto commercially available 
nerve graft substitutes by testing whether (I) the NeuraGen® Nerve Guide and the Avance® 
Nerve Graft affect the viability of human MSCs, (II) human MSCs can be dynamically seeded 
and distribute uniformly onto these nerve substitutes, and (III) dynamic seeding and optimized 
timing improves the efficiency of MSC-seeding.
MTS assays demonstrated that both the Avance® Nerve Graft and the NeuraGen® Nerve 
Guide did not affect the metabolic activity or survivability of human adipose derived MSCs. 
The human MSCs were able to adhere in a uniform manner of the surfaces of both nerve 
substitutes, with an optimal dynamic seeding duration of 12 hours. The significantly better 
seeding efficiency of NeuraGen® Nerve Guides after 12 hours of seeding is most likely due to 
their hollow conduit configuration, enabling MSCs to adhere on the outer and inner surface of 
the conduit. The MSCs did not migrate inside the Avance® Nerve Graft or into the substrate 
of the NeuraGen® Nerve Guides. It is hypothesized that the decrease in seeding efficiency 
after 12 hours of dynamic seeding is related to cell damage due to the rotational forces of the 
seeding process, leading to a decreased ability of cells to adhere to the surfaces of the nerve 
substitutes. 
The concept that MSCs inside a nerve substitute support the regeneration of axons is 
relevant for the applicability of the dynamic seeding strategy. MSCs used in peripheral nerve 
repair potentially differentiate into Schwann cells in vivo, and may have a structural function 
by replacing injured tissue. However, studies supporting that MSCs need to be delivered 
inside nerve substitutes are limited and most papers show that only a fraction of the added 
MSCs are differentiated into actual Schwann cells and survive on the long term.33, 34 Other 
studies reported trophic effects of MSCs, producing proteins and molecules that stimulate 
tissue regeneration, form extracellular matrix components, enhance angiogenesis, inhibit 
scar formation, and attenuate inflammation without the MSCs actually being physically 
integrated into the regenerating tissue.35-39  Robust expression of secreted proteins including 
growth factors and morphogens by MSCs when introduced to injured tissues supports the 
concept that MSCs may be more effective as tissue repair catalysts rather than architectural 
participants.40, 41
The trophic concept forms the basis of the proposed delivery method of MSCs. Considering 
the shown mismatch in size between the axon fascicules and the MSCs (figure 6), delivery of 
MSCs inside a graft may block the ingrowth of regenerating axons. As MSCs do not need to 
be delivered inside the nerve graft to produce growth factors and cytokines that support nerve 
regeneration, it is preferred that MSCs are added in a simple, efficient and systematic manner 
that is non-traumatic and avoids damage to the nerve substitute. In contrast to microinjection 
and soaking methods, the dynamic seeding strategy of Rbia and colleagues meets these 
requirements.22, 26-28 This strategy has demonstrated to enhance the neuroregenerative gene 
expression in the MSCs 19, 20 and revealed an in vivo survival of the MSCs up to 29 days.42 
The absence of MSCs on the inner surface of the Avance®  Nerve Graft therefore does not 
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implicate that this combination by definition results in less nerve regeneration enhancement 
that the combination of MSCs and the NeuraGen®  Nerve Guide. In vivo studies using the 
described techniques should indicate whether MSC-seeding location (inner or outer surface) 
has implications for their effect on nerve regeneration.
Seeding efficiency was indirectly determined by cell-counts in the supernanent after the 
seeding duration time passed. Although multiple cell counts were performed with small 
standard errors and subjective assessment of the obtained live/dead and Hoechst images 
imply high seeding efficiencies,  seeding efficiency could theoretically be overestimated 
by this indirect strategy as MSCs might have attached to the conical tube or have clumped 
together.32 Group sizes were limited due to the costs associated with the use of the various 
products. Another limitation is that we did not test our chimeric cell/graft models yet in animal 
models. 
Despite the limitations, this study is a preliminary but essential step towards considering 
the use of dynamic seeding in a clinical setting. This study clearly demonstrates that MSCs 
can be seeded on the Avance® Nerve Graft and the NeuraGen® Nerve Guide. MSCs more 
efficiently adhered to the inner and outer surface of the NeuraGen® Nerve Guide than to the 
Avance® Nerve Graft, MSCs are evenly distributed on the surface and do not migrate into 
the nerve or substrate.
CONCLUSION
The NeuraGen® Nerve Guide and the Avance® Nerve Graft do not negatively influence the 
viability of human MSCs. After 12 hours of dynamic seeding, 66% (Avance) to 94% (NeuraGen) 
of the administered dose of MSCs adhered to the nerve substitutes, with a statistically 
significant higher efficiency for the NeuraGen Nerve Guide. The vast majority of adhered 
MSCs survived and were distributed in a uniform manner among the surface of both nerve 
substitutes and did not migrate into the nerve or collagen material.  Future human or animal 
studies will permit determination of the effects of MSCs seeded on nerve graft substitutes on 
motor regeneration or sensory re-innervation in large nerve deficits. 
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As the functional outcome of clinically available nerve graft substitutes remains inadequate 
to replace the use of autograft nerves in peripheral nerve injuries, it was hypothesized that 
Mesenchymal Stem Cells (MSCs) could provide the necessary trophic factors when seeded 
onto the surfaces of these commonly used nerve graft substitutes. We aimed to determine 
the gene expression of MSCs when influenced by Avance® Nerve Grafts or NeuraGen® 
Nerve Guides.
Methods
Human adipose derived MSCs were cultured and dynamically seeded onto 30 Avance® Nerve 
Grafts and 30 NeuraGen® Nerve Guides for 12 hours. At 6 different time points after seeding, 
qPCR analyses were performed for 5 samples per group. Neurotrophic (NGF, GDNF, PTN, 
GAP43, BDNF), myelination (PMP22 and MPZ), angiogenic (VEGF-a and PECAM1/CD31), 
extracellular matrix (ECM) (COL1A1, COL3A1, FBLN1, LAMB2) and cell surface marker (CD96) 
gene expressions were quantified. Unseeded Avance® Nerve Grafts and NeuraGen® Nerve 
Guides were used to evaluate the baseline gene expression, and unseeded MSCs provided 
the reference gene expression of MSCs. 
Results
The interaction of MSCs with the Avance® Nerve Grafts led to a short-term upregulation 
of neurotrophic (NGF, GDNF and BDNF), myelination (PMP22 and MPZ) and angiogenic 
genes (CD31 and VEGF-a) and a long-term upregulation of BDNF, VEGF-a and COL1A1. The 
interaction between MSCs and the NeuraGen® Nerve Guide led to short term upregulation 
of neurotrophic (NGF, GDNF and BDNF) myelination (PMP22 and MPZ), angiogenic (CD31 
and VEGF-a), ECM (COL1A1) and cell surface (CD96) genes and long-term upregulation 
of neurotrophic (GDNF and BDNF), angiogenic (CD31 and VEGF-a), ECM genes (COL1A1, 
COL3A1, FBLN1) and cell surface (CD96) genes. Analysis demonstrated MSCs seeded onto 
NeuraGen® Nerve Guides expressed significantly higher levels of neurotrophic (PTN), 
angiogenic (VEGF-a) and ECM (COL3A1, FBLN1) genes on the long term compared to MSCs 
seeded onto Avance® Nerve Grafts.
Conclusion
The interaction between human MSCs and Avance® Nerve Grafts and NeuraGen® Nerve 
Guides resulted in a significant upregulation of the expression of numerous genes important 
for nerve regeneration over time. The in vitro interaction of MSCs with the NeuraGen® Nerve 
Guide was more pronounced, particularly in the long term (>14 days after seeding). These 
results suggest that MSC-seeding has potential to be applied in a clinical setting, which needs 
to be confirmed in future in vitro and in vivo research.
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INTRODUCTION
Peripheral nerve injuries result in a major social and economic burden by causing loss 
of function of target muscles.1-3 In order to restore nerve function when the nerve gap is 
not suitable for direct end to end coaptation, (sensory) autografts, allografts and artificial 
guides can be used to bridge the gap. While resulting in optimal recovery rates, autograft 
nerve options are limited in diameter and length and associated with donor side morbidity.4 
Avance® Nerve Grafts and NeuraGen® Nerve Guides are commercially available nerve 
substitutes, approved for clinical use and are theoretically unlimited in supply. If their 
clinical outcome would be similar to autografts, these nerve graft substitutes may supplant 
autograft nerves. 
Sensory nerve gaps (<2.5cm) can be effectively restored by either nerve conduits or 
processed nerve allografts 5, but their application in mixed or motor nerve defects with 
greater defect length and larger diameters results in varying outcomes.6-9 In daily clinical 
practice, processed nerve grafts are described to only lead to good outcomes in mixed/
motor nerves with maximal gap lengths of 6mm and diameters between 3 and 7mm.10 
In cases that exceed these dimensions, autograft nerves remain the gold standard by 
surpassing the results of nerve conduits and allografts.10-12 However, particularly in nerve 
injuries with large gaps or multiple nerve injuries (i.e. brachial plexus injuries) there are often 
not enough autologous nerve graft sources to optimally reconstruct the defects.13
Seeding of mesenchymal stem cells (MSCs) on nerve graft substitutes may potentially 
reduce the outcome differences between nerve substitutes and nerve autografts. MSCs can 
interact with the extracellular matrix (ECM) of the nerve graft substitute to produce trophic 
factors necessary for tissue regeneration that supplement endogenous trophic sources.14-18 
To benefit from these trophic properties, dynamic seeding of MSCs is beneficial as it permits 
atraumatic introduction of MSCs to the ECM of graft substitutes prior to implantation while 
preventing damage to both the cells and the graft substitutes. 
In peripheral nerve injury, a defined process occurs commencing from Wallerian degeneration 
to  axonal regeneration and muscle reinnervation. This includes a nine step process from 
injury to regeneration: 1. response to stimulus (Schwann cells and neurons change their 
state and become activated, 3-7 days), 2. regional inflammation (macrophage infiltration, 
3-7 days), 3. immune response (7 days), 4. cell proliferation (formation of Bunger bands, 3-7 
days), 5. cell migration (Schwann cell migration, 7-14 days), 6. axon guidance (7-14 days), 
7. myelination (initiated by Schwann Cells, 14 days), 8. extracellular matrix (7-14 days), 9. 
growth factor activity for axonal regeneration (3-14 days).19
 
To determine the exact potential of MSC-seeding in clinical practice and to understand its 
mode of action within the described regeneration process, it is essential to elucidate the 
interaction between human MSCs and the ECM of clinically available nerve substitutes. The 
purpose of this study was to examine this interaction by measuring expression of mRNA 
biomarkers for myelination, neurotrophic and angiogenic processes, ECM deposition 
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and immune responses in human MSCs as a function of time after dynamic seeding onto 
Avance® Nerve Grafts and NeuraGen® Nerve Guides. 
MATERIALS AND METHODS
General design
Human adipose derived mesenchymal stem cells were cultured and seeded onto 30 
Avance® Nerve Grafts (AxoGen, Inc., Alachua, Florida, USA) and 30 NeuraGen® Nerve 
Guides (Integra LifeSciences Corporation, Plainsboro, New Jersey, USA). At 6 different 
time points after seeding, quantitative polymerase-chain-reaction (qPCR) analyses were 
performed (5 samples per group). Five additional unseeded Avance® Nerve Grafts and 
5 unseeded NeuraGen® Nerve Guides provided the baseline gene expression of the 
nerve substitutes; 5 samples of unseeded MSCs provided the reference gene expression 
of MSCs. 
Human mesenchymal stem cells
The Mayo Clinical Human Cellular Therapy laboratory (Rochester, Minnesota, USA) 
provided the human MSCs used in this experiment. They complied with the criteria defined 
by the International Society for Cellular Therapy.20 Multi-lineage potential, presence of 
cell surface markers (CD73, CD90, CD105, CD44, CD14 and CD45) and RNA-sequence 
transcriptome profiles have all been tested previously.(23-25) MSCs were cultured in 
growth media composed of Advanced MEM (a-MEM, 1x; Gibco by Life TechnologiesTM, 
Cat #12492013), 5% platelet lysate (PLTMax®; Mill Creek Life Sciences), 1% penicillin/
streptomycin (Penicillin-Streptomycin (10.000 U/mL); Gibco by Life TechnologiesTM Cat 
#15140148), 1% GlutaMAX (GlutaMAXTM Supplement 100X; Gibco by Life Technologies, 
Cat #35050061) and 0.2% heparin (Heparin Sodium Injection, USP, 1.000 USP units per mL; 
NOVAPLUS®). The MSCs were cultured in an incubator at 37°C (5% CO2), growth medium 
was changed every 72 hours and cells were split at 80% confluence. Passage 5 MSCs were 
used in this study.21-23 
Nerve allografts and guides
Avance® Nerve Grafts are human nerve allografts that have been decellularized and 
irradiated to obtain non-immunogenic, sterile human nerves with remaining ultrastructure. 
The NeuraGen® Nerve Guides are composed of purified bovine type I collagen and are 
empty conduits that do not contain any ultrastructure in the central portion of the guide.24 
Both the Avance® Nerve Graft and the NeuraGen® Nerve Guide have been approved by 
the Food and Drug Administration for human clinical use since 2007 and 2001, respectively. 
A total of 35 Avance® Nerve Grafts and 35 NeuraGen® Nerve Guides of 15mm in length 
were voluntarily provided by Axogen® (Axogen Corporation, Alachua, Florida, USA) and 
Integra (Integra LifeSciences Corporation, Princeton, New Jersey, USA) respectively. Five 
samples of each group were used to determine the baseline gene expression and 30 of 
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each group were used to study the interaction with MSCs over time. 
MSC seeding
To seed MSCs on nerve substitutes in a non-traumatic manner, a previously described 
seeding strategy was applied.25, 26 Previous studies have demonstrated a 66% and 94% 
seeding efficiency for the Avance® Nerve Grafts and the NeuraGen® Nerve Guides, 
respectively.27 Prior to seeding, the Avance® Nerve Grafts and the NeuraGen® Nerve 
Guides were soaked in a-MEM to restore the salt balance and to remove any harmful 
detergents. The nerve substitutes were placed in conical tubes containing 1 million MSCs 
in 10mL growth medium. The conical tubes were rotated for 12 consecutive hours on a 
bioreactor placed in a 37°C incubator. 
Quantitative PCR analysis
Quantitative PCR analysis was performed on 5 duplicates per group before seeding (n=5 
per group, baseline gene expression) and at 6 time points after seeding: directly after 
seeding, 1 day, 3 days, 7 days, 14 days and 21 days (n=5 per group per time point). Between 
seeding and qPCR analysis, the samples were placed in wells containing growth media. To 
determine the baseline gene expression of the MSCs, qPCR analysis was performed on 5 
samples of MSCs only.
At each time point, the seeded nerve substitutes were removed from the wells, placed 
in Qiazol and frozen at -80°C. The seeded nerve substitutes were minced with a sterile 
needle to ensure the DNA of the MSCs was dissolved in the fluid. Ribonucleic acid 
(RNA) extraction took place according to the manufacturer’s protocol (Direct-zolTM RNA 
MiniPrep Kit; Zymo Research, Irvine, CA, USA). RNA concentration was measured with 
the NanoDropTM 2000/2000c Spectrophotometer (ThermoFisher Scientific, Waltham, 
MA, USA). Subsequently, complementary deoxyribonucleic acid (cDNA) was obtained 
(SuperScript III, Invitrogen, Carlsbad, CA; 3 minutes at 65°C, 90 minutes at 37°C and 5 
minutes at 95°C) and diluted to establish a concentration of 10ng/µL. The obtained cDNA 
was combined with the selected primers (all manufactured by Sigma, table 1) and real time-
qPCR master mix (Qiagen, MD, USA) and amplified by real time-qPCR using a thermocycler 
(Bio-rad Laboratories, Inc., CA, USA) under the following parameters: 15 minutes at 95°C, 
followed by 50 cycles of 95°C for 20s, 60°C for 35s and 72°C for 35s. This provided the 
mRNA expression levels of the investigated genes.  
Analysis of mRNA biomarkers
In relation to the described Wallerian degeneration and axon regeneration process, 
the neurotrophic effects of the interaction between MSCs and nerve substitutes were 
measured by assessing a panel of mRNA biomarkers, including nerve growth factor (NGF), 
glial cell line-derived neurotrophic factor (GDNF), pleiotrophin (PTN), growth associated 
protein 43 (GAP43) and brain-derived neurotrophic factor (BDNF). The expression of 
myelination marker genes peripheral protein 22 (PMP22) and myelin protein zero (MPZ) 
were measured. The angiogenic potential of the seeded MSCs was measured by the gene 
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expression of platelet endothelial cell adhesion molecule 1 (PECAM1/CD31) and vascular 
endothelial cell growth factor alpha (VEGF1). Establishment of the ECM was assessed by 
monitoring expression of collagen type I (COL1A1), collagen type III (COL3A1), Fibulin 1 
(FBLN1) and laminin subunit beta 2 (LAMB2). Immunoglobulin expression was determined 
by quantification of cluster of differentiation 96 (CD96), a cell surface marker. 
Both Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) and AKT Serine/Threonine 
Kinase 1 (AKT1) were used as reference genes. Expression of the AKT1 gene was 
determined to be more stable and considered the most optimal housekeeping gene 
based on BestKeeper analysis and therefore was used as reference gene in the analysis.28 
The 2-ΔΔCT method was used to calculate the mRNA levels which were expressed as a 
ratio of AKT1.29-31 Primer sequences for each of the genes that were analyzed are displayed 
in table 1. 
Table 1. mRNA primer sequences. ECM = extracellular matrix.
NGF = nerve growth factor, GDNF = glial cell line-derived neurotrophic factor, PTN = pleiotrophin, 
GAP43 = growth associated protein 43, BDNF = brain-derived neurotrophic factor, PMP22 = peripheral 
myelin protein 22, MPZ = myelin protein zero, VEGF-a = vascular endothelial cell growth factor alpha, 
PECAM = platelet endothelial cell adhesion molecule 1, COL1A1 = collagen tpe 1, COL3A1 = collagen 
type III, FBLN1 = fibulin 1, LAMB2 = laminin beta 2 subunit, CD96 = cluster of differentiation 96, AKT1 = 
threonine kinase 1, GAPDH = glyceraldehyde-3-phosphate dehydrogenase. 
Gene ID Biology Forward primer Reverse primer
NGF Neurotropic marker ATACAGGCGGAACCACACTCAG ATACAGGCGGAACCACACTCAG
GDNF Neurotropic marker CACCAGATAAACAAATGGCAGTGC CACCAGATAAACAAATGGCAGTGC
PTN Neurotropic marker ACTGGAAGTCTGAAGCGAGC CTTCTTCTTAGATTCTGCTTGAGGT
GAP43 Neurotropic marker GTCCACTTTCCTCTCTATTTC TGTTCATTCCATCACATTGA
BDNF Neurotropic marker AGAGGCTTGACATCATTGGCTG CAAAGGCACTTGACTACTGAGCATC
PMP22 Myelination marker GTTAAAGGGAACGCCAGGA AGTTTCTGCAGCCCAAAGGA
MPZ Myelination marker GAGGAGGCTCAGTGCTATGG GCCCGCTAACCGCTATTTCT
VEGF-a Angiogenic marker ATCTGCATGGTGATGTTGGA GGGCAGAATCATCACGAAG
PECAM/
CD31
Angiogenic marker AACAGTGTTGACATGAAGAGCC AACAGTGTTGACATGAAGAGCC
COL1A1 ECM protein GTAACAGCGGTGAACCTGG CCTCGCTTTCCTTCCTCTCC
COL3A1 ECM protein TTGAAGGAGGATGTTCCCATCT ACAGACACATATTTGGCATGGTT
FBLN1 ECM protein AGAGCTGCGAGTACAGCCT CGACATCCAAATCTCCGGTCT
LAMB2 ECM protein ACACGCAAGCGAGTGTATGA AATCACAGGGCAGGCATTCA
CD96 Cell surface marker / 
immunoglobulin
AGATTGTGTGATGAAGGACATGG AGATTGTGTGATGAAGGACATGG
AKT1 Household gene ATGGCGCTGAGATTGTGTCA CCCGGTACACCACGTTCTTC
GAPDH Household gene CCCGGTACACCACGTTCTTC TGTGGTCATGAGTCCTTCCA
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Statistical analysis
The gene expression profiles of the seeded MSCs on both nerve substitutes were expressed 
as a ratio of the average gene expression of unseeded MSCs (= reference group). Gene 
expression ratios of MSCs seeded onto Avance® Nerve Grafts were compared to gene 
expression ratios of MSCs seeded onto NeuraGen® Nerve Guides over time and were 
analyzed using a 2-factor ANOVA with repeated measures of one factor, with post-hoc 
Bonferroni correction. This analysis provided insight in the effects of the type of nerve 
substitute and the time passed after seeding. All results are expressed as the mean +/- SEM. 
A a<0.05 was considered statistically significant. 
RESULTS
Control experiments with nerve substitutes
The presence of RNA was examined in unseeded Avance® Nerve Grafts (n=5) and NeuraGen® 
Nerve Guides (n=5) and no RNA was detected. 
Neurotrophic gene expression (Figure 1)
Expression of five neurotrophic factors (NGF, GDNF, PTN, GAP43 and BDNF) was measured 
by qPCR to assess whether nerve substitutes can induce neurotrophic factors in MSCs. 
Nerve Growth factor (NGF)
NGF is endogenously produced by cells like neurons and Schwann cells and is crucial for 
neuroplasticity since it promotes neuron maturation and can induce cell repair and apoptosis.32, 
33 The factor time solely had a significant effect on NGF expression (p<0.001), while the type 
of nerve substitute did not (p=0.228). Directly after seeding, MSCs on Avance® Nerve Grafts 
expressed significantly increased levels of NGF compared to MSCs on NeuraGen® Nerve 
Guides (5.304 ±0.731 versus 2.530 ±0.419, p<0.001), while MSCs on NeuraGen® Nerve 
Guides expressed significantly increased NGF expression ratio 1 day after seeding (1.226 
±0.187 versus 3.868 ±1.379, p=0.002). After 1 to 3 days after seeding, the NGF expression 
of MSCs in both groups was comparable to the expression in unseeded MSCs. Thus, NGF 
expression is transiently elevated in MSCs seeded onto nerve substitutes shortly after seeding 
and  subsides over time.  
Glial cell line-derived neurotrophic factor (GDNF)
GDNF is described to have a crucial role in neuronal migration, proliferation and 
synaptogenesis.34, 35 Enhanced GDNF delivery has demonstrated to result in earlier regeneration 
after nerve crush injuries 36 and its expression decreases coincidentally with the ingrowth of 
regenerating axons.35 The GDNF expression ratio of seeded MSCs was significantly affected 
by culture duration after seeding (p<0.001); the expression slowly diminished over time with 
the exception of GDNF expression after 21 days in MSCs seeded onto Avance® Nerve Grafts. 
No significant differences were found in GDNF expression between both groups. The GDNF 
expression curves of both groups approximated the unseeded MSC expression from 1 day 
onwards.




PTN expression was measured as it is involved in neurite outgrowth and synaptogenesis after 
peripheral nerve injury.37, 38 The expression ratio of PTN was modulated in MSCs by the type of 
nerve substitute (p<0.001) and by the time after seeding (p=0.001). PTN expression decreased 
up to 7 days after seeding for both groups, after which particularly the PTN expression of MSCs 
seeded on NeuraGen® Nerve Guides increased again up to 21 days after seeding. The MSCs on 
the NeuraGen® Nerve Guide expressed a significant higher PTN ratio than MSCs on Avance® 
Nerve Grafts after 14 (0.590 ±0.151 versus 0.174 ±0.037, p=0.011) and 21 days (0.718 ±0.29 versus 
0.116 ±0.050, p<0.001).  Although the PTN expression of MSCs on NeuraGen® Nerve Guides 
approximated the baseline gene expression of unseeded MSCs after 21 days, measures at all the 
other time points demonstrated downregulation of the baseline expression. 
Growth associated protein 43 (GAP43)
GAP43 expression increases after axotomy, eventually leading to enhanced axon density in 
regenerating nerve fibers.39 The GAP43 expression of seeded MSCs was significantly affected 
by the time after seeding (p=0.008) and the type of nerve substitute (p=0.046). The GAP43 
expression of MSCs on both nerve substitutes increased over time, of which the expression of 
MSCs on Avance® Nerve Grafts most evenly increased over time. There were no significant 
differences in GAP43 expression between both nerve substitutes. All measured expression ratios 
were below 1, implicating downregulation of the baseline GAP43 expression. 
Brain-derived Neurotrophic Factor (BDNF)
BDNF induces neuronal cell survival and differentiation and accelerates axonal outgrowth 40, 
but also is involved in synapse formation.41, 42 The BDNF expression ratio of seeded MSCs was 
significantly affected by the time passed after seeding (p<0.001). The BDNF expression in MSCs 
seeded on Avance® Nerve Grafts (3.846 ±0.636) was significantly higher after 14 days compared 
to the expression in MSCs on NeuraGen® Nerve Guides (1.720 ±0.164)(p=0.020). The expression 
ratio in both groups approximated 1 directly after seeding, and increased up to 4 (i.e. a fourfold 
of the baseline BDNF expression in unseeded MSCs) on various time points in later phases (1 
day and 21 days after seeding for the NeuraGen® Nerve Guide, 7, 14 and 21 days after seeding 
for the Avance® Nerve Grafts).
Myelination gene expression (Figure 2)
Peripheral myelin  protein 22 (PMP22)
The PMP22 gene is mainly expressed in Schwann cells and encodes a relatively minor 
but crucial component of the myelin sheeth.43 Duplication or deletion of PMP22 leads to 
demyelination and axon loss, resulting in common demyelinating neuropathies.44, 45 PMP22 
expression ratio was significantly affected by the time after seeding (p=0.0.26), but not by 
the type of nerve substitute (p=0.542) on which the MSCs were seeded. The expression 
ratio started high for both groups (1.90 ±0.231 for Avance® Nerve Grafts, 1.78 ±0.663 for 
NeuraGen® Nerve Guides) and decreased to a level comparable to unseeded MSCs after 
21 days (0.716 ±0.278 for Avance® Nerve Grafts, 0.928 ±0.102 for NeuraGen® Nerve Guides). 
There were no significant differences between groups over time. 
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Figure 1. Gene expression curves of human MSCs seeded onto Avance® Nerve Grafts and NeuraGen® 
Nerve Guides concerning neurotrophic genes NGF, GDNF, PTN, GAP43 and BDNF at 6 different time 
points after seeding.  * = p<0.05, ** = p<0.01, *** = p<0.001. Error bars = Standard error of the mean
Figure 2. Gene expression curves of MSCs seeded onto Avance® Nerve Grafts and NeuraGen® Nerve 
Guides concerning myelination genes PMP22 and MPZ at 6 different time points after seeding.  
Error bars = Standard error of the mean
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Myelin protein zero (MPZ)
MPZ is also expressed by Schwann cells and is the main protein of (compact) myelin. Reduced 
expression of MPZ results in instable myelination, leading to neuropathies and axonal loss. 
MPZ is therefore pivotal in successful nerve regeneration.43 The MPZ gene expression ratio 
was not significantly affected by type of nerve substitute (p=0.936), nor by the time passed 
after seeding (p=0.650). Compared to the baseline MPZ expression in unseeded MSCs, 
the expression ratio in both groups was increased both at the beginning (up to 3 days after 
seeding) and at the end (21 days) of the experiment. There were no significant differences in 
MPZ expression over time between groups. 
Angiogenic gene expression (Figure 3)
Vascular Endothelial Growth Factor alpha (VEGF-a)
Neoangiogenesis occurs from two days onwards after nerve injury and facilitates the delivery 
of trophic factors at the nerve stump and guides Schwann cells in the right direction.46-48 
Enhanced expression and production of VEGF-A induces local angiogenesis, playing an 
important role in  the peripheral nerve regeneration process.49 The type of nerve substitute 
had no significant effect on the VEGF-a expression of seeded MSCs (p=0.107). Time passing 
did have a significant effect on the VEGF-a expression of seeded MSCs (p<0.001). The VEGF-a 
expression in both groups was high (4 to 12 fold of the baseline expression) in the first 24 
hours after seeding, equal to unseeded MSCs around 3 to 7 days after seeding and then 
increased again (3 to 8 fold of the baseline expression) up to 21 days after seeding.  The 
VEGF-a expression was significantly higher in the MSCs seeded on NeuraGen® Nerve Guides 
directly after seeding (11.006 ±0.33 versus 6.698 ±1.502, p=0.020) and 21 days after seeding 
(8.690 ±2.062 versus 4.118 ±1.847, p=0.011). 
Platelet Endothelial Cell Adhesion Molecule (PECAM-1/CD31)
CD31 regulates endothelial cell adhesion, being crucial in the process of angiogenesis.50 The 
factor time significantly influenced the CD31 expression ratio (p<0.001), but the type of nerve 
substitute did not have a significant impact (p=0.77). When comparing groups over time, 
MSCs seeded onto NeuraGen® Nerve Guides had a significant higher CD31 expression ratio 
compared to MSCs seeded onto Avance® Nerve Grafts directly after seeding (3.016 ±0.364 
versus 1.096 ±0.13, p=0.025) and 21 days after seeding (2.254  ±0.815 versus 0.244  ±0.123, 
p=0.017). The expression in the NeuraGen® Nerve Guide group was significantly lower 
than in the Avance® Nerve Graft group 1 day after seeding (p<0.001). With the exception 
of directly, 1 day and 21 days after seeding, all other time points demonstrated significant 
downregulation of the baseline CD31 expression of unseeded MSCs.
Extracellular matrix gene expression (Figure 4)
Collagenase type 1 (COL1A1)
The COL1A1 gene encodes for the main component of type 1 collagen. This ECM-component 
regulates Schwann cell proliferation and differentiation, but overexpression of COL1A1 could 
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impede axon sprouting by inducing scarring.51 The time passed after seeding (p=0.014) and 
the type of nerve substitute (p=0.033) both had a significant effect on the COL1A1 gene 
expression ratio. Directly after seeding, MSCs on NeuraGen® Nerve Guides (2.468 ±0.064) 
had a significant higher COL1A1 expression ratio than MSCs on Avance® Nerve Grafts (1.152 
±0.332) (p=0.008). Aside from increased COL1A1 expression directly (NeuraGen® Nerve 
Guide), 14 (Avance® Nerve Graft) and 21 days (NeuraGen® Nerve Guides) after seeding, the 
COL1A1 expression in the NeuraGen® Nerve Guide group was comparable to the baseline 
COL1A1 expression of unseeded MSCs. 
Collagenase type 3 (COL3A1)
Just like type 1, collagenase type 3 is a fibril forming collagen and an ECM component in the 
peripheral nervous system, regulating Schwann cell differentiation and axonal guidance.51, 52 
The COL3A1 gene expression ratio was significantly affected by time after seeding (p<0.001) 
and the type of nerve substitute (p=0.014). The expression curve of both groups was u-shaped 
and approximated a ratio of 1 (i.e. comparable to baseline COL3A1 expression), with a 
significant higher expression ratio of MSCs seeded onto NeuraGen® Nerve Guides after 21 
days (1.696 ±0.132 versus 0.664 ±0.192, p<0.001). 
Fibulin-1 (FBLN1)
FBLN-1 expression was assessed as it is a component of the perineurium of peripheral nerves 
and fulfills a axonal guiding and supporting function.53 Time after seeding (p<0.001) and 
type of nerve substitute (p=0.002) both significantly affected the FBLN1 expression ratio. 
When comparing groups over time, the MSCs seeded onto NeuraGen® Nerve Guides had a 
significant higher FBLN1 expression ratio after 14 (0.760 ±0.193 versus 0.236 ±0.079, p=0.037) 
and 21 days (1.962 ±0.318 versus 0.340 ±0.183, p<0.001). The expression in the Avance® Nerve 
Graft group remained low over time, while the expression in the NeuraGen® Nerve Guide 
group seemed to arise from 7 days onwards, demonstrating significant upregulation of the 
baseline FBLN1 expression. 
Laminin Beta 2 subunit (LAMB2)
LAMB2 is a basis laminin protein that is essential in proper synaptogenesis at neuromuscular 
junctions.54 There was no significant effect of either the time passed after seeding (p=0.247) 
nor the type of nerve substitute (p=0.354). No significant differences between groups 
occurred over time, while the expression in both groups remained lower than the expression 
in unseeded MSCs. 
Immunoglobulin  expression (Figure 5)
Cluster of Differentiation 96 (CD96)
CD96 is an immunoglobulin family member that interferes in the adhesive interactions 
between cells, in the late phase immune response.55 Only the factor time significantly affected 
the CD96 expression rate (p=0.011). 21 days after seeding, the expression in MSCs seeded 
onto NeuraGen® Nerve Guides (2.226  ±0.443) was significantly higher than the expression 
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in MSCs seeded onto Avance® Nerve Grafts (1.326 ±0.097, p=0.030). The expression curve 
of the NeuraGen® Nerve Guide group seemed to increase on the long term, while the 
expression curve of the Avance® Nerve Graft group remained stable on the long term. The 
obtained CD96 expressions demonstrated a slight upregulation in comparison to baseline 
gene expression of unseeded MSCs at most time points.
Figure 3. Gene expression curves of MSCs seeded onto Avance® Nerve Grafts and NeuraGen® Nerve 
Guides concerning angiogenic genes VEGF-a and CD31  at 6 different time points after seeding.  
* = p<0.05, Error bars = Standard error of the mean
Figure 4. Gene expression curves of MSCs seeded onto Avance® Nerve Grafts and NeuraGen® Nerve 
Guides concerning extracellular matrix genes COL1A1, COL3A1, FBLN1 and LAMB2 at 6 different time 
points after seeding.  
** = p<0.01, *** = p<0.001, Error bars = Standard error of the mean
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Figure 5. Gene expression curve of MSCs seeded onto Avance® Nerve Grafts and NeuraGen® Nerve 
Guides concerning the immunoglobulin marker CD96 at 6 different time points after seeding.  
Error bars = Standard error of the mean
DISCUSSION
Secondary to their regenerative ability, MSCs are of broad biomedical relevance.56-62 While 
differentiation of MSCs into specific cell types (i.e. differentiation into Schwann type cells) 
has been described as one mode of action 63, 64, secretion of essential trophic factors is 
a functionally different and possible more plausible explanation for their regenerative 
capacities.14, 16, 65, 66 This putative tissue-specific trophic expression of MSCs occurs in 
response to cues from their micro-environment.18, 67, 68 
In this study, gene expression profiles of human MSCs seeded onto Avance® Nerve Grafts 
and NeuraGen® Nerve Guides were examined over time in order to provide mechanistic 
insight in the interaction of MSCs seeded on nerve substitutes. Expression curves of a 
select panel of prominent neurotrophic, myelination, angiogenic, ECM and cell surface 
marker/immunoglobulin genes have been analyzed. 
The displayed gene expressions of seeded MSCs are all expressed as a ratio of the gene 
expression in unseeded MSCs, the reference group. Considering a gene expression ratio 
of 1.0 meaning that the interaction between MSCs and the nerve substitutes did not result 
in changes in gene expression, one could argue that the interaction of MSCs with the 
Avance® Nerve Grafts leads to a clear upregulation in the first hours to days after seeding 
of neurotrophic genes NGF, GDNF and BDNF, myelination markers PMP22, MPZ and 
angiogenic genes CD31 and VEGF-a. In the long term, the interaction between MSCs and 
the Avance® Nerve Grafts causes an upregulation of BDNF, VEGF-a and COL1A1. The 
interaction between MSCs and the NeuraGen® Nerve Guide led on the short term to an 
upregulation of neurotrophic genes NGF, GDNF and BDNF, myelination markers PMP22 
and MPZ, angiogenic genes CD31 and VEGF-a, ECM gene COL1A1 and cell surface 
marker CD96. In the long term, the expression of neurotrophic genes GDNF and BDNF, 
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angiogenic genes CD31 and VEGF-a, ECM genes COL1A1, COL3A1 and FBLN1 and cell 
surface marker CD96 were all upregulated by the interaction between the MSCs and the 
NeuraGen® Nerve Guide. Genes of which the expression was downregulated for both 
groups were PTN, GAP43 and LAMB2. A summary of the described gene expression trends 
and differences is displayed in table 2. 
The described steps of Wallerian degeneration and axon regeneration in which the 
evaluated genes are hypothetically involved are illustrated in figure 6. It displays the 
proposed mechanism of MSC-seeding; MSCs are seeded on the outer surface, gene 
expression of the MSCs is changed by the ECM, resulting in production of trophic factors 
that are involved in Wallerian degeneration and axon regeneration inside the nerve 
substitutes. 
Table 2. Summary of interaction-induced relative changes in gene expression of human MSCs on the 
short and long term. The signs under significance display whether there were significant differences 
between the groups at the first two (directly and 24 hours after seeding, separated by a forward slash) and 
the final two (14 days and 21 days after seeding, separated by a forward slash) time points. 
↑↑↑ = extreme enhancement
↑↑ = moderate enhancement, ↓↓ = moderate reduction
 ↑ = slight enhancement, ↓ = slight reduction
≈ = no enhancement, no reduction
- = no significant difference, * = p<0.05, **=p<0.01, ***=p<0.001
Gene ID Biology Short term (0 - 24 hours) Long term (14 - 21 days)
Avance® NeuraGen® Significance Avance® NeuraGen® Signifi-
cance
NGF Neurotrophic marker  ↑↑  ↑↑ *** / ** ↓↓ ↓↓ - / -
GDNF Neurotrophic marker  ↑↑  ↑↑ - / - ≈  ↑↑ - / -
PTN Neurotrophic marker ↓↓ ↓↓ - / - ↓↓ ≈ * / ***
GAP43 Neurotrophic marker ↓↓ ↓↓ - / - ↓ ↓ - / -
BDNF Neurotrophic marker  ↑  ↑↑ - / -  ↑↑  ↑↑ * / -
PMP22 Myelination marker ↑  ↑ - / - ≈ ≈ - / -
MPZ Myelination marker  ↑  ↑ - / -  ↑  ↑ - / -
VEGF-a Angiogenic marker  ↑↑  ↑↑↑ * / -  ↑↑  ↑↑↑ - / *
PECAM/
CD31
Angiogenic marker  ↑  ↑ - / - ↓  ↑ - / -
COL1A1 ECM protein ≈  ↑ ** / -  ↑  ↑ - / -
COL3A1 ECM protein ≈  ↑ - / - ≈  ↑ - / ***
FBLN1 ECM protein ↓ ≈ - / - ↓ ↑ * / ***
LAMB2 Extracellular matrix 
protein
↓ ↓ - / - ↓ ↓ - / -
CD96 Cell surface marker / 
immunoglobulin
 ↑  ↑ - / - ≈  ↑ - / -
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As described NGF, GDNF, PTN, GAP43 and BDNF play a part in the stimulation of axonal 
outgrowth and the proliferation of neurons and Schwann cells (step 4 and 9, figure 6).69-71 
Previous in vivo research in a rat model demonstrated that particularly NGF is expressed in a 
significant higher manner in nerve autografts than in decellularized allografts.72 In our study, 
NGF and GDNF expression was enhanced in the first 0-24 hours after seeding and the GDNF 
expression after 21 days seemed to increase again in the NeuraGen® Nerve Guide group. 
BDNF expression was enhanced in both groups among the entire follow-up period (up to 21 
days), but PTN and GAP43 expressions did not increase in comparison to unseeded MSCs 
(ratio <1.0). The long-term low expression of PTN and GAP43 and the enhanced expression 
of BDNF after seeding was correspondingly described in in vitro research using human 
nerve allografts that were processed with elastase and stored at 4°C. In the study of Rbia 
and colleagues enhanced BDNF expression also led to enhanced levels of BDNF growth 
factor production. In contradiction to our findings, NGF and GDNF were not enhanced in 
that particular study, which might be due to differences in the ECM as a result of the different 
decellularization process.73 Our results suggests that the interaction between MSCs and the 
ECM of nerve substitutes stimulates neural proliferation or may enhance neural outgrowth, 
particularly by upregulation of NGF, GDNF and BDNF. 
MPZ and PMP22 are mainly expressed in Schwann cells, which initiate axon myelination, 
occurring approximately 2 weeks after injury (step 7, figure 6).19 The short-term (first 24 
hours) enhanced expression of PMP22 and MPZ demonstrated in this study corresponds 
to previous in vitro research using the same seeding strategy on different nerve allografts.73 
Since transdifferentiation into Schwann-like cells is unlikely to have occurred in the described 
time-span, the elevated level of PMP22 might be subscribed to its role in the development of 
intercellular junctions.74 The PMP22 and MPZ expression was not significantly altered on the 
long term (from 7 days onwards) by the interaction with the nerve substitutes in the current 
study; this could be due to the absence of Schwann cells in this in vitro setting. Previously, rat 
autograft nerves did not express significantly different levels of PMP22 and MPZ in vivo than 
unseeded processed allografts, which could insinuate that these genes are not pivotal for 
improving nerve regeneration in processed nerve allografts to a level equal to autografts.72
VEGF-a functions particularly in axon regeneration and guidance (step 6 and 9, figure 6) by 
stimulating formation of blood vessels and enhancing Schwann cell and neuron survival.71, 
75 In vivo, rat autograft nerves previously demonstrated to express significantly higher levels 
of VEGF-a than unseeded processed nerve allografts.72 The demonstrated upregulation 
of VEGF-a expression in this study in the first 24 hours and from two weeks onwards after 
seeding is in accordance with the described nerve regeneration cascade and with previous in 
vivo research, supporting the role that MSCs can play in revascularization.72 CD31 is a platelet 
endothelial cell adhesion molecule (Pecam1) that is required for the motility and organization 
of endothelial cells, essential for angiogenesis (step 9, figure 6).76 Autografts do not express 
significantly different levels of CD31 in vivo than processed nerve allografts.72 Our data 
describes enhanced CD31 expression directly after seeding that diminishes after 1 to 3 days 
after seeding. 
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Figure 6. Proposed mechanism of MSC-seeding on nerve substitutes. The interaction between MSCs 
and the nerve substitute results in changes in gene expression profiles, leading to production of trophic 
factors that are involved in Wallerian degeneration and axon regeneration.
GF = growth factor
ECM components derived from genes like COL1A1, COL3A1, FBLN1 and LAMB2 are 
essential for creating a pro-regenerative environment in the early stages after nerve injury 
and facilitate reinnervation in later stages by guiding the growth cone in the right direction 
(figure 6).19, 77 Although autografts previously demonstrated a trend of enhanced expression 
of these ECM markers in vivo compared to unseeded allografts, none of the differences were 
statistically significant.72 In the current study, MSCs seeded onto NeuraGen® Nerve Guides 
demonstrated a U-shaped expression of COL1A1, COL3A1 and FBLN1, corresponding to the 
described cascade and previous in vitro studies.73, 78 Considering the absence of detectable 
RNA levels of unseeded Avance® Nerve Grafts and NeuraGen® Nerve Guides, the influence 
of the material components of the nerve substitutes on itself on the ECM gene expression is 
estimated as negligibly small.   
CD96 is a membrane protein that is involved in the late phase immune response by interfering 
in adhesive interactions between cells (step 3, figure 6), which potentially explains why its 
expression remains more or less stable over time.55 
When studying the demonstrated expression curves, some inconsistent expression ratios can 
be identified. Measures were taken to minimize the vulnerabilities during the obtainment 
of the mRNA levels like using five replicates per time point, a stable reference gene and 
experienced researchers. Besides, not all these inconsistent ratios differ significantly from the 
measures before and after that specific time point. Studying the demonstrated expression 
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curves, we identified four general trends; a linear decline (NGF, GDNF, CD31)  a linear increase 
(PTN, GAP43, BDNF), a stable curve (PMP22, MPZ, COL1A1, LAMB2, CD96) and a U-shaped 
curve (VEGF-a, COL3A1, FBLN1). We believe that those trends are more reliable and therefore 
a more important finding than the individual expression ratios at each of the time points.
The in vitro setting of our study does not provide the required micro-environmental signals 
that are essential to mimic the described regeneration cascade. Studying the effects on gene 
expression that is solely caused by the interaction between MSCs and nerve substitutes, does 
demonstrate the potential of MSCs to interfere in the previously mentioned cascade steps 
when dynamically seeded on the outer surface of clinically available nerve graft substitutes. It 
is recognized that corroborating the mRNA expression changes to protein expression changes 
could have contributed to the described findings. However, measuring protein levels is a 
costly technique, vulnerable to flaws and the absence of environmental regenerative signals in 
vitro would have resulted in outcomes that cannot per definition be related to in vivo protein 
expression and would still need translation to an in vivo model. Therefore, this study is used to 
demonstrate that interaction between MSCs and the nerve substitutes occurs, effects a wide 
range of genes and that it lasts on the long term, while limiting the costs and still preventing 
unnecessary sacrifices of extra animals in the future.
Although it was hypothesized that the biological composition of the Avance® Nerve Grafts 
(i.e. neural tissue) would lead to more expression of neurotrophic genes in MSCs, analysis 
demonstrated that the MSCs seeded onto NeuraGen® Nerve Guides expressed higher levels 
of neurotrophic (GDNF and PTN), angiogenic (CD31 and VEGF-a), ECM (COL3A1 and FBLN1) 
and immunoglobulin (CD96) genes. Higher seeding efficiency and a different composition of 
the guide may have resulted in improved sustainability of the graft/MSCs in vitro and better 
cell proliferation in the long-term, leading to the described enhanced gene expressions. Most 
neurotrophic factors mediate other processes that are not involved in nerve regeneration 
which could explain enhanced gene expression levels in the absence of any neural material in 
the NeuraGen® Nerve Guide group.13 
While our data suggest that nerve autograft substitutes could benefit from the addition of 
MSCs, future studies are necessary to determine gene expression patterns and the resulting 
trophic factor production of MSCs in the presence of injured nerve tissue. Furthermore, the in 
vivo effects on functional outcomes of the described interactions need to be correlated and 
compared to determine the clinical relevance of our findings. 
CONCLUSION
When human MSCs are dynamically seeded onto the surfaces of Avance® Nerve Grafts and 
NeuraGen® Nerve Guides, their interaction with the ECM of these nerve substitutes results 
in a change and mostly an upregulation of the expression of numerous genes important for 
nerve regeneration over time. The in vitro interaction of MSCs with the NeuraGen® Nerve 
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Guide is greater than the Avance® Nerve Grafts, particularly in the long-term (>14 days 
after seeding). Future studies should focus on translation to an in vivo model to confirm the 
potential of the described techniques and mRNA expression changes for clinical application. 
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BACKGROUND
Peripheral nerve injuries that have led to nerve gaps not repairable by direct coaptation 
of both nerve ends need to be bridged by nerve grafts. Ideally these grafts are autografts 
as they are known to result in the best functional outcomes.1 However, autografts are not 
endlessly available and donor site morbidity should be taken into account.2, 3 The off-the-
shelve available nerve allografts currently do not lead to equal results as autograft nerves, 
hypothetically due to the absence of essential elements like a proficient vascular bed and 
adequate intrinsic trophic factors. First the role of mesenchymal Stem Cells (MSCs) will be 
described as they possess trophic capacities and have been hypothesized to be able to 
fulfill a role in improving the outcomes of nerve allografts. Second our studies to assess 
vascularization of the allograft will be discussed.
The neural regenerative capacities of mesenchymal stem cells (MSCs) have been 
extensively tested in the past. Although some results were hopeful, their absence in 
current clinical practice reveals the continuing uncertainties regarding the ideal delivery 
strategy, their mechanism of action and perhaps most important their capacities to improve 
functional outcomes of peripheral nerve repair. This thesis aimed to get more insight 
in the mechanisms of action of MSCs when delivered to decellularized nerve allografts 
and conduits with a recently described innovative seeding strategy.4 The effects on gene 
expression, vascularity and functionality of undifferentiated MSCs were compared to MSCs 
differentiated into Schwann cell-like cells and the clinical potential was explored using FDA 
approved nerve graft substitutes in a study model.
One of the first proposed mechanisms of the MSCs to aide in neural regeneration was their 
ability to transdifferentiate into cells essential in this process. An often used hypothesis 
was that MSCs could differentiate into Schwann Cells and thus support and regulate 
neural regeneration. Over the years, only a few research groups claimed to have proven 
that delivered MSCs have a structural function, by differentiating into Schwann cells in 
vivo and by replacing injured cells in the regenerated nerve.5-7 However, the beneficial 
effects of delivered MSCs have not been convincingly demonstrated. When studying MSC-
dimensions, one could consider that the MSCs are disproportionally big compared to the 
single nerve fiber/axon on which the MSCs are supposed to exert their effect. Blockage of 
ingrowing axons and damage to the inner ultrastructure of nerve substitutes are therefore 
not unthinkable consequences.8-10 Also, in previous studies MSCs have been mostly 
delivered inside nerve substitutes by injection. The smaller the injection-needle diameter, 
the less harm is caused to the ultrastructure of the nerve substitutes. This is opposite to 
MSC viability: the smaller the needle, the more pressure is built up in the syringe resulting 
in a more impaired viability of the MSCs.11-13 Inefficient delivery and fascicle blockage 
may explain the numerous studies that did not demonstrate a beneficial effect of MSCs 
delivered inside nerve substitutes despite their differentiational capacities.14, 15 
Derived from other fields of research, the theory evolved that MSCs can have a trophic 
effect on regenerating tissues without being built into the new tissue.16, 17 This trophic theory 
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is supported by in vitro studies demonstrating improved neurite outgrowth and enhanced 
levels of trophic factors in culture media in the presence of MSCs.18-20 Furthermore, studies 
reported positive effects of MSCs in vivo without confirmed in vivo differentiation or long 
term survival.18, 21 This trophic concept led to the insight that MSCs could influence nerve 
regeneration without being delivered inside nerve grafts. Trophic factors can theoretically 
penetrate the epineurium by diffusion, just like they do from surrounding vasculature. To 
avoid injection, dynamic seeding on nerve substitutes was proposed and led to a uniform 
distribution of MSCs on the outer surface of nerve grafts.4 Drawbacks of this strategy 
are the minimal 12 hours needed to let the MSCS adhere to the nerve grafts and the 
potential vulnerability of the MSCs as they are on the outer surface of the graft during 
surgery. However, MSCs survived up to 29 days in vivo, implying that they can withstand 
the mechanical impacts during surgery.22 Due to its practicability and efficient cell delivery, 
dynamic seeding is labeled as an effective strategy to non-traumatically adhere MSCs to 
nerve grafts, after which they ideally exert their trophic function. 
IN VITRO RESEARCH
After nerve injury, Schwann cells change to a proliferating state23, 24, producing trophic 
factors that contribute to formation of the growth cone, angiogenesis, bands of Büngner 
and axon regeneration.25-32 Although undifferentiated MSCs possess trophic characteristics, 
it is uncertain if they meet up to the trophic levels of Schwann cells normally present at the 
side of nerve regeneration. Since Schwann cells are essential for nerve regeneration but 
require autologous nerve tissue, differentiating MSCs into Schwann cell-like cells has been 
suggested as required addition to processed nerve grafts to hopefully have even greater 
effects on nerve regeneration than undifferentiated MSCs.20
Compared to undifferentiated MSCs, MSCs differentiated into Schwann cell-like cells 
demonstrated to express enhanced levels of neurotrophic and angiogenic factors in vitro 
and led to comparable nerve regeneration in vivo in previous studies.18, 20, 33-36  However, 
delivery strategies have never been tested on differentiated MSCs in specific. As this is 
fundamental to fairly compare effects of undifferentiated and differentiated MSCs in vitro 
and in vivo, both their capabilities to adhere to the surface of decellularized nerve allografts 
were analyzed in chapter 3. This revealed a seeding efficiency of 80% for undifferentiated and 
95% for differentiated MSCs. Although not significant, the difference cannot be subscribed 
to laminin levels, previously described to improve cell attachment, since both cell types 
expressed comparable levels over time (chapter 4).37 The difference might subjectively 
be attributed to the tendency of differentiated MSCs to cluster together. The fact that 
undifferentiated and differentiated MSCs can be equally seeded onto decellularized nerve 
grafts is essential preliminary knowledge to further fairly compare both cell-types in their 
capabilities to enhance angiogenesis and nerve regeneration. 
                                                                                                                                                                                                                                                     
In chapter 4 the genes expressed by the different cell-types at multiple time points after 
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seeding on a decellularized allograft are described. Environmental signals are absent 
in this in vitro setting and the actual production of trophic factors was not quantified, 
but both gene expression profiles were altered by the extracellular matrix of the nerve 
allografts. The most striking suggestion described in this study, is the different effective 
phase of undifferentiated and differentiated MSCs. It seemed that undifferentiated MSCs 
needed some time to interact with the ECM to enhance expression of the appropriate 
genes, while differentiated MSCs directly expressed enhanced levels of genes essential 
for nerve regeneration. In accordance to our findings, previous studies also demonstrated 
that the ECM significantly enhances the neurotrophic characteristics of differentiated 
MSCs in particular on the short term, but these studies lack long term evaluation points 
or did not make direct comparisons to undifferentiated MSCs.20, 37, 38 By all means, the 
enhanced short-term gene expression of differentiated MSCs and the enhanced long-
term gene expression of undifferentiated MSCs perhaps suggest that a cocktail of both 
undifferentiated and differentiated MSCs together provide a better cover for the trophic 
factors needed during the entire Wallerian degeneration and axon regeneration process 
and deserves to be studied in future research. 
IN VIVO EVALUATION STRATEGIES OF FUNCTIONAL OUTCOMES
Many measurements to evaluate functional outcome are possible, we however have chosen 
for compound muscle action potentials (CMAP), isometric tetanic force (ITF), muscle mass 
and cross-sectional tibial muscle area. Behavioral studies like walking track analysis were 
deliberately not used to evaluate nerve regeneration since they are very sensitive to several 
flaws. This includes dependency on walking velocity, weight shifts as a compensatory 
mechanism, difficulty to acquire representative paw prints and dependency on sensory 
feedback.39 Likewise, CMAP and ITF outcomes are affected by electrode placement, 
manipulation of the nerve which can result in neuropraxia and overstimulation of the 
nerve and muscle leading to muscle fatigue.40 However, muscle function was determined 
to represent the most relevant outcome factor for clinical practice and CMAP, ITF and 
muscle mass were rated to most optimally represent muscle function. Despite their flaws, 
we estimated CMAP and ITF to be less vulnerable than behavioral studies and our analyses 
resulted in significant differences with acceptable standard errors.
The rationale of the non-invasive ultrasound evaluation of cross-sectional tibial muscle 
area is logical, but it seems to be not sensitive enough to significantly demonstrate subtle 
cross-sectional muscle area differences within groups in the rat model. Due to its inability 
to detect differences between groups, it is questionable if the ultrasound technique 
should be used in future research in rat-models. However, ultrasound evaluation does not 
require the sacrifice of extra animals, it has great intra-rater and inter-rater reliabilities, 
it demonstrates regeneration curves and might reveal significant differences in bigger 
animal/muscle models.41-43 For future studies in larger muscle models it is therefore still 
recommended to use this non-invasive muscle function evaluation strategy. 
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ANGIOGENESIS & GENE EXPRESSION
Our research was aimed to  correlate the level of angiogenesis to the expression of angiogenic 
genes and to describe if the functional outcomes trace back to the demonstrated expression 
levels of the evaluated trophic genes. To answer these questions the correlations between 
each of the studied subjects (angiogenesis and gene expression, angiogenesis and functional 
outcomes, functional outcomes and gene expression) will be discussed sequentially. 
Angiogenesis is crucial for the supply of nutrients and trophic factors, but also influences the 
alignment of bands of Büngner.30, 31 VEGF-a has been extensively studied and demonstrated 
to be an indispensable factor in the angiogenesis process and therefore also for nerve 
regeneration.31, 44-46 When studying the VEGF-a gene expression of differentiated and 
undifferentiated MSCs in chapter 4, it occurred that the VEGF-a expression of both cell-types 
was significantly enhanced after interacting with the extracellular matrix of the decellularized 
nerve graft. For undifferentiated MSCs, this was previously demonstrated in vitro and in vivo 
while using the same seeding strategy.47, 48 The VEGF-a expression of differentiated MSCs 
was significantly higher than of undifferentiated MSCs directly after seeding (p=0.003), lower 
at the longer term time points and approached the expression of undifferentiated MSCs 
again at 21 days after seeding. Enhanced expression of VEGF-a directly after differentiating 
MSCs was demonstrated before18, but longitudinal VEGF-a expression after seeding has not 
been compared to this extent. Translating these findings to a long-term in vivo model, it 
was hypothesized that undifferentiated MSCs would enhance vascularization to an equal 
or even augmented level compared to differentiated MSCs. Although there were no 
significant differences concerning the level of revascularization between undifferentiated 
and differentiated MSCs in chapter 6, only differentiated MSCs significantly improved 
vascularization of decellularized allografts. This partly contradicts the expectations based on 
the demonstrated VEGF-a expressions described in chapter 4.
In an attempt to explain the subjective discrepancy between the in vitro and in vivo findings 
one could argue that the time frame of both studies is completely different. The in vitro 
data suggested an increasing VEGF-a expression trend in differentiated MSCs from 14 
days onwards, while the expression in undifferentiated MSCs slowly decreased from 7 days 
onwards. The hypothesis that VEGF-a expression of differentiated MSCs will overtake the 
expression of undifferentiated MSCs on the long term is supported by previous research 
reporting significantly higher VEGF-a expression in differentiated MSCs after 12 weeks in vivo, 
which matches our in vivo angiogenesis findings.49 
The long term follow up in vivo might as well have minimized the between group differences 
due to the superlative nerve regeneration capacities of rats50, 51 which could be based on 
superposed revascularization capacities.52 Another hypothetical explanation is the absence 
of environmental signals in the in vitro setting, what might have caused the differentiated 
MSCs to lose their differentiational state, leading to different gene expression patterns. The 
differentiational state of MSCs is better preserved in vivo by signals from the surrounding 
regenerating nerve.53 Therefore, in vivo outcomes are believed to represent the effects of 
Proefschrift.indd   172 19-07-21   22:26
10
General discussion and future perspectives
173
differentiated MSCs to a better extent than in vitro outcomes, resulting in the assumption 
that differentiated MSCs enhance angiogenesis in nerve allografts to a greater extent than 
undifferentiated MSC. 
ANGIOGENESIS & FUNCTIONAL OUTCOMES
The used techniques to measure angiogenesis validated in chapter 5, are unique and 
innovative in describing 2D and 3D angiogenesis. Disadvantages of these techniques are 
the dependency on the effective pixel size of the used micro CT and adequate injection of 
the radiopaque compound. However, Microfil® has demonstrated before to reach even the 
smallest vessels, allowing analysis of the entire vascular network and adequate compound 
injection can be easily checked at the nailbeds of the rats.54 Even if no micro CT is available, 
an impression of the vascular network and analysis of the vascular surface area can be readily 
obtained with the 2D technique. Although the 2D and 3D techniques cannot be combined with 
histological analysis of vessels since they require different processing techniques, histological 
evaluation falls short in quantifying and describing vascularity volumes and vascularization 
patterns and forms therefore no loss to the evaluation of angiogenesis. Vascular distribution 
and vessel sizes analyses on micro CT samples could add valuable information about 
neoangiogenesis in future studies in addition to vascular volume and surface area. 
Compared to unseeded, decellularized nerve allografts, both MSC-groups enhanced 
functional outcomes, which could be allocated to their improved angiogenesis described 
in chapter 6. Since angiogenesis is granted a crucial role in axon guidance and nerve 
regeneration, it was expected that particularly differentiated MSCs would improve the 
functional outcomes of nerve allografts. There were no significant differences between the 
functional outcomes of undifferentiated and differentiated MSCs. However, compared to 
unseeded allografts, undifferentiated MSCs led to significantly improved CMAP and ITF 
outcomes, while differentiated MSCs only led to significantly enhanced CMAP outcomes. 
The small study groups and small animal model can be put forward as explanations that other 
significant differences were absent.
Although most motor outcomes of both MSC-groups equaled the motor outcomes of 
nerve autografts, autografts histologically outperformed MSC-seeded allografts despite the 
comparable or even enhanced level of neoangiogenesis in the MSC-groups. The alignment 
of the new vasculature can be a clarification to this subtle discrepancy between the level 
of angiogenesis, the histological outcomes and the functional outcomes, as measured by 
CMAP, ITF and muscle mass. The vasculature was significantly enhanced in nerve grafts 
seeded with differentiated MSC in particular, but it led to an extensive, non-aligned network 
of small vessels. Considering their guiding role, enhanced angiogenesis should lead to 
improved regeneration, but might be counterproductive if it extents a particular level or 
becomes less aligned. When subjectively comparing the angiogenesis samples of the MSC-
groups and the autograft group, the mal-alignment of vasculature seems to be of greater 
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extent in the differentiated MSC-group in particular. This might explain the very subtle 
differences in functional and histological outcomes between both MSC-groups (in benefit 
for undifferentiated MSCs) and the autografts (in benefit for the autografts). Future studies 
should focus on ways to quantify vessel diameters and vessel alignment in order to confirm 
the hypothesis that alignment of vasculature is of major importance for nerve regeneration 
efficiency.
GENE EXPRESSION & FUNCTIONAL OUTCOMES
Differences in functional outcomes between groups cannot be completely traced back to the 
level of neoangiogenesis, so other processes and genes must have affected nerve regeneration 
as well. Since the baseline gene expression of both MSC-groups was significantly altered upon 
interaction with processed nerve allografts, leading to production of trophic factors, it is very 
plausible that the MSCs not only have caused enhanced angiogenesis, but improved axon 
regeneration in its entirety as well. It is impossible to solidly relate the barely differing functional 
outcomes of differentiated and undifferentiated MSCs to each of the individual gene expression 
curves. Expression curves of PTN, GAP43, NGF, FBLN1 and CCNB2 particularly differed 
between undifferentiated and differentiated MSCs in vitro, mostly in benefit for differentiated 
MSCs. Although these differences apparently do not lead to significantly enhanced nerve 
regeneration, one should not jump to the conclusion that these genes don’t significantly affect 
nerve regeneration. The subtle discrepancies between in vitro gene expression and functional 
outcomes in vivo are the consequence of limited numbers per group, enormous differences 
in signals from surrounding tissues between in vitro and in vivo settings and the completely 
different time frames of both studies. 
The different effective phases of both cell types suggested by their gene expression in chapter 4, 
might be relatable to the demonstrated tibial muscle area recovery over time. The degeneration 
of tibial muscles in the groups treated with differentiated MSCs only seems to occur in the first 
two weeks after surgery after which muscle area increases again, while in the undifferentiated 
MSC-group the muscle degeneration continued until four weeks after surgery. This might be 
due to differentiated MSCs being able to interact faster with the ECM than undifferentiated 
MSCs, although none of the muscle area differences between groups were significant. 
In contradiction to undifferentiated MSCs22, in vivo survivability of dynamically seeded 
differentiated MSCs has not been studied yet. Although differentiation of MSCs sensitizes 
MSCs to toxic effects55, it has been suggested that differentiated MSCs possess even greater 
survivability than undifferentiated MSCs.6 The significant improvement of functional outcomes 
of nerve allografts by both cell types and the absence of significant differences between 
undifferentiated and differentiated MSCs described in chapter 7 are in accordance with these 
findings, suggesting at least sufficient survivability of both cell types to exert their effect. 
Nevertheless, it would be interesting to analyze the relation of vitality and survivability of both 
cell types and functional outcomes in future in vivo studies. 
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BENCH TO BEDSIDE TRANSLATION
Considering the discussed gene expression profiles and their effect on angiogenesis, nerve 
regeneration and functional outcome, no scientifically funded specific preference can be 
expressed for either undifferentiated or differentiated MSCs. Usage of undifferentiated MSCs 
requires approximately half of the preparation time and even less than half of the costs of 
differentiated MSCs. Like previously described, applying a combination of differentiated and 
undifferentiated MSCs to processed nerve allograft might have undiscovered potential, but 
will reduce the ease of MSC-seeding per definition since both culturing techniques would 
need to be combined. As clinical applicability is crucial when estimating future potential of 
both cell-types, usage of undifferentiated MSCs is advised for future studies. 
Anticipatory to a clinical setting, we envision that adipose tissue is derived from patients with 
peripheral nerve injury as soon as possible after trauma, using a minimally invasive technique 
which can be performed on the ER or outpatient clinic. MSCs are obtained from this adipose 
tissue and cultured for approximately 2 weeks. Thereafter, the MSCs are dynamically seeded 
for 12 hours onto an off-the-shelf available nerve allograft, immediately prior to surgery. To 
test whether this would be technically possible in the future, we examined in chapter 8 if 
human MSCs can be dynamically seeded onto nerve substitutes currently available in clinic; 
the NeuraGen® Nerve Guide and the Avance® Nerve Graft. Surprisingly, MSCs adhered 
significantly more efficient to the surface of NeuraGen® Nerve Guides. This is attributed to 
the adherence of MSCs to both the inner and the outer surface of the nerve guides, while 
MSCs only adhered to the outer surface of Avance® Nerve Grafts as expected. Although the 
adherence of MSCs on the inner surface of NeuraGen® Nerve Guides hypothetically leads 
to enhanced concentrations of trophic factors that reach the regeneration site in NeuraGen® 
Nerve Guides, in vivo studies should indicate whether the MSC adherence location truly has 
implications for their effect on axon regeneration. 
The interaction between (undifferentiated) MSCs and both clinically available nerve 
substitutes resulted in an altered gene expression profile of the MSCs, described in 
chapter 9. Most trends of the expression curves were relatable to physiological Wallerian 
degeneration and axon regeneration processes, implying potential benefit of the addition of 
MSCs to regenerating nerves.56 Contrary to expectations considering the biological material 
components of both nerve substitutes, MSCs on NeuraGen® Nerve Guides demonstrated 
most gene expression adjustments appropriate for nerve regeneration. These results are 
hopeful, but like demonstrated with the rat MSCs in chapters 4, 5 and 6, the in vitro findings 
might not be completely relatable to in vivo results. Due to the neural tissue composition of 
Avance® Nerve Grafts, the interaction with the MSCs and the micro-environment might be 
more significant than NeuraGen® Nerve Guides. Contrarily, effects of MSCs on NeuraGen® 
Nerve Guides might be more prominent since part of the adhered cells lie protected on the 
inner surface, being closer to the regenerating nerve and avoiding mechanical stress during 
surgery. Besides this in vitro analysis, the result of the interaction between MSCs and the 
Avance® Nerve Graft and the NeuraGen® Nerve Guide on a gene-expression level should 
therefore be analyzed in vivo as well. 




The presented thesis demonstrates cautious potential of MSC seeding in the repair of peripheral 
nerve injuries. As with all forms of basic science research, small research steps will have to follow 
to confirm this potential. 
MSC optimization
MSC-function and viability has been described to significantly variate between donors.57, 58 For 
example, proliferation capacities decreases with increasing donor age59, female MSCs have 
more anti-inflammatory capacities than male MSCs60 and auto-immune diseases reduce the 
immunosuppressive capacities of MSCs.61 Efforts to select ideal MSC donors, either in light of 
allogenous MSC transplantation or in light of patient selection that are more prone to benefit 
from autologous MSC therapy, might extend the described enhancing effect of MSCs. 
A big hurdle in translating MSC-seeding to a clinical trial, are safety concerns and with that FDA 
approval. However, with sufficient data from animal studies and extensive descriptions of the 
deriving, culture and implementation steps, usage of adipose derived MSCs might be allowed 
to be studied under an investigational new drug application (IND). As this allowance will be 
easier obtained for usage of autologous MSCs than for allogenous MSCs, this thesis focused on 
autologous MSC application.
Contrary to MSCs, stromal vascular fraction (SVF) does not need to be manipulated or cultured 
prior to use, which limits the risk of contamination, making it safer and subject to lesser 
regulatory criteria. Stromal vascular fraction is a heterogeneous collection of cells, including 
MSCs, macrophages and pericytes and has demonstrated regenerative capabilities in multiple 
clinical settings like neurodegenerative disorders62, alopecia areata63 and perianal fistulizing 
Crohn’s disease.64 SVF can be easily and quickly derived from autologous adipose tissue, 
contains high concentrations of stromal cells and can be directly used after its acquisition.65 SVF 
has demonstrated comparable effects as MSCs in other fields of research, but they have not 
been thoroughly compared in peripheral nerve repair yet.66, 67 It would therefore be interesting 
to test if and at what efficiency SVF can be dynamically seeded onto nerve substitutes, to be 
able to fairly compare its effect on peripheral nerve regeneration to that of MSCs.    
In vivo gene expression and growth factor production
The in vivo gene expression and the release of trophic factors of MSCs when seeded on nerve 
grafts should be studied to get a complete mechanistic insight in the effect of MSCs. This is 
preferably done at multiple time points, particularly short term, in an in vivo model to get the 
most reliable outcomes. Unfortunately this does require the use of many animals since qPCR 
analysis and trophic factor release analysis is preferably performed on five replicates per group 
per time point. To bypass the need for extra animals, one could consider another in vitro study, 
in which the micro-regenerative environment is simulated by presence of an unprocessed 
cut nerve segment in the same culture dish as the MSC-seeded decellularized nerve grafts. 
Although suboptimal, presence of a nerve segment in an in vitro culture, might simulate an in 
vivo setting while exposing the MSCs to trophic signals of the cut nerve segment. 
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Translation to bigger nerve gap models
Rats are often used as animal-model to perform fundamental studies prior to translation to a 
bigger animal. We choose to do so as well as they can be easily housed, are relatively cheap, they 
can endure anesthesia and surgery quite well, plenty of rat-specific reagents (needed for qPCR 
analysis for example) are available and most nerve studies have been performed in rats making 
results easy comparable to other studies. The major disadvantage of using a rat-model is their 
described superposed neuroregenerative capacities compared to humans, particularly due to 
the limited nerve gap that can be obtained.50, 51 After fundamental studies have been performed 
to clarify details of the neuroregenerative capacity of MSCs in vivo, we suggest to translate 
studies to a bigger animal model like the rabbit. Needless to say, considering alternative animal-
free study options and critically assessing the necessity and size of another animal-study must 
precede future animal-studies. 
Surgical angiogenesis
As described in several chapters of this thesis, MSCs demonstrated to improve functional 
outcomes of peripheral nerve repair due to release of trophic factors that, among other things, 
enhance angiogenesis. Angiogenesis is postulated to be a crucial element in nerve regeneration 
and therefore other or complementing strategies to enhance angiogenesis are estimated to 
be valuable future research subjects. A vital, well vascularized wound bed has shown to be 
essential for regenerating tissues, providing trophic factors and enhancing outgrowth of blood 
vessels.68, 69 A vascularized fat flap that envelopes an implanted decellularized nerve allograft 
is hypothesized to improve axon regeneration. The blood vessels and the stromal cells (MSC 
relatives) that are present in the fat tissue might lead to less fibrosis, enhanced vascularization 
and improved regeneration. Moreover, it would be interesting to study whether this surgical 
angiogenesis technique can work synergistic with the MSC-seeding technique presented in 
this thesis. One could hypothesize that a vascularized wound bed leads to more extensive 
delivery of trophic factors to the MSCs, resulting in extended survival times or enhanced activity/
vitality of MSCs. On their turn, the trophic factors of the MSCs might decrease the immune 
response resulting in less fibrosis of the fat flap and potentially stimulate the outgrowth of blood 
vessels from the flap inside the nerve graft. Perhaps this also influences the distribution and 
orientation of vessels inside the nerve. The hypothesized synergistic effect of MSCs and surgical 
angiogenesis is illustrated in figure 1. The effect on peripheral nerve regeneration of stem-cell 
therapy combined with surgical angiogenesis deserves to be studied in future in vitro and in 
vivo settings. 
Immunomodulation
Adjuvant therapies like immunomodulation have also demonstrated future potential to 
improve outcomes of peripheral nerve regeneration. Tacrolimus (FK506) is a regularly used 
immunosuppressant, often chronically systemically administered after organ transplantation. 
Besides, it demonstrated to have neuroprotective characteristics by influencing pathways 
that lead to enhanced GAP43 and NGF synthesis, which hypothetically results in accelerated 
Wallerian degeneration and axon regeneration.70 Although this suggests a role for Tacrolimus 
in peripheral nerve regeneration, substantial systemic doses of Tacrolimus not only results in 
undesirable immunosuppression, but also in neurotoxicity, inducing peripheral neuropathy. 
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Figure 1. Illustration of the hypothesized synergistic effect on axon regeneration between surgical 
angiogenesis and MSC-seeding. 
Local delivery of Tacrolimus would therefore be ideal.71 Hydrogel is described to facilitate this 
local delivery, containing microspheres that encapsulate Tacrolimus.72 Hydrogel delivery of 
Tacrolimus has resulted in improved in vitro and in vivo outcomes after peripheral nerve repair 
73, but uncertainties like its mechanism of action, ideal dosage, duration of treatment and their 
interaction with MSCs remain to be studied before clinical translation can be considered.74
Cell delivery
Besides factors like Tacrolimus, NGF and BDNF75, microspheres have shown to be able to 
encapsulate MSCs76, potentially facilitating local delivery of MSCs to regenerating nerves. 
Since MSC-delivery in peripheral nerve repair is a rather underexposed research topic, it 
would be interesting to directly compare delivery efficiencies of different strategies like MSC-
injection and microsphere encapsulation to that of dynamic seeding. 
IN CONCLUSION
Contemplating the described outcomes, correlations and limitations, the chapters of this 
thesis have demonstrated that undifferentiated and differentiated MSCs can be efficiently 
seeded onto processed nerve allografts. Both cell types can interact with the extracellular 
matrix of processed nerve allografts, mostly leading to an upregulation of neurotrophic, 
angiogenic and extracellular matrix genes. Compared to unseeded processed nerve 
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allografts, the angiogenic factors resulting from the interaction between MSCs  (differentiated 
MSCs in particular) and processed nerve allografts, led to enhanced neoangiogenesis in an 
in vivo model. Together with multiple enhanced neurotrophic and extracellular matrix factors, 
the enhanced angiogenesis caused by the MSCs results in improved functional outcomes 
of processed nerve allografts. There were no significant differences between the functional 
outcomes of undifferentiated and differentiated MSCs, resulting in a preference for the 
use of undifferentiated MSCs due to practical benefits. The dynamic seeding technique 
is applicable to human MSCs and nerve graft substitutes available in clinical practice and 
results in an interaction between the MSCs and the extracellular matrix of the grafts. Ideally, 
MSC seeding with all its beneficial effects on nerve regeneration will be combined in future 
studies with other initiatives to improve nerve regeneration like optimization of MSC quality, 
immunomodulation and surgical angiogenesis.
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SUMMARY
In the general introduction, chapter 1, the aims and scope of this thesis are elucidated. The 
overall goal of this thesis is to improve the results of autograft substitutes like processed nerve 
allografts and nerve conduits when used in peripheral nerve repair. MSCs are hypothesized to 
possess regenerative capacities beneficial for nerve regeneration in these nerve substitutes, 
which is most plausibly caused by their secretion of trophic factors. As Schwann cells are 
essential for the function and regeneration of nerves by excreting numerous trophic factors, 
MSCs differentiated into Schwann cell-like cells might excrete enhanced levels of trophic 
factors leading to improved nerve regeneration. With this thesis, we literally strained every 
nerve to determine if the addition of differentiated and undifferentiated adipose derived 
MSCs to nerve substitutes could provoke the desired improvement in peripheral nerve 
regeneration.
In chapter 2 a review of the currently available literature was performed to create the fundament 
for our experimental research. An overview of the current available MSC-differentiating 
methods is provided, delivery strategies and cell dosing are discussed and previous in vitro 
and in vivo outcomes of naïve and differentiated MSCs are described. Optimal delivery and 
dosing of (differentiated) MSCs has not been explored extensively, but dynamic seeding seems 
to deliver undifferentiated MSCs in a timely and non-traumatic manner. The neural induction 
of MSCs by chemicals combined with growth factors is the preferred and most extensively 
described method to obtain Schwann cell-like differentiation. Although differentiated MSCs 
demonstrated more potential in vitro compared to undifferentiated MSCs, their beneficial 
effect has not been convincingly confirmed in previous in vivo studies. Since differentiation 
of MSCs requires extra preparation time and costs, convincing in vivo results are required to 
determine which type of MSCs has most clinical potential.  
Chapter 3 focuses on the development of a delivery strategy that is applicable to both 
undifferentiated and differentiated MSCs. To test whether differentiated MSCs could be 
dynamically seeded comparable to undifferentiated MSCs, the experimental set-up of the 
described study comprised multiple samples of 1x10^6 (undifferentiated or differentiated) 
MSCs that were placed in a conical tube containing a processed nerve graft, which was 
rotated for either 6, 12 or 24 hours. Viability, seeding efficiency and cell distribution on the 
outer surface of the nerve allografts were evaluated. We concluded that differentiated MSCs 
can be dynamically seeded, leading to a similar cell-distribution as seeded undifferentiated 
MSCs. Twelve hours of seeding was estimated to provide the most efficient cell adherence 
for both cell-types, but differentiated MSCs had a significantly higher cell adherence than 
undifferentiated MSCs (95% versus 80%). This might indicate that differentiation of MSCs 
improves in vitro cell adherence to processed nerve allografts. 
To understand the biological differences of undifferentiated and differentiated MSCs before 
and after seeding onto processed nerve allografts, the gene expression profiles of both 
cell-types are compared in chapter 4. Gene expression of both cell-types was quantified 
by quantitative polymerase chain reaction (qPCR) analysis of neurotrophic, angiogenic, 
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extracellular matrix and cell cycle genes at multiple time points after seeding. The gene 
expression profile of both cell-types changed significantly upon interaction with processed 
nerve allografts. Undifferentiated MSCs demonstrated enhanced expressions of neurotrophic 
(NGF, GDNF, PMP22), extracellular matrix (FBLN1, LAMB2) and regulatory cell cycle genes 
(CCNB2) 7 days after seeding. Differentiated MSCs expressed enhanced levels of neurotrophic 
(NGF, GDNF, GAP43), angiogenic (VEGF1), extracellular matrix (FBLN1) and regulatory cell 
cycle genes (CASP3, CCNB2) in the first 72 hours after seeding. The differences in gene-
profiles and effective phases suggests that both cell-types can affect nerve regeneration in 
different ways and at different time points, which should be confirmed in vivo. 
Vascularization has been postulated to be essential for nerve regeneration by guiding 
regenerating nerves and providing the supply of necessary trophic factors. As tools to 
visualize and quantify vascularization patterns in transplanted nerves are lacking, the study 
described in chapter 5 focusses on the development of a technique that provides a three-
dimensional visualization and quantification of the peripheral neural vascularity in a rodent 
model. Vascularization in autografts (n=12) and untreated nerves (n=12) was quantified by 
the vascular surface area using conventional photography (2D) and the vascular volume was 
calculated using micro-computed tomography (3D). Combining both methods accurately 
reflects the degree of vascularization in rat nerves. This easily reproducible strategy allows 
objective assessment of the level and the organization of vascularization in nerves and
 could be extrapolated to any other desired organ ex vivo. 
In chapter 6, the technique validated in chapter 5 is used to determine the beneficial 
effect on vascularization when seeding undifferentiated and differentiated MSCs onto a 
decellularized nerve allograft in a rat sciatic nerve defect model. The vascularization of normal 
nerves, autografts, allografts seeded with differentiated MSCs and allografts seeded with 
undifferentiated MSCs was quantified and compared at 16 weeks after surgery. Unseeded 
allografts had a significantly lower vascular surface area percentage than normal non-
operated nerves and allografts seeded with differentiated MSCs. Although it was significantly 
correlated to the vascular surface area, no significant differences in vascular volume were 
obtained between groups. The vascularization pattern in MSC-seeded allografts consisted 
of an extensive non-aligned network of micro-vessels with a centripetal pattern, while the 
vessels in autografts and normal nerves were more aligned with longitudinal patterns. The 
more extensive network might facilitates better oxygen and nutrient supply throughout the 
graft, but can be detrimental for the alignment of sprouting axons considering the directional 
function of vasculature. 
The study in chapter 7 aimed to determine whether the previous elucidated rationale of MSC-
seeding onto nerve allografts could be confirmed by in vivo evaluation of functional outcomes. 
Autografts (n=20), allografts (n=20), allografts seeded with undifferentiated MSCs (n=20) and 
allografts seeded with differentiated MSCs (n=20) were used to reconstruct a ten millimeter 
sciatic nerve defect in a rodent model. Cross sectional tibial muscle ultrasound measurements 
evaluated functional recovery over time. At 12 and 16 weeks after surgery (n=10 per group 
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per time point) isometric tetanic force, compound muscle action potentials, muscle mass, 
histology and immunofluorescence analyses were performed. Both cell-types significantly 
improved part of the functional outcomes of processed allografts and equaled the majority 
of autograft results at 12 weeks of follow-up. Differences between undifferentiated and 
differentiated MSCs were not statistically significant. Considering the increased preparation 
time and costs of differentiated MSCs, undifferentiated MSCs are more clinically applicable.
In chapter 8 a preliminary but essential step towards translating the use of dynamic seeding 
into a clinical setting is described. The purpose of the study was to examine if human 
adipose derived MSCs could be dynamically seeded onto the clinically available Avance® 
Nerve Graft (processed nerve allograft) and the NeuraGen® Nerve Guide (hollow collagen 
conduit). Viability of MSCs, seeding efficiency and cell distribution were determined for both 
nerve substitutes. The viability of MSCs was not negatively affected by the composition of 
the nerve substitutes. The optimal seeding duration was 12 hours, leading to a significant 
higher seeding efficiency of NeuraGen® Nerve Guides compared to Avance® Nerve Grafts 
(94% versus 65% of the administered dose of MSCs). This was hypothetically related to the 
cell distribution on both nerve substitutes; dynamic seeding led to a uniform distribution of 
MSCs over the surfaces of both nerve substitutes, but only to adherence of MSCs on the inner 
surface of the NeuraGen® Nerve Guide. These results demonstrate that human MSCs can be 
effectively and efficiently seeded on commercially available nerve autograft substitutes in a 
timely fashion.
The interaction between human adipose derived MSCs and the extracellular matrix of the 
clinically available Avance® Nerve Grafts and NeuraGen® Nerve Guides was assessed in 
chapter 9. Quantitative PCR analyses on multiple time points (up to 21 days) after MSC-seeding 
demonstrated the course of the expression of neurotrophic (NGF, GDNF, PTN, GAP43, BDNF), 
myelination (PMP22, MPZ), angiogenic (VEGF-a, CD31), extracellular matrix (COL1A1, COL3A1, 
FBLN1, LAMB2) and immunoglobulin (CD96) genes. The interaction resulted in a change and 
mostly an upregulation of the expression of numerous genes important for nerve regeneration 
over time. Despite the absence of micro-environmental signals in this in vitro study, the (timing 
of) upregulation of most genes could be correlated to processes occurring during Wallerian 
degeneration and axon regeneration of injured peripheral nerves. It was hypothesized that the 
biological composition of the Avance® Nerve Grafts (i.e. neural tissue) would lead to more 
expression of neurotrophic genes, but the in vitro interaction of MSCs with the NeuraGen® 
Nerve Guide was greater, particularly in the long-term results. These outcomes suggest that 
clinically available nerve autograft substitutes could benefit from the addition of MSCs. 
In chapter 10, the main findings of this thesis are described and placed in a broader 
perspective. Suggestions for future research are illustrated and substantiated. By enhanced 
expression of trophic factors leading to increased vascularization and axon regeneration, 
dynamic seeding of MSCs leads to improved functional outcomes of decellularized allografts. 
Seeding of undifferentiated MSCs is more cost-efficient than differentiated MSCs and can be 
applied to clinically available nerve graft substitutes. 




In de algemene inleiding, hoofdstuk 1, worden de doelen van dit proefschrift uiteengezet. 
Het algemene doel is het verbeteren van de uitkomsten van gedecellulariseerde allogene 
zenuwtransplantaten die gebruikt worden in het geval van perifeer zenuw letsel. Mesenchymale 
stamcellen bevatten regeneratieve eigenschappen die mogelijk gunstige effecten hebben op 
zenuw regeneratie wanneer ze gebruikt worden in combinatie met zenuwtransplantaten. Deze 
regeneratieve eigenschappen van stamcellen zijn het gevolg van de productie en excretie van 
trofische (groei) factoren. Omdat schwann-cellen essentieel zijn voor functionerende, maar 
zeker ook voor regenererende zenuwen, zou het differentiëren van stamcellen in schwann-cell 
achtige cellen mogelijk leiden tot nog meer excretie van trofische factoren die van belang zijn 
bij zenuw regeneratie. In dit proefschrift hebben we gepoogd te analyseren of het toevoegen 
van stamcellen, al dan niet in een gedifferentieerde vorm, de gewenste verbetering van de 
uitkomsten van zenuwtransplantaten kan bewerkstelligen. 
Hoofdstuk 2 beschrijft de rationale van dit proefschrift, waarin relevante beschikbare 
literatuur wordt samengevat. Hierin komen differentiatie-technieken, strategieën om cellen 
in of op zenuwen te bezorgen en eerder beschreven uitkomsten van ongedifferentieerde en 
gedifferentieerde stamcellen aan de orde. Het induceren van een neurale differentiatiestaat 
van stamcellen wordt in voorgaande studies voornamelijk op een efficiënte manier bereikt 
door de cellen te kweken in een mengsel van chemicaliën en groeifactoren. Cel-doseringen 
en optimale toedieningstechnieken zijn onvoldoende onderzocht, maar het dynamisch 
zaaien van ongedifferentieerde stamcellen lijkt een efficiënte en atraumatische methode om 
stamcellen gelijkmatig te verdelen over het oppervlak van een zenuwtransplantaat. Hoewel 
gedifferentieerde cellen in vitro meer zenuw-regeneratie potentie lijken te hebben, hebben 
eerdere onderzoeken dit voordeel nog niet kunnen bevestigen in vivo. Het differentiëren van 
stamcellen vergt extra tijd en materiaalkosten. Het is derhalve essentieel om overtuigende in 
vivo resultaten te verkrijgen om te bepalen welk celtype de meeste potentie heeft om in de 
toekomst in de kliniek toegepast te worden.
Hoofdstuk 3 focust op de ontwikkeling van een stamcel-toedieningsstrategie die toepasbaar 
is op zowel ongedifferentieerde als gedifferentieerde stamcellen. Om te bepalen of de eerder 
beschreven dynamische zaaiings-strategie vergelijkbaar toepasbaar is op gedifferentieerde 
stamcellen, werden samples van 1x10^6 stamcellen (ongedifferentieerd of gedifferentieerd) 
samen met een gedecellulariseerd zenuwtransplantaat in een reageerbuis geplaatst. Deze 
reageerbuizen werden vervolgens geroteerd voor 6, 12 of 24 uur. Cel-vitaliteit, bezaaiings-
efficiëntie en cel-distributie over de oppervlakte van de zenuwtransplantaten werden 
geëvalueerd. Gedifferentieerde cellen konden gezaaid worden, leidend tot een vergelijkbare 
cel-distributie als het zaaien van ongedifferentieerde cellen. Twaalf uur zaaien leidde tot 
de meest optimale cel bedekking voor zowel ongedifferentieerde en gedifferentieerde 
cellen, maar gedifferentieerde stamcellen hadden een significant hogere bedekking 
dan ongedifferentieerde stamcellen (95% versus 80%). De bevindingen wijzen erop dat 
het differentiëren van stamcellen de in vitro aantrekkingskracht op gedecellulariseerde 
zenuwtransplantaten vergroot.
Proefschrift.indd   190 19-07-21   22:26
11
Summary and Dutch summary
191
Om de biologische verschillen tussen ongedifferentieerde en gedifferentieerde stamcellen 
voor en na het zaaien op gedecellulariseerde, allogene zenuwtransplantaten beter te 
begrijpen, werden in hoofdstuk 4 de genexpressie profielen van beide celtypes in kaart 
gebracht en met elkaar vergeleken. De genexpressie werd gekwantificeerd door middel 
van ‘quantitative polymerase chain reaction’ (qPCR) analyse van neurotrofe, angiogene, 
extracellulaire matrix en celproliferatie genen op meerdere tijdstippen na het bezaaien. 
De genexpressieprofielen van ongedifferentieerde en gedifferentieerde stamcellen 
veranderden significant na de blootstelling aan het oppervlak van de gedecellulariseerde 
zenuwtransplantaten. Ongedifferentieerde stamcellen toonden een toename in de expressie 
van neurotrofe (NGF, GDNF, PMP22), extracellulaire matrix (FBLN1, LAMB2) en celproliferatie 
genen (CCBN2) vanaf 7 dagen na het zaaien. Gedifferentieerde stamcellen toonden 
een verhoogde expressie van neurotrofe (NGF, GDNF, GAP43), angiogene (VEGF1-a), 
extracellulaire matrix (FBLN1) en celproliferatie genen (CASP3, CCNB2) in de eerste 72 uur na 
het zaaien. De beschreven interacties en verschillen tussen de celtypes suggereren dat beide 
type stamcellen een positief effect kunnen hebben op zenuw regeneratie, maar dat ze op 
verschillende manieren en tijdspunten effectief zijn. 
Vascularisatie wordt als essentieel geacht voor zenuwregeneratie omdat het regenererende 
axonen kan voorzien van de benodigde trofische factoren en als leidraad werkt voor de 
regeneratie richting. Adequate methodes om de hoeveelheid vascularisatie in zenuwen te 
kwantificeren ontbreken. Derhalve wordt in hoofdstuk 5 een techniek beschreven waarin 
de vascularisatie zowel in 2D (vascularisatie oppervlakte door middel van conventionele 
fotografie) als in 3D (vascularisatie volume door middel van ‘micro-computed tomography’, 
micro-CT) kan worden gekwantificeerd. Deze technieken worden geverifieerd met behulp 
van 12 autogene zenuwtransplantaten en 12 normale zenuwen. De beschreven technieken 
zijn makkelijk te reproduceren en faciliteren een objectieve beoordeling van de vascularisatie 
in zenuwen.
In hoofdstuk 6 worden de in hoofdstuk 5 geverifieerde technieken gebruikt om het effect 
van ongedifferentieerde en gedifferentieerde stamcellen te analyseren betreffende de 
vascularisatie van zenuwtransplantaten. De vascularisatie van normale zenuwen, autologe 
zenuwtransplantaten, gedecellulariseerde allogene zenuwtransplantaten, en allogene 
zenuwtransplantaten bezaaid met ongedifferentieerde of gedifferentieerde stamcellen werden 
met elkaar vergeleken 16 weken na de implementatie van de zenuwen in een rat-model. 
Onbezaaide allogene zenuwtransplantaten hadden een significant kleinere vascularisatie 
oppervlakte dan normale zenuwen en allogene zenuwen bezaaid met gedifferentieerde 
stamcellen. Ondanks een significante correlatie tussen het vasculaire oppervlakte en het 
vasculaire volume, werden er geen significante verschillen vastgesteld tussen de groepen 
wat betreft het vasculaire volume. Het vascularisatie-patroon van met stamcellen bezaaide 
zenuwtransplantaten was anders (uitgebreider maar minder georganiseerd) dan dat in 
autologe zenuwtransplantaten en normale zenuwen.  
In hoofdstuk 7 werd onderzocht of de hiervoor uiteengezette rationale van het gebruik van 
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stamcellen in perifeer zenuwherstel ook bevestigd kon worden in een in vivo evaluatie van de 
functionele uitkomsten. Autologe zenuwtransplantaten (n=20), allogene zenuwtransplantaten 
(n=20), allogene zenuwtransplantaten bezaaid met ongedifferentieerde stamcellen (n=20) 
en allogene zenuwtransplantaten met gedifferentieerde stamcellen (n=20) werden gebruikt 
om een 10mm zenuw defect in een ratmodel te reconstrueren. Echografie van spieren werd 
gebruikt om tussentijds het zenuwherstel te meten. 12 en 16 weken na de operatie (n=10 
per groep per tijdspunt) werden elektrofysiologie, isometrische tetanische kracht, spiermassa, 
histologie en immunofluorescentie gebruikt om de zenuwregeneratie te beoordelen. Na 12 
weken zorgden beide cel-varianten voor significante verbetering van een groot deel van 
de functionele uitkomsten van allogene zenuwtransplantaten en bereikten grotendeels 
resultaten die vergelijkbaar waren met die van autologe zenuwtransplantaten. De verschillen 
tussen de uitkomsten van ongedifferentieerde en gedifferentieerde stamcellen waren niet 
significant. Gezien de extra tijd en materiaalkosten die het gebruik van gedifferentieerde 
stamcellen met zich mee brengt, hebben ongedifferentieerde stamcellen een hogere 
klinische toepasbaarheid.
In hoofdstuk 8 wordt een preliminaire maar essentiële stap naar het toepassen van het bezaaien 
van zenuwtransplantaten met stamcellen in de kliniek beschreven. Humane stamcellen 
werden bezaaid op de commercieel beschikbare Avance® Nerve Graft (gedecellulariseerd 
zenuwtransplantaat) en NeuraGen® Nerve Guide (holle, collagene buis). Vitaliteit, bezaaiings-
efficiëntie, en cel-verdeling werden voor beide zenuwvervangers beoordeeld na 6, 12 en 24 uur 
zaaien. De vitaliteit van stamcellen werd niet negatief beïnvloed door de extracellulaire matrix 
van beide zenuwvervangers. Optimale bezaaiings-efficiëntie werd bereikt na 12 uur zaaien en 
leidde tot 94% bezaaiings-efficiëntie op de NeuraGen® Nerve Guide en 65% op de Avance® 
Nerve Graft (significant verschil). Dit verschil komt waarschijnlijk doordat stamcellen zowel aan 
de buitenkant als aan de binnenkant van de NeuraGen® Nerve Guide vast kleefden. Beide 
zenuwvervangers kunnen effectief en efficiënt bezaaid worden met humane stamcellen. 
De interactie tussen humane stamcellen en de extracellulaire matrix van de in hoofdstuk 8 
beschreven klinisch beschikbare zenuwvervangers werd onderzocht in hoofdstuk 9. Opnieuw 
werd qPCR op verschillende tijdspunten na het bezaaien ingezet om de expressie van 
neutrotrofe (NGF, GDNF, PTN, GAP43, BDNF), myelinisatie (PMP22, MPZ), angiogene (VEGF-a, 
CD31), extracellulaire matrix (COL1A1, COL3A1, FBLN1, LAMB2) en immunoglobuline (CD96) 
genen te kwantificeren. De interactie resulteerde in beide groepen in een verandering en 
voornamelijk een verhoging van de expressie van verscheidene genen die belangrijk zijn voor 
zenuwregeneratie. Hoewel de normaal aanwezige signalen uit de micro-omgeving van een 
regenererende zenuw ontbraken in deze in vitro studie, konden de meeste veranderingen 
in genexpressie en de timing daarvan worden gerelateerd aan processen die optreden 
tijdens Wallerse degeneratie en axon regeneratie.  Ondanks dat de Avance® Nerve Graft 
uit natuurlijk zenuw-materiaal bestaat, lijkt de interactie tussen stamcellen en de NeuraGen® 
Nerve Guide groter, voornamelijk op de lange termijn. Deze bevindingen suggereren dat 
klinisch beschikbare zenuwvervangers voordeel kunnen ondervinden van het bezaaien met 
humane stamcellen.
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In hoofdstuk 10 worden de voornaamste bevindingen uit dit proefschrift beschreven en 
in een breder perspectief geplaatst. Hierin worden suggesties voor toekomstig onderzoek 
belicht en onderbouwd. Dynamisch zaaien van stamcellen op allogene zenuwtransplantaten 
leidt tot een toegenomen vascularisatie en axon regeneratie door een toegenomen 
expressie en productie van trofische factoren. Het zaaien van ongedifferentieerde stamcellen 
is meer kosteneffectief dan gedifferentieerde stamcellen en heeft dus een hogere klinische 
toepasbaarheid.
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All data obtained during my PhD research trajectory at the Radboudumc have been stored in 
secured files at the department drive on the Radboudumc server and in the secured Digital 
Research Environment (DRE) of the Radboudumc. The rat studies described in Chapter 3, 4, 
5, 6 and 7 were approved by the Institutional Animal Care and Use Committee of the Mayo 
Clinic (Rochester, Minnesota, USA) (IACUC protocol A2464-00 and IACUC protocol A3348-18). 
The Mayo Clinical Human Cellular Therapy laboratory (Rochester, Minnesota, USA) provided 
the human Mesenchymal Stem Cells used in chapter 8 and 9. These Mesenchymal Stem Cells 
were obtained and used with approval of local institutional review boards (IRB #07-008842). 
Experimental primary and secondary data and analysis are available from the associated 
corresponding authors on request. 
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Femke Mathot was born on November 5th , 1991 in Boskoop, The Netherlands, where she 
grew up with her parents and her two brothers. After graduating high school in 2009, she 
attended medical school at the Erasmus Medical Center in Rotterdam. For her master thesis 
she went to Melbourne, Australia to perform a study which eventually resulted in her first 
scientific publication. A minor on reconstructive surgery from head to hands in her fourth 
year of medical school, introduced her to plastic and reconstructive surgery and caused her 
growing interest into this medical field. After completing her senior internship at the plastic 
and reconstructive surgery department of the Erasmus Medical Center, she obtained her 
medical degree in 2016 and started working as a resident not in training at the general surgery 
department of the Maasstad Hospital in Rotterdam. In October 2016, she was invited for a 
research fellowship at the Mayo Clinic in Rochester, Minnesota, USA. Until November 2017 
she worked in the microvascular research lab of the Mayo Clinic as a research fellow under the 
supervision of Dr. A.Y. Shin, Dr. A.T. Bishop and Prof. Dr. S.E.R. Hovius. The basic science studies 
she performed during that time laid the foundation of this PhD thesis. During her research 
fellowship she contributed to a NIH grant application, which was granted to the microvascular 
research lab just before her return to the Netherlands. This grant enabled the continuation 
of the research on peripheral nerve regeneration. Upon her return in the Netherlands, she 
combined her PhD trajectory with clinical work as a resident not in training at the plastic 
surgery department at the Radboudumc, under the supervision of prof. dr. D.J.O. Ulrich. In 
October 2018 she was admitted to the residency program of this department. She started 
residency at the general surgery department at the IJsselland Hospital under the supervision 
of dr. P.G. Doornebosch in April 2019. In October 2020 she returned to the Radboudumc for 
the continuation of the final 4 years of her residency in plastic surgery. 
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Velen hebben een bijdrage geleverd aan de totstandkoming van dit proefschrift; een aantal 
mensen zou ik graag expliciet willen bedanken. 
Geachte professor Hovius, beste prof; als promotor heeft u mij de kans gegeven om het 
onderzoeksavontuur aan te gaan dat tot dit proefschrift heeft geleid. U heeft mij de vrijheid 
gegeven om mijzelf wetenschappelijk te ontwikkelen en was te allen tijde beschikbaar voor 
advies. Relativeren, op z’n tijd wat water bij de wijn doen en gesprekstechnieken tijdens 
‘onderhandelingen’ (voor gevorderden) zijn dingen die ik van u heb mogen leren waar ik 
de rest van mijn carrière profijt van ga hebben. Gedurende mijn fellowship in Amerika, maar 
ook tijdens mijn klinische werkzaamheden heb ik heel duidelijk uw onvoorwaardelijke steun 
mogen ervaren (en die ervaar ik nog steeds!) en daar ben ik u enorm dankbaar voor. Wat een 
geluk dat ik nu op de valreep ook nog van uw chirurgische expertise mag leren. 
Geachte professor Ulrich, beste prof; bedankt dat u mij heeft opgenomen in uw team. Ik 
ben trots dat ik me bij deze ambitieuze club heb mogen aansluiten waarvan u absoluut de 
aanvoerder bent. Patiëntenzorg, onderwijs en onderzoek; u neemt op al deze gebieden 
alleen genoegen met het uiterste en daarmee tilt u de kwaliteit van de gehele afdeling tot 
een hoger niveau. Dat het harde werken wordt afgewisseld met gezellige afdelingsuitjes en 
heerlijke skitrips maakt dat ik me geen betere opleidingsplek had kunnen wensen. Bedankt 
voor het vertrouwen en dat u van mij de beste versie van mijzelf als plastisch chirurg wilt 
maken. 
Dear dr. Shin; thank you so much for the many opportunities you gave me while working 
in your renown lab at the Mayo Clinic. You gave me the freedom to develop new research 
techniques, to work on many of your innovative research projects and to present our studies 
at meetings throughout the United States. You never hesitated to invite me to all sorts of 
hands-on labs and courses and introduced me to many other inspiring nerve researchers and 
surgeons. Some professional, fruitful discussions were required to finish the final papers, for 
which I am very grateful as they led to the best versions of the manuscripts. Thank you for 
everything!
Dr. Nijhuis, beste Tim, bedankt voor jouw rotsvaste vertrouwen! Vanaf het allereerste moment 
heb je mij gesteund en zonder die steun had ik hier nu zeker niet gestaan. Jouw aansporingen 
(‘strooi met je talent’) en oneindige positivisme zijn aanstekelijk. Wat een mooie eigenschap 
om toekomstige collega’s mee te nemen in je eigen succes zodat ook zij succesvol kunnen 
zijn. Een echte teamplayer; bedankt dat je daarmee zo’n goed voorbeeld voor me bent. Ik 
vind het ontzettend leuk dat onze samenwerking zich heeft voortgezet in Nijmegen en ik nu 
de fijne kneepjes van de plastische chirurgie van je mag leren. 
Dear dr. Bishop, I am so grateful that I got to work in your inspiring lab and learn from the 
best! Not only am I impressed by your intellect and surgical skills; together with your modesty 
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and hospitality you set high standards as a role model. Needless to say, Gail was a great 
contributor to this hospitality. I will always remember decorating the (giant) Christmas tree, 
curving pumpkins for Halloween and all the other lovely dinners we had with your family. 
Thank you for making me feel at home in Rochester! 
Geachte prof. dr. Bartels, prof. dr. Coert en dr. van Alfen; veel dank voor het willen lezen en 
beoordelen van dit proefschrift als leescommissie. Prof. dr. van Osch, dr. Ruigrok en dr. de 
Ruiter; bedankt dat jullie bereid zijn om plaats te nemen in de promotiecommissie. Ik kijk uit 
naar jullie inzichten. 
Dear Pat, you were absolutely indispensable during the experiments. I would especially like 
to thank you for thinking along when I brought up another strange idea (I still remember you 
sitting on one of the counters of the lab taking pictures of nerves hidden under a selfmade 
box). Thank you for all those nice memories!
Dear dr. van Wijnen, dear Andre. Thank you for giving me the opportunity to use all the 
facilities of your impressive lab. You always stimulated me to critically evaluate our outcomes 
and you were really helpful during the writing process of the papers. 
Dear Roman, it was ideal to have a ‘supervisor’ in the lab that was always around. Many times 
I have bothered you with questions and you always took the time to help me. Not to mention 
that you took care of my babies (my cells) when I was away; thank you for that. 
Beste Elisa, wat hebben we veel mee gemaakt samen gedurende de vele uurtjes in (maar 
ook buiten) het lab. Het was fijn om iemand te hebben waarmee ik lief en leed kon delen, 
eindeloos kon kletsen en uren kon doorbrengen in de bioscoop. En ook jij Dolph, bedankt 
voor alle nodige afleiding binnen en buiten het lab. Ik ben zo blij dat we nu allemaal plastisch 
chirurg in wording zijn!
Beste Nadia, als mijn directe voorganger heb je veel voorwerk voor mijn onderzoeken verzet. 
Bovendien was je altijd bereid me te helpen en mee te denken voor een zo goed mogelijk 
resultaat. Bedankt!
Beste Mana, bang dat mijn onderzoek niet goed opgevolgd zou worden ben ik nooit 
geweest. Vanaf moment één ben je doortastend en ambitieus en een gouden match met dr. 
Shin. Ik ben onder de indruk van je netwerk-vaardigheden en heb er vertrouwen in dat je gaat 
bereiken wat je wilt bereiken. 
Beste Caroline, Liselotte, Maiwand en Tara; ook jullie zijn allemaal onderdeel van de ‘nerve 
research mafia’ (aldus dr. Shin), ieder met z’n eigen kwaliteiten. Bedankt voor het uitvoeren 
van de experimenten die voorafgingen en zullen volgen op de studies beschreven in dit 
proefschrift. Het zou toch mooi zijn als we uiteindelijk met elkaar een klinische verandering 
teweeg kunnen brengen in de behandeling van perifeer zenuwletsel.




Beste Hanneke Tielemans, Pieter Hupkens, Till Wagner, Franz Pronk, Erik Walbeehm, Tim de 
Jong, Brigitte van der Heijden, Marielle Vehmeijer en Stefan Hummelink; bedankt voor jullie 
interesse in mijn onderzoek en jullie bereidheid mij alle ins en outs van ons mooie vak te leren. 
Lieve collega assistenten; Claire, Nicholas, Vera, Anne Sophie, Tycho, Lennart, Kaj, Bo, Harm, 
Saskia en Vivian, lieve oud-collega’s; Marijn, Inge, Pepijn en Laura en onderzoekers van de 
afdeling; wat is het top om met zulke leuke, enthousiaste en ambitieuze collega’s samen te 
mogen werken. Bedankt voor jullie collegialiteit en gezelligheid. 
Erik de Laat, Nienke Gort, Yasmille Winnen en Stephan van Raay; jullie hebben allemaal je 
eigen rol binnen de afdeling en vervullen die met verve. Bedankt daarvoor! 
Alle poli-assistenten, OK-assistenten, medewerkers van het secretariaat en verpleegkundigen 
van de afdeling; zonder jullie natuurlijk geen goede patiëntenzorg. Bedankt voor jullie inzet 
en het verhogen van mijn werkplezier. 
Alle lieve ijsvogels en in het bijzonder dr. Doornebosch; bedankt voor de mooie eerste jaren 
van mijn opleiding. Het fundament van mijn chirurgische loopbaan is bij jullie gelegd. 
Lieve vrienden en vriendinnen;
Lieve meiden; wat voel ik me rijk met jullie vriendschap! Het is een geruststellend idee dat 
we elkaar nooit echt uit het oog zullen verliezen, want hoewel ik daar al serieuze pogingen 
voor heb gedaan (ik noem een half jaar Australië of een jaar Amerika); jullie springen gewoon 
in het vliegtuig om me op te komen zoeken. Yvet, jouw zorgzaamheid en interesse zorgen 
altijd voor goede gesprekken en ons matchende DNA geeft een speciale band. Liek, ik ken 
niemand zo creatief als jij en je droge humor heeft voor zeer ontspannende lach-sessies 
gezorgd. Manon, of eigenlijk Kuijf, jij bent overal voor in en met jouw eindeloze hoeveelheid 
energie ben je een echt organisatietalent, maar ook een heerlijk feestnummer. Merel, je bent 
ondernemend en enthousiast en we delen onze ‘passie’ voor lekker eten, wat fijn! Britt, onze 
knapste vriendin; ik kan altijd zo enorm met (en soms ook om) jou lachen, maar bovenal ben 
je ondernemend, altijd in voor gezelligheid en zorg je er ook nog voor dat onze wenkbrauwen 
‘on fleek’ zijn. De vroegere stapvakanties hebben inmiddels plaats gemaakt voor volwassen 
(wijn)tripjes en de vele thee/wijn-avondjes zijn een zeer welkome afwisseling geweest op het 
zwoegen aan dit proefschrift. Onwijs bedankt voor alle afleiding en voor wie jullie zijn! Het is 
heerlijk dat ook onze leuke mannen zo’n goede match zijn; ik kijk met veel plezier uit naar alle 
toekomstige mooie momenten met jullie!
Lieve kratjes, jullie zorgen er met elkaar voor dat iedere activiteit, barbecue of feest memorabel 
is en daarom ben ik altijd graag van de partij. De skitrips, en dan in het bijzonder die van 
vorig jaar, zijn hier zeker een voorbeeld van. Dankzij jullie inzet hebben we er niet alleen voor 
gezorgd dat Boskoop en Reeuwijk voorop liepen in het ontwikkelen van groepsimmuniteit, 
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maar ook hebben de twee weken in quarantaine een significante bijdrage geleverd in het 
afronden van de laatste manuscripten van dit proefschrift. Bedankt!
Lieve laaiblikkers, hoewel de frequentie van gezamelijke uitjes is afgenomen nu we allemaal 
in andere levensfases zitten, weet ik dat ik op jullie kan rekenen als er iets te vieren valt. 
Lieve Tahnee en Karlijn, de basis die we in Australië hebben gelegd zorgt nu nog steeds 
voor mooie middagen, avondjes en zelfs hele weekendjes weg. Bedankt voor jullie fijne 
vriendschap.
Lieve familie;
Lieve Piet, José, Bas en Déwy, bedankt dat ik vanaf het begin in een warm bad bij jullie 
terecht ben gekomen. Ik ben wellicht niet de ideale schoondochter/zus met mijn regelmatige 
afwezigheid door diensten/reizen/onderzoek, maar jullie interesse bleef onverminderd 
aanwezig en de spelletjesavonden en de gezamenlijke weekendjes weg koester ik. 
Lieve Martine, ik ben vrij selectief als het gaat om potentiële vriendinnetjes voor mijn broers, 
maar jij was vanaf moment één door de selectie. Naast je liefde voor Vin en Novée ben je 
onwijs sportief, enthousiast, lief en altijd geïnteresseerd in mijn carrière-ontwikkelingen en 
daarmee ben je een zeer welkome aanvulling voor ons gezin. 
Lieve Rens en Vin, mijn broers en nu ook mijn paranimfen! Hoewel ik wist dat mama ontroerd 
zou zijn van het feit dat ik jullie als paranimfen zou vragen, is dat niet mijn (enige) motivatie 
geweest. Rens, ik kijk op tegen jouw welbespraaktheid, je snelle humor en je intelligentie. 
Tijdens de vele discussies aan de keukentafel zijn we aan elkaar gewaagd en dat maakt het 
nooit saai. Vin, het enthousiasme waarmee je over werk, vakanties of jouw nieuwe kleine 
liefde Novée kunt vertellen is een jaloersmakend mooie eigenschap. Je nuchterheid en 
ondernemingsdrang maken van jou een grote broer om trots op te zijn. Wie denkt dat ik na 
het afleveren van dit proefschrift misschien naast mijn schoenen zou gaan lopen, kent mijn 
broers nog niet. Zij zullen er met veel liefde en aandacht voor zorgen dat ik lekker met beide 
voetjes op de vloer blijf staan. Bedankt daarvoor en voor het feit dat jullie op de grote dag 
naast mij willen staan!
Lieve pap en mam, wat fijn dat ik op deze manier de gelegenheid krijg om jullie te vertellen 
hoe dankbaar ik jullie ben voor de zorgeloze jeugd die jullie mij hebben bezorgd, voor het 
stimuleren om het beste uit mezelf te willen halen zonder mij druk op te leggen, voor het 
leggen van de basis van mijn zelfvertrouwen (en voor het voorkomen van het doorslaan 
daarvan), voor jullie nuchterheid, voor jullie onvoorwaardelijke steun, voor het altijd 
willen luisteren naar mijn verhalen en dan ook nog eens de moeite doen om de namen te 
onthouden (mama dan), voor al jullie warmte en liefde. Wat een voorbeeld zijn jullie voor 
mij. Ik had me oprecht geen betere ouders kunnen wensen!




Lieve Sjelle, als er iemand is die met name tijdens de jaren waarin ik werkte aan dit proefschrift 
heeft afgezien, ben jij het wel. Je hebt bewezen dat je geduld onuitputtelijk is en ik ben je 
eeuwig dankbaar dat je altijd als mijn rots in de branding hebt willen fungeren. Met je humor, 
je zorgzaamheid, je vrolijkheid, je nuchterheid en je liefde maak je ook van mij een leuker 
mens. Ik kijk enorm uit naar alle mooie en fijne avonturen die we samen zullen gaan beleven. 
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